

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b> C12N 15/00, 1/20, 5/00 C12N 7/00, C12P 19/34, 21/06 A61K 39/12, 37/00, A01N 63/00	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/03596</b>  <b>(43) International Publication Date:</b> 17 February 1994 (17.02.94)
<b>(21) International Application Number:</b> PCT/US93/07179  <b>(22) International Filing Date:</b> 30 July 1993 (30.07.93)  <b>(30) Priority data:</b> 921,104 30 July 1992 (30.07.92) US  <b>(71) Applicant:</b> UNIVERSITY OF HAWAII [US/US]; 2800 Woodlawn Drive, Suite 280, Honolulu, HI 96822 (US).  <b>(72) Inventors:</b> HU, Wen ; WANG, Jie ; 1330 Kinau Street, #16, Honolulu, HI 96814 (US).  <b>(74) Agent:</b> BYRNE, Thomas, E.; Nixon & Vanderhye, 8th Floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).	<b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> ANTISENSE VIRUSES AND ANTISENSE-RIBOZYME VIRUSES  <b>(57) Abstract</b>  Antisense viruses and antisense ribozyme viruses are disclosed. The novel artificial viruses, their synthesis and their use in preventing and treating viral infections are presented.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## Field of the Invention

## Background of the Invention

```

      SENSE                                ANTISENSE
DNA   5' -ACGGTACGTAA-3'                5' -ttacgtaccgt-3'
      |||||
      3' -tgccatgcatt-5'                3' -AATGCATGGCA-5'
      |                                   |
RNA:  5' -ACGGUACGUAA-3'                5' -uuacgtaccgu-3'
      \                               /
      --X--                           --X--
COMPLEX:  SENSE --> 5' -ACGGUACGUAA-3'
          |||||
          3' -ugccaugcauu-5' <-- ANTISENSE
              |
              X
              |
            (PROTEIN)

```

## APPROACHES BY OTHER RESEARCHERS RELATED TO ANTISENSE STRATEGY

## A. Antisense Expression Constructs

Genes are composed of two strands of DNA, only one of which is normally transcribed into mRNA. If the protein-coding portion of the gene is flipped over, the gene's regulatory sequence will cause the other - or "wrong" - strand to be transcribed, allowing a cell to produce antisense RNA. The antisense RNA produced by the flipped gene will bind and inactivate the RNA produced by the normal gene.

Izant JG & Weintraub H. Cell 36:1007-15 (1984) showed that the synthesis of the enzyme thymidine kinase (TK) could be blocked in mouse cells if a flipped version of the thymidine kinase gene was introduced into the cells along with the normal gene.

Two independent groups (Sheehy RE et al. Proc Natl Acad Sci USA 85:8805, 1988; Smith CJS et al. Nature 334:724, 1988; Smith CJS et al. Plant Mol Biol 14:369, 1990) created mush-resistant tomatoes by genetically engineering the plant to contain a flipped version of the gene for polygalacturonase, an enzyme that breaks down plant cell walls. As a result production of the enzyme was reduced up to 99% without directly disrupting the expression of other genes. Otherwise, the tomato plants appeared normal (Moffat AS. Science 253:510, 1991).

Oeller et al, Science 254:437 (1991) describe reversible inhibition of tomato fruit senescence by antisense RNA. The authors chose one of the other targets to control tomato fruit ripening. They introduced into tomato plants an antisense RNA expression vector to 1-aminocyclopropane-1-carboxylate (ACC) synthase, the rate-limiting enzyme in the biosynthetic pathway of ethylene which controls fruit ripening. The expression of the antisense RNA in the transgenic tomato plants inhibited tomato ripening and the biochemical changes associated with it, such as softening, color and aroma development. Administration of exogenous ethylene or propylene reversed the inhibitory effect. The authors noted that expression of antisense RNA to ACC synthase may



ameliorate losses due to over-ripening of fruits and vegetables during transportation or because of lack of refrigeration.

Day AG et al. Proc Natl Acad Sci USA 88:6721-5, 1991, report the application of antisense RNA technology, in plants, to achieve resistance to infection by a geminivirus. The authors constructed transgenic tobacco plants carrying a genetic cassette including an antisense DNA sequence of the virally encoded AL1 gene of the geminivirus tomato golden mosaic virus (TGMV). AL1 encodes a protein absolutely required for TGMV DNA replication. After infection of plants with TGMV, the frequency of symptom development was very significantly reduced in a number of antisense lines, and no DNA replication was seen in five of the six antisense lines studied, in contrast to controls.

Han L, Yun JS & Wagner TE. Proc Natl Acad Sci USA 88:4313-4317 1991, genetically engineered mice to express an antisense RNA to the Moloney murine leukemia virus (M-MuLV) proviral packaging sequences, which are needed to make infectious particles of the leukemia-causing virus. When these transgenic mice were infected with M-MuLV on the day of birth, none developed any symptoms of leukemia, although 31% of the control animals did.

The Wagner group's results caused molecular geneticist John Rossi of the city of Hope Medical Center in Duarte, California, to declare that "antisense is going to be a powerful antiretroviral tool." It might be possible, Wagner suggested, to genetically engineer lymphocytes, one of the major cell types infected by the AIDS virus, with antisense constructs that prevent the virus from replicating (Moffat AS. Science 253:510, 1991).

#### B. Synthetic Antisense RNAs or DNAs

Melton's group (Melton DA. Proc Natl Acad Sci USA 82:144, 1985; Rebagliati MR & Melton DA. Cell 48:614, 1987) showed that synthesis of

specific proteins could be prevented in frog eggs simply by injecting them with synthetic antisense RNAs.

Calabretta's group (Szczylik C et al. Science 253:562-65, 1991) made a short, single-stranded antisense DNA, just 18 nucleotides long, that specifically recognizes the junction of the ABL hybrid gene resulted by "philadelphia chromosome translocation". The antisense construct stops the growth of the cancer cells but not that of the normal cells from which the cancer cells were derived.

#### ANTISENSE STRATEGY RELATING TO HIV-1

##### A. Antisense Oligonucleotides

Vickers, et al, Nucleic Acids Res., 25 19(12):3359-68 (1991) describe inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR elements. A series of phosphodiester and phosphothioate antisense oligonucleotides were constructed which specifically bind to the HIV TAR element. The reason for using the phosphothioate analogues was based on the fact that these analogues are more resistant to degradation by DNase activities, enabling higher oligonucleotide concentration inside the cells.

Renneisen, et al, J. Biol. chem., 25 265(27):16337-42 (1990), describe inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposome containing antisense RNA to the env region. Treatment of HIV-1IIIB infected H9 cells with in vitro synthesized viral env region antisense RNA encapsulated in liposomes targeted by antibodies specific for the T-cell receptor molecule CD3 almost completely inhibited HIV-1 production. The viral env segment covered a part of exon II of HIV-1 tat gene. No anti-HIV activity could be detected with similarly targeted liposome-encapsulated sense env RNA or with pol RNA synthesized in either the sense or antisense orientations, or with env region antisense RNA free in solution, r

encapsulated in liposomes in the absence of the targeting antibody. A semiquantitative evaluation revealed that 4000-7000 RNA molecules became cell-bound in targeted liposomes; the half-life of the intracellularly present hybridizable antisense env RNA was approximately 12 hours. Western blots showed that antisense env RNA suppressed tat gene expression by approximately 90% and gp160 production by 100%. These data were confirmed by immunoprecipitation studies. Northern blots (using an env probe) demonstrated the existence of all major HIV RNA species (9.3-, 4.3-, and 2.0-kb mRNA) in HIV-infected cells treated with antisense env RNA although at a reduced level. It was concluded that the antisense env RNA inhibited viral protein production at the translational level.

#### B. Antisense Expressing Constructs

Rhodes et al, J. Gen. Virol., 71(pt9):1965-74 (1990), describe inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. Six regions from HIV-1IIIB were inserted into retroviral gene expressing vector in antisense orientation. Two of these expressed antisense RNAs were found to reduce significantly the replication of HIV-1IIIB in cell culture. The inhibitory antisense RNAs contain sequences complementary to the AUG initiation codon of the tat gene. Inhibition was substantial (over 70%) but transient. At least part of the inhibitory effect is at the posttranscriptional level.

Rhodes et al, AIDS, 5(2):145-51 (1991), describe inhibition of heterologous strains of HIV by antisense RNA. The longer (600 bases) of the two inhibitory antisense RNAs inhibits replication of HIV strains RF, MN and SF2 to at least as great an extent as it does the homologous strain IIIB. The shorter one (71 bases) does not inhibit the replication of the heterologous strains. The level of inhibition of HIV-1IIIB replication varied according to the cell line in which it was expressed, but in all cases was significant.

Rittner et al, Nucleic Acids Res., 19(7):1421-6 (1991) disclose

identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Antisense RNA, transcribed intracellularly from constitutive expression cassettes, inhibits the replication of HIV-1 as demonstrated by a quantitative microinjection assay in human SW480 cells. Infectious proviral HIV-1 DNA was co-microinjected together with a fivefold molar excess of plasmid expressing antisense RNA complementary to a set of ten different HIV-1 target regions. The most inhibitory antisense RNA expression plasmid were targeted against a 1 kb region with the gag open reading frame and against a 562 base region containing the coding sequences for the regulatory viral proteins tat and rev.

#### Objects of the Invention

It is an object of the invention to provide novel compounds and methods of treating and preventing viral infections including HIV infections.

It is an object of the invention to provide therapeutic agents for the treatment and prevention of AIDS having:

- (1) the ability to target HIV;
- (2) the power to inactivate (disable or eliminate) HIV;
- (3) the specificity to act only on HIV;
- (4) the potential to protect the cells against HIV;
- (5) a long in vivo life.

It is an object of the invention to provide a method of producing antisense viruses.

It is an object of the invention to provide a method of producing antisense-ribozyme viruses.

Summary of the Invention

The present invention provides an antisense virus comprising a viral coat sufficiently duplicative of a naturally occurring virus viral coat to allow the infectivity of the naturally occurring virus, and nucleic acid including an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for the naturally occurring virus to replicate. The antisense fragment encodes antisense RNA capable of binding and inactivating mRNA encoded by the gene encoding a transactivating protein.

The invention further provides a process for the production of an antisense virus. The process comprises the steps of a) growing under suitable nutrient conditions procaryotic or eucaryotic host cells transfected in a manner allowing expression of said antisense virus, with:

- i) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for the naturally occurring virus to replicate, and
- ii) a second DNA sequence encoding the transactivating protein, and b) isolating the antisense virus.

Also comprehended by the invention is a method of treating or preventing a viral infection comprising administering to an infected animal a therapeutically effective amount of an antisense virus.

Also provided is an antisense-ribozyme virus comprising a viral coat sufficiently duplicative of a naturally occurring virus viral coat to allow the infectivity of the naturally occurring virus, and nucleic acid including an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for the naturally occurring virus to replicate. The antisense fragment encodes antisense RNA capable of binding and inactivating mRNA encoded by the gene encoding a transactivating protein. The antisense fragment also encodes at least

ne ribozyme capable of cleaving the mRNA.

The invention further provides a process for the production of an antisense ribozyme virus. The steps include a) growing under suitable nutrient conditions procaryotic or eucaryotic host cells transfected in a manner allowing expression of the antisense ribozyme virus, with:

- i) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for the naturally occurring virus to replicate. The antisense fragment encodes antisense RNA capable of binding mRNA encoded by the gene encoding a transactivating protein. The antisense fragment also encodes at least one ribozyme capable of cleaving the mRNA, and
- ii) a second DNA sequence encoding the transactivating protein, and b) isolating the antisense ribozyme virus.

Also included in the invention is a method of treating or preventing a viral infection comprising administering to an infected animal a therapeutically effective amount of an antisense-ribozyme virus.

The invention also provides a method of connecting a first DNA segment to a second DNA segment, when the first DNA segment and the second DNA segment are separated by a length of DNA or located on different molecules. The method comprises carrying out polymerase chain reaction using the DNA segments as templates, and using a primer A complementary to the 5' end of the first DNA segment, a primer B complementary to the 3' end of the second DNA segment, and a bridging primer comprising DNA complementary to the 3' end of the first DNA segment as its 5' half, and DNA complementary to the 5' end of the second DNA segment as its 3' half, as primers.

### **Brief Description of the Drawings**

FIGURE 1 shows pX (short for pHXB2gptX). Three arrows point to three EcoNI sites. When sites #2 and #3 are eliminated, pX becomes pXE.

FIGURE 2 shows the genomic structure of HIV-I. Each of the nine known genes of HIV-1 are shown, and their recognized primary functions summarized. The 5' and 3' long terminal repeats (LTRs) containing regulatory sequences recognized by various host transcription factors are also depicted, and the positions of the Tat and Rev RNA response elements (TAR (transactivation response) element and Rev response element) are indicated.

FIGURE 3 shows a schematic diagram of the HIV-1 Virion. Each of the virion proteins making up the envelope (gp120<sup>env</sup> and gp41<sup>env</sup>) and nucleocapsid (p24<sup>gag</sup>, p17<sup>gag</sup>, p9<sup>gag</sup>, and p7<sup>gag</sup>) is identified. In addition, the diploid RNA genome is shown associated with reverse transcriptase, an RNA-dependent DNA polymerase.

FIGURE 4a is a diagram of pXE.

FIGURE 4b is a diagram of pXE-a.

FIGURE 4c is a diagram of pXE-ar.

FIGURE 5 shows the plasmid structure of SFneo.

FIGURE 6 shows the genetic organizations of HIV-1, HIV-2 and SIV.

FIGURE 7a is a diagram of SFneo-tat(+).

FIGURE 7b is a diagram of SFneo-tat(-).

### **Detailed Description of the Invention**

The subject invention relates to antisense viruses (ASV) and antisense ribozyme viruses, their synthesis, and their use in treating and preventing viral infections.

Antisense viruses are artificial viruses carrying antisense nucleotide sequences to their natural counterparts. Antisense RNAs expressed by the antisense viruses bind to the mRNAs expressed by the naturally occurring viruses and prevent the mRNAs from being translated into proteins, thereby preventing the naturally occurring virus from replicating. The antisense viruses maintain the infectivity of the naturally occurring viruses, allowing antisense RNAs to reach the mRNAs of the natural viruses. Antisense virus strategy provides a new therapy for viral, including retroviral diseases.

The antisense virus of the invention comprises the viral coat (i.e., the envelope and optionally the capsid in the case of enveloped viruses, and the capsid in the case of viruses without an external envelope) sufficiently duplicative of a naturally occurring viral coat to give the antisense virus the infectivity of the naturally occurring virus, and nucleic acid including an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate. The antisense fragment encodes antisense RNA which is capable of binding and inactivating mRNA encoded by the gene encoding a transactivating protein. Typically, the viral coat of the antisense virus is identical to the corresponding naturally occurring virus. The nucleic acid of the antisense virus typically contains all the structural genes of the naturally occurring virus. Further, nucleic acid typically includes all of the regulatory genes of the naturally occurring virus except the gene encoding the transactivating protein. Advantageously, the nucleic acid of the antisense virus is the same as the nucleic acid of the corresponding virus with the exception of the antisense fragment (which replaces a section of a gene). Since the antisense virus does not contain a gene required for replication of the virus, the antisense virus is replication defective. The antisense fragment is part or all of the gene encoding the protein required for replication, turned antisense. The length of the antisense fragment must be sufficient to permit the antisense RNA transcribed from the antisense fragment to bind and inactivate the mRNA encoded by the gene encoding the required protein of the naturally



occurring virus, thus thwarting replication of the naturally occurring virus. Thus, the antisense fragment is part or all of the target gene turned antisense. As used herein, the term "section of a gene" refers to part or all of the gene(s) encoding the transactivating protein(s) required for the naturally occurring virus to replicate.

The antisense virus of the subject application is made for use in treating or preventing disease caused by a wide variety of naturally occurring viruses. Antisense viruses is made to treat or prevent animal or plant viral infections. Further, antisense viruses are made to render inactive DNA as well as RNA viruses. Further, the antisense virus of the invention is used to treat or prevent infections caused by retroviruses.

Since the antisense virus of the subject invention is replication defective, a special host cell is required to produce the antisense virus in vitro. The antisense virus is replication defective since it does not contain a gene encoding a protein required for replication. In order for the host cell to be able to construct an antisense virus, it must contain a gene encoding the protein which the antisense virus requires. This protein must be a transactivating protein since it is supplied by a source other than the nucleic acid of the antisense virus. In order to avoid the antisense RNA encoded by the antisense fragment from binding the mRNA transfected from the complementary gene, the complementary gene sequence is typically "diversified" such that the antisense RNA will not bind the mRNA transcribed from the complementary gene. The amino acid sequence of the protein produced by the complementary gene, however, is the same as the corresponding protein of the naturally occurring virus.

In order to construct the cell line which produces the antisense virus, the complementary gene can be transfected into the host cell before, at the same time, or after transfection of the host cell with the gene encoding the antisense virus.

The subject invention also relates to antisense-ribozyme viruses (ARV) which are the same as antisense viruses except one or more ribozyme

catalyst sequences have been incorporated into the antisense sequence(s). The antisense-ribozyme viruses are structured such that the binding of the antisense RNA to a particular mRNA will meet the requirements for the formation of specific structure enabling ribozymes to cleave the particular mRNA at predetermined positions. The ability of ribozymes to cleave RNA plus the binding specificity of antisense RNA give antisense-ribozyme viruses the ability to eliminate the natural viruses.

Antisense viruses and/or antisense-ribozyme viruses are often referred to collectively herein as "antisense/ribozyme viruses" or "ASV/ARV".

Although antisense viruses and/or antisense-ribozyme viruses to HIV-1, HIV-2 (human immunodeficiency viruses type 1 and 2) and SIV (simian immunodeficiency virus) are exemplified herein, the strategy is applicable to other viruses.

#### Definitions

##### ANTISENSE/RIBOZYME HIV-1 CLONES


#### A. Full-Length Proviral Molecular Clones and Antisense/Ribozyme Proviral Molecular Clones:

pX: Short for pHXB2gptX. HXB2 is a functional HIV-1 molecular clone which has been widely employed in many kinds of experiments all over the world. The plasmid construct of pX is shown in Figure 1.


The genomic structure of HIV-1 is shown in Figure 2. A schematic diagram of the HIV-1 virion is shown in Figure 3.

The genetic organization of parental pX (HIV-1111B) is shown below. Only those restriction enzyme sites to be used during the construction

procedures are shown.




**pNL:** Short for pHIVNL4-3. An infectious recombinant HIV-1 clone that contains DNA from HIV isolates NY5 (5' half) and BRU (3' half). The site of recombination is the unique EcoRI site at nt 5743-5748. The vpr coding region of pNL is 18 amino acid residues longer than that of pX, due to a single "T" base deletion at nt 5770. The genetic organization of pNL is almost the same as pX, but the vpr is longer, and the ClaI site and the first EcoRI site are missing.



**pXE:** Modified from pX to facilitate the construction of antisense/ribozyme clones. A "T" to "G" point mutation has been introduced at nt 7633 in order to abolish the second EcoRI restriction site within the proviral sequence. The EcoRI site outside the proviral sequence has also been removed by polymerase fill-in and religation. pXE is considered the same as pX, but has only one EcoRI cleavage site at nt 5966 in the whole clone. The point-mutation introduced does not change the protein sequences.


Genetic organization of pXE is as follows (see also Figure 4). Note

the second EcoNI site has been deleted. The deletion, however, did not change the genetic organization.



**pXE-a:** A DNA fragment of 171 base pairs, from nt 5795 to nt 5965, covering 45 amino acid codons of the N-terminus of the TAT protein, has been turned antisense. Consequently, the production of the whole TAT protein would be eliminated.


Genetic organization of antisense clone pXE-a is as follows (see also Figure 4). The sequence between SmaI and EcoNI sites has been turned antisense. As a consequence of this inversion, the tat gene is destroyed and the whole clone becomes replication defective.



**pXE-b:** Same as pXE-a plus the nt 5970 "T" has been mutated to "G". As the consequence of this point-mutation, the initiation codon of rev is erased as is the whole REV protein.


Genetic organization of antisense clone pXE-b is as follows. The sequence between SmaI and EcoNI sites has been turned antisense. Consequently, the tat gene is destroyed and the whole clone becomes

replication defective. Additionally, the initiation codon of rev gene has been mutated and the rev gene too is eliminated.




**pXE-ar:** A ribozyme catalytic domain has been incorporated into the antisense sequence of pXE-a, thus adding the RNA cleavage activity to the antisense clone.

Genetic organization of antisense clone pXE-ar is similar to pXE-a (see Figure 4). Note the position of the ribozyme.




**pXE-br:** A ribozyme catalytic domain has been incorporated into the antisense sequence of pXE-b, thus adding the RNA cleavage activity to the antisense clone.

Genetic organization of antisense clone pXE-br is similar to pXE-b. Note the position of the ribozyme.



**B. HIV-1 Subclones:**


**pX-N:** Made from pX. An NdeI fragment of 1281 bps, from 5121 to 6402, has been removed from pX and religated. Included in the removed fragment, among other things, are the unique NcoI-5674, SalI-5785 and a EcoNI-5966. pX-N contains 2 other EcoNI sites, one at nt 7631 and the other outside the proviral sequences.



**pX-N-E:** Made from pX-N with the two EcoNI sites eliminated. The EcoNI-7631 has been point-mutated, and the outside EcoNI has been enzymatically erased.




**pX-E2:** The fragment of ClaI(829)-BamHI(8474) from pX has replaced the corresponding fragment of pX-N-E, thus putting back the 1281-bp NdeI fragment. Also put back are the EcoNI sites at nt 5966 and nt 7631.




**pXE:** The EcoNI site at nt 7631 has been point-mutated

s the whole clone carries a unique EcoNI site at nt 5966. See also "Full-Length Molecular Clones or Mutants" above.



#### C: Gene-Expression Vector Clones:

**pX-CS:** A truncated HIV-1 clone made from pX and used as tat-expression vector. Removed from this clone are 4484 bps, from nt 836 to nt 5319 including most part of gag, all of pol and 5' half of vif open reading frames. The vpr, tat, rev, env, and nef genes and two LTRs are intact.



**pX-CSneo:** A 1146-bp neo(r) cassette containing an XhoI-Sall fragment has been inserted into the unique XhoI site in pX-CS. This clone has been endowed with neomycin resistance, but the insertion disrupts the nef gene.

**pX-neo:** Made from pX-CSneo. The Sall(5785)-XhoI(8896) (3111 bps) fragment, covering tat, rev and env coding regions, has been deleted from pX-CSneo. Essentially, pX-neo contains 2 HIV-1 LTRs with a neomycin resistant gene in between. This clone is used as neo(r)-only control.

**SFneo:** Retroviral gene expression vector which employs Spleen Focus Forming Virus (SFFV) LTR promoter to drive the

expression of the gene to be inserted into the unique EcoRI site. This clone is used also as neo(r)-only control. The plasmid structure is shown in Figure 5.

SFneo-t/r(+): Tat as well as rev reading frames in continuation has been inserted in right orientation into the EcoRI site of SFneo. This clone expresses sense tat and rev mRNA.

SFneo-t/r(-): Tat as well as rev reading frames in continuation has been inserted in wrong orientation into the EcoRI site of SFneo which employs Spleen Focus Forming Virus (SFFV) LTR promotor to drive the expression of the inserted gene. This clone expresses antisense tat and antisense rev mRNA.

SFneo-tat(+): Inserted in right orientation into SFneo vector at EcoRI site the chemically synthesized nucleotide sequence which is different from the natural nucleotide sequence. This clone expresses sense mRNA which is translated into TAT protein with amino acid sequence identical to that of the natural HIV-1.

SFneo-tat(-): Inserted in wrong orientation into SFneo vector at EcoRI site the chemically synthesized nucleotide sequence which is different from the natural nucleotide sequence. This clone expresses antisense RNA.

\* \* \*

#### ANTISENSE VIRUSES

An antisense virus (ASV) is an artificial virus that expresses antisense RNA to one or more genes of its natural counterpart. An



antisense virus is generally replication defective, necessitating an antisense virus production system in order to produce large quantities of antisense viruses for therapeutic and preventive applications. The antisense virus production system comprises three components:

- (1) an antisense proviral molecular clone;
- (2) a complementary gene expression vector;
- (3) an antisense virus producer cell line (host cells).

An antisense-ribozyme virus production system uses the same components (2) and (3) combined with an antisense-ribozyme proviral molecular clone (discussed below).

The function and establishment of each component of the antisense virus production system will be exemplified in detail for an antisense virus for HIV-1. Similar systems for other human viruses such as HIV-2 and SIV are easily developed by a person skilled in the art because of the similarity of genetic organizations between HIV-1, HIV-2 and SIV. The genetic organizations of HIV-1, HIV-2 and SIV are shown in Figure 6. Similar systems for other types of viruses can also be developed.

#### HIV-1 Antisense Proviral Clones

An HIV-1 antisense proviral molecular clone is made from a functional (infectious) HIV-1 molecular clone. It retains all of the natural HIV-1 structures and machinery except a part (or parts) of the genome has been turned antisense by sequence inversion. The antisense proviral clone is basically an intact molecular clone but the sequence inversion inactivates some functionally critical gene(s) and renders the whole clone replication-defective. However, the antisense proviral clone is constructed such that the function(s) of the inversion-inactivated gene(s) can be complemented by gene product(s) provided by another source or sources than the antisense clone itself. In other words, replication of the antisense clone depends on gene product(s) from source(s) other than the antisense clone itself.

In the presence of the gene product(s) provided by a "complemental gene expression vector" for functional complementation, the antisense proviral clone makes virus particles (antisense viruses) in the antisense virus producer cell line. The constant presence of gene product(s) is achieved by engineering the antisense virus producer cell line to express the protein(s) constitutively before, during or after the antisense proviral clone is transferred into the cells. With this antisense virus production system the antisense viruses are made in quantity in vitro.

The antisense virus is infectious and has the same "targeting" or "homing" specificity as the naturally occurring (wild type) virus. The antisense HIV-1 virus is able to attach to and enter CD4(+) cells, mediated by its normal envelope proteins (gp120 and gp41) just as the natural virus. Once inside the cells, the viral nucleocapsid reverse-transcribes its RNA genome into DNA, then integrates the viral DNA into the host genome, just as the natural virus does. But the antisense virus is non-replicative, hence non-pathogenic, in the absence of the gene product(s) that the antisense virus is missing. In the case where the antisense virus enters a healthy cell where no viral protein is being synthesized for functional complementation, the antisense virus will not replicate.

In the case where the antisense virus enters a cell which has already been infected by natural virus(es), the antisense virus will compete for survival (replication) with the natural virus(es) for the gene product(s) provided only by the latter. Once replicating, the antisense transcript (antisense RNA) will bind the natural transcript. The binding will shut off the natural viral protein synthesis; and vice versa. The consequence will be the inhibition, and eventually eradication, of the natural viruses and the antisense viruses.

If the antisense virus enters a cell which becomes infected later by a natural HIV-1 virus, the dormant antisense provirus (having integrated into the human genome) is re-activated by the gene product(s) encoded by the natural virus. Its transcription produces antisense RNA which shuts

off the natural virus.

If the cell never becomes infected by any natural HIV-1 virus, the antisense provirus will remain dormant and eventually be eliminated with the natural death of the cell. Potentially, the integrated antisense provirus, though unable to make virus without gene product(s) provided from other source(s), will divide with the cell, thus "arming" each daughter cell with one copy of the antisense proviral DNA.

#### Construction of Antisense HIV-1 Proviral Clones

The antisense HIV-1 proviral molecular clones are constructed with well-known functional (infectious) molecular clones, e.g., HIV-1IIIB and HIV-1NL4-3. The antisense RNA, once transcribed, will carry the same sequences (only some area in antisense orientation) as the wild type mRNA. The sense and antisense RNA sequences form complexes, a basic requisite for the antisense strategy to work.

In case an antisense clone made from an existing molecular clone does not work well with a particular patient's viruses because of sequence heterogeneity, an individualized antisense clone is made, using as a template the very virus strain infecting the particular patient. An antisense clone made in this way has exactly the same sequence (only in antisense orientation) as, and be able to form perfect duplexes with, that of the HIV-1 strain hosted by the patient (described further below).

#### Choosing Gene(s) for Inversion in HIV-1

An antisense clone is made by inverting part or all of one or more genes of the naturally occurring virus to be neutralized. To be eligible for the inversion, the gene(s) must be indispensable for the replication of the virus, but must not be the structural genes. Structural genes,

i.e., in the case of HIV: gag, pol, and env, are necessary for the assembly of infectious virus particles. Infectious virus particles are employed as vehicles to deliver the antisense sequences effectively and specifically to the locations where the naturally infecting viruses reside. It is important for the antisense virus to preserve the natural devices and to retain the same "targeting" or "homing" function as that of the naturally occurring virus.

The rev gene encodes a 19-kd phosphoprotein which is essential for the replication of HIV-1. The Rev protein appears to exert its regulatory activity at a post-transcriptional level by activating the cytoplasmic expression of the unspliced and singly spliced forms of HIV-1 RNA that encode the products of the gag, pol, and env genes. In the absence of Rev, these incompletely spliced viral mRNAs remain sequestered in the nucleus, where they are either degraded or completely spliced. Apparently, Rev positively regulates the formation of virus particles. Since the rev gene overlaps with tat, it is impossible to turn rev antisense without also affecting tat. Thus, the complementary gene expression vector would have to express both rev and tat. Another consideration is that there is a splice junction site at the beginning of rev gene. If the splice junction sequence is turned over, the splicing may be lost, or placed at the wrong location, which would potentially impair the formation of infectious virus particles.

An antisense proviral clone can be made that knocks out the function of the rev gene while keeping the sequence basically unchanged. This goal is achieved by changing the "T" in rev initiation codon (position 5970) into a "G". The single base substitution will (1) abolish the rev gene product; (2) preserve the splice junction site; (3) preserve the unique EcoNI site which is critical in reconstructing antisense clone(s); and (4) create a new restriction enzyme site for AvrII, facilitating recombinant clone screening.

Advantageously, the tat gene is turned antisense. TAT corresponds to an 86-amino-acid nuclear protein that is essential for the replication

f HIV-1. TAT potently trans-activates the expression of all viral genes. The TAT protein appears to contain three primary structural domains, including a proline-rich N-terminus, a cysteine-rich central portion, and a positively charged distal segment. The cysteine-rich domain (located between amino acids number 21-37 of the protein) probably mediates dimerization of the this trans-activator, whereas the positively charged distal segment is responsible for both RNA binding and nuclear-nucleolar localization. Thus far, no clear function has been ascribed to the proline-rich domain (located at the first 18 amino acids). TAT acts through an RNA stem-loop structure termed the "transactivation response element (TAR)", located at the beginning of all HIV-1 mRNAs. The preponderance of evidence suggests that it acts primarily at the level of transcription initiation, elongation, or both. TAT protein is trans-acting, therefore the TAT function abolished in the antisense clone can be easily compensated by introducing into the cultured cells a TAT-expressing cassette. The TAT protein expressed by this cassette will regulate the replication of antisense HIV-1 whose tat gene has been flipped over and rendered functionless.

Below is a description of a region of the tat gene being turned antisense.

#### Analyzing the Selected Area for Inversion in the TAT GENE

The original sequences between positions 5774 to 5986 in the HIV-1 molecular clone HXB2 are as follows [numbering according to GenBank, LOCUS HIVHXB2CG, 9718 bp, VRL 25-SEP-1987. DEFINITION: Human immunodeficiency virus type 1 (HXB2), complete genome; HIV1/HTLV-III/LAV reference genome. ACCESSION K03455]. Notice the coding sequences for the end part of vpr (which is different between clone pNL4-3 and HXB2), the beginning of tat-1 and rev-1, the two splice acceptor (sa) sites at positions 5776G/5777A and 5975G/5976G, the unique restriction enzyme sites of Sal-I and EcoNI (positions 5785 and 5966 respectively, both shown underlined). In the subject application, all restriction enzyme

sites are indicated by the first base of the enzymes' recognition sequences). EcoNI is unique in plasmid clone pXE but not pX, as detailed later. The area written in bold-type [nucleotides (nt) 5795-5965] is to be turned antisense by sequence inversion.

```

5774   HXB2VPR<--|      5795                                |-->TAT
| \sa
CAGAATTGGGTGTCGACATAGCAGAAATAGCGTTACTCGACAGAGGAGAGCAAGAAATCGAGCCA
Q N W V S T *
R I G C R H S R I G V T R Q R R A R N G A
                                M E P
NLVPR<--|
GTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAAGTCCTTGTACCAATTC
S R S *
V D P R L E P W K H P G S Q P K T A C T N C
                                5965
CTATTGTAAAAAGTGTTCCTTTCATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCT
Y C K K C C F H C Q V C F I T K A L G I S
|-->REV      5986
| \sa
ATGGCAGGAAGAAGCCGA-3'
M A G R S G
Y G R K K R

```

---



---

Three- and one-letter codes for amino acids:

---

Amino Acid	Three-letter Code	One-letter Code
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic Acid	Asp	D
Cysteine	Cys	C
Glutamic Acid	Glu	E
Glutamine	Gln	Q
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P

Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

The inversion involves a total of 171 base pairs (bps). The sequence involvement for HIV1 was decided according to the following considerations. The sequence involvement for other viruses is also decided according to the following considerations.

First, the inversion advantageously should cover as much tat c ding sequence as possible, especially the initiation codon (ATG) and the functionally important cysteine codons, in order for the antisense RNA expressed by the antisense viruses to bind as effectively to the natural viral tat mRNA as possible. The wide coverage also minimizes the possibility that the antisense proviral clones remain self-functioning.

Secondly, the inversion should cover as little other gene coding sequences and RNA processing signals as possible, especially the rev gene and splice junctions, in order for the antisense viruses to retain as much other gene functions as possible. The involvement with fewer genes minimizes the complexity for gene complementation by the complementary gene expression vectors.

Thirdly, the inversion should be between, but as close as possible to, two unique restriction enzyme sites in order for the construction of antisense clones to be convenient and easy. The two unique restriction enzyme sites can be either naturally existing or recombinantly created. In the case of antisense HIV-1 proviral clones, the chosen unique restriction sites are Sall and EcoNI, both of which occur only once in the whole plasmid pXE. The inversion is right before the EcoNI site but 4 bps after Sall site only to spare the vpr stop codon (TAG).

The sequences involved are 100% homologous between HIV-1 clones HXB2 and NL4-3. The coding regions, however, are different. In HXB2, the sequence consists of 35-bp non-encoding area located between vpr and tat

(after the stop codon of vpr and before the initiation codon of tat). Of note is that the vpr in this clone is believed to have been truncated and rendered functionless. The inverted 171 bps sequence further consists of 136-bp in the tat-1 open reading frame where the first 45 amino acids are encoded, including all seven cysteine residues in TAT protein. As a result of the inversion, the following 27 amino acids of TAT-1 (#46-72) are also eliminated because of the frame-shift and the loss of initiation codon. In total, the 72-amino-acid TAT-1 protein is not made. In clone NL4-3, the coding for tat-1 is the same as HXB2, but the carboxyl terminus of vpr extends 55 bps into the inverted region, including a 20-bp overlap with tat-1. Vpr in clone NL4-3 is believed to be intact and functional. The two splice junction sites [splice donor (sd) and splice acceptor (sa) are often collectively referred to as splice junctions] immediately before and after the area are not affected by the inversion. The inverted area, after transcribing into mRNA, is able to bind and block the natural HIV-1 mRNA specifically and effectively.

\* \* \*

An antisense virus proviral molecular clone is constructed from a functional proviral molecular clone of a naturally occurring virus by inverting ("turning antisense") a section (i.e., part or all) of one or more genes. The inverted section of a selected gene is referred to as the "antisense fragment" herein. To be eligible for selection, the naturally occurring gene must meet two prerequisites. First, this gene must be required for the naturally occurring virus to replicate; and second, the gene must encode a protein product which is transactivating. Other genes are usually not affected during the antisense proviral molecular clone construction. In choosing the sequence of a gene to be inverted, special attention is paid to the gene involved and to its relationship to neighboring genes.

The sequence inversion can be accomplished by conventional recombinant technologies. A new strategy, however, has been developed to construct any antisense virus proviral molecular clone easily and



precisely. Recombinant polymerase chain reaction (r-PCR or PCR) technology is employed. The PCR technology is known to those skilled in the art. See U.S. patents 4,683,195 and 4,983,728 hereby incorporated by reference. The strategy of the subject invention (applicable to other viruses as well as HIV1) comprises the steps of:

- 1) Inserting DNA encoding a naturally occurring virus into a DNA cloning vector. Molecular cloning vectors such as plasmids (including phagemids), bacterial phage lambda and cosmids, are useful as cloning vectors.
- 2) Selecting a section of the viral DNA to be inverted. The selected section of the viral DNA is part or all of a gene that encodes a transactivating protein product which is required for the naturally occurring virus to replicate. The selected section of the viral DNA is flanked by a unique restriction enzyme site A at its 5' end and by another unique restriction enzyme site B at its 3' end. The unique restriction enzyme sites A and B are either naturally existing or recombinantly created;
- 3) Carrying out a polymerase chain reaction, using the selected section of the viral DNA as the template, and two specially designed "antisense primers" that target the selected section (in practice, the whole vector containing the whole proviral genome is typically used as the template - there is no need to isolate the selected section in view of the primers used). Antisense Primer 1 comprises at its 3' half a portion of DNA complementary to the 5' end of the selected section of the viral DNA, and at its 5' half a portion of DNA containing the unique restriction enzyme site B. Antisense Primer 2 comprises at its 3' half a portion of DNA complementary to the 3' end of the selected section of the viral DNA, and at its 5' half a portion of DNA containing the unique restriction enzyme site A. The PCR amplification product (the "antisense fragment"), when aligned with the naturally occurring section of the viral DNA, is antisense to the latter between the two unique restriction enzyme sites A and B;

- 4) Digesting the vector containing the naturally occurring viral DNA with restriction enzymes A and B to release the selected section of DNA;
- 5) Digesting the PCR amplification product with restriction enzymes A and B to release the antisense fragment;
- 6) Ligating the antisense section of DNA into the vector in place of the selected sense section of DNA; and
- 7) Isolating antisense virus proviral molecular clones by standard procedures of transforming appropriate strains of cells such as *E. coli* followed by colony screening.

See also Example 1.

#### Construction of Antisense HIV-2 Proviral Clones

Methods similar to those used above with HIV-1 are employed to construct antisense HIV-2 proviral clone(s). The construction starts with an infectious HIV-2 plasmid clone named pSE (Hu W et al. *Virology* 173:624-630, 1989). A similar PCR strategy is applied to turn over the fragment between nt 5793 and nt 6062 totaling 270 bp in length (numbering according to Guyader M et al. *Nature* 326:662-669, 1987). This area covers the 3' portion of *vpr* and 5' portion of *tat-1*. Because HIV-2 *VPR* is dispensable for replication and cytopathogenicity (Dedera et al., *J. Virology*, 63:3205-3208, 1989), only TAT function has to be provided for the production of antisense HIV-2 viruses.

#### Construction of Antisense SIV Proviral Clones

Similarly, the construction of antisense SIV proviral clone(s) starts with full-length infectious SIVmac plasmid clone p239F (Kestler,

et al. Science 248:1109-1112, 1990) or pK102 (Niederman et al. J. Virol. 65:3538-3546, 1991). Similar PCR strategies are utilized to turn over the fragment between nt 5751 and nt 5988, totaling 238 bp in length (numbering according to Chakrabarti et al. Nature 328:543-547, 1987). This area also covers the 3' portion of vpr and 5' portion of tat-1. Because SIV VPR is probably dispensable for replication and cytopathogenicity, only TAT function has to be provided for the production of antisense SIV viruses.

#### Construction of Antisense Proviral Clones of Other Retroviruses

The construction strategies for antisense proviral clones presented herein apply to all retroviruses. The genes which can be turned antisense, partially or wholly, include all those with transactivation activity. Examples are as follows:

Tax and rex genes of human T-lymphotropic viruses (HTLV-1 and HTLV-2) and of bovine leukemia virus,

S gene of Visna Virus,

S1 and/or S2 genes of Equine Infectious Anemia Virus (EIAV)

(see SJ O'Brien ed. Genetic Maps, locus maps of complex genomes, 5th edition, book 1, viruses, CSH, 1990).

For the oncogene-containing oncoviruses (acutely transforming viruses, ATVs), the oncogenes contained, partially or wholly, are selected to be turned antisense.

### Construction of Antisense Clones of Other Viruses

The antisense virus strategies also apply to viruses which contain DNA (not RNA) in their virions, provided that the virus at issue has one or more genes whose translation products are transactivating hence whose inactivation by sequence inversion can be compensated by gene products provided by a gene-expression vector (complemental expression vector), and that a cell culture system is available for making an antisense virus producer cell line. Examples of these viruses and the genes which can be turned antisense are:

X gene of hepatitis B virus,

E1A genes of adenoviruses,

E2 genes of papillomaviruses,

T genes of simian virus 40 and of polyomaviruses, and

genes encoding alpha proteins of herpes viruses

(see SJ O'Brien ed. Genetic Maps, locus maps of complex genomes, 5th edition, book 1, viruses, CSH, 1990).

\* \* \*

### ANTISENSE-RIBOZYME VIRUSES


Antisense-ribozyme viruses are the same as antisense viruses but include one or more ribozymes in the antisense sequence(s) which cleave mRNA of the naturally occurring target virus.

The sequence inversion in the aforementioned HIV-1 antisense clones involved 171 base pairs. The sequence included 3' vpr (with pNL) and 5'

tat, where it covers the initiation methionine codon and all seven cysteine codons of tat gene. It is possible to form stable complexes between the antisense RNA and the tat mRNA to block the latter from being translated into TAT protein. However, the formation of RNA complexes does not mean the destruction of the RNAs. On the contrary, the complex formation may provide protection to the tat mRNA against degradation in vivo. Ribozyme catalytic sequences incorporated into the antisense RNAs, however, are able to devitalize the bound mRNA molecules by cleaving them into pieces. The combination of antisense strategy with the ribozyme strategy magnifies the antiviral capability of the artificial viruses.

Ribozymes are RNA molecules that catalyze RNA cleavage [Cech, Science 236, 1532-9 (1987); Uhlenbeck OC., Nature (London) 328, 596-600 (1987) ; Forster et al, Cell 49, 211-220 (1987)], i.e., ribozymes are RNA that cut RNA. The simplest of the catalytic motifs of ribozyme is the autocleavage domain of certain plant pathogens (viroids) and viral satellite RNAs (virusoids) called the hammerhead (Forster et al, Cell 49, 211-220 1987). Some other forms from the continuously expanding list of ribozymes are those associated with the self-splicing large ribosomal RNA intron of Tetrahymena, the M1 RNA component of the Escherichia coli RNase P enzyme, and another type of self-cleavage domains of plant viroid and virusoid RNA, the "hairpin" (Rossi JJ et al. AIDS Research and Human Retroviruses 8:183-9, 1992). The hammerhead consists of three stems and a catalytic center, all containing 13 conserved nucleotides:

5'GAAAC(N)nGUX(N)nCUGA(N)GA3'



Ribozymes, like protein enzymes, require specific structures for their catalytic activity. Natural catalytic centers may be formed by contiguous regions on the RNA or by regions separated by a large number of nucleotides. Cleavage by hammerhead ribozyme occurs 3' to the GUX triplet where X can be C, U, or A, generating 2', 3'-cyclic phosphate and 5' hydroxyl termini. The essential constituents of the hammerhead can be on separate molecules, with one strand serving as a catalyst and the other as a substrate. RNA sequences containing only the conserved cleavage domain (GUX) can serve as compatible substrates (Sarver, et al, Science 247, 1222-5 1990). Ribozymes have been attempted, with success to various extent, as potential therapeutic agents for acquired immunodeficiency syndrome (AIDS) against gag (Sarver, et al. *ibid*), integrase (Sioud et al, Proc Natl Acad Sci U S A 88, 7303-7, 1991); vif (Lorentzen et al, Virus Genes 5, 17-23, 1991); and other sequences (Goodchild et al, Arch Biochem Biophys 284, 386-91, 1991). Ribozymes cleavage activity can be directed to cut very specifically pre-determined sequences on RNA molecules, both in cell-free system and within the cells, by the flanking RNA sequences which are antisense to the ribozyme's target, i.e., a ribozyme relies on antisense sequences to locate its positions of cutting. The antisense sequence binds to the mRNA and the ribozyme cuts the mRNA.

#### Construction of Antisense-Ribozyme HIV-1 Proviral Clones

The addition of RNA cleavage activity of ribozymes to increase the antisense virus's ability to neutralize a naturally occurring virus was accomplished by incorporating one or more of the 22-nucleotide-long catalytic domains, containing the consensus sequence, into the antisense sequences. The ribozyme(s) will cut the tat mRNA at 3' to the triplets GUX (X = A, C or U) which occur eight times in the area that has been turned antisense. While three of the GUX have actually been chosen, any one of them is potentially a target site for ribozyme cleavage. The designing procedure is illustrated as follows:

The original sequences between nt 5775 and 5986 of pX are as below.

The bold-type area is where the inversion occurs.

```

5774   HXB2VPR<--|      5795      |-->TAT
|  \sa
CAGAATTGGGTGTTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCA
Q  N  W  V  S  T  *
R  I  G  C  R  H  S  R  I  G  V  T  R  Q  R  R  A  R  N  G  A
                                M  E  P
NLVPR<--|
GTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAATTG
S  R  S  *
V  D  P  R  L  E  P  W  K  H  P  G  S  Q  P  K  T  A  C  T  N  C
                                5965
CTATTGTAAAAAGTGTTCCTTTTCATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCT
|
Y  C  K  K  C  C  F  H  C  Q  V  C  F  I  T  K  A  L  G  I  S
|-->REV      5986
|  \sa
ATGGCAGGAAGAAGCGGA-3'
M  A  G  R  S  G
Y  G  R  K  K  R

```

Below is the sense version of the double-stranded DNA sequence:

```

5774   HXB2VPR<--|
|  \sa
CAGAATTGGGTGTTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCA
gtcttaaccacagctgtatcgtcttatccgcaatgagctgtctcctctcgttctttacctcggg
Sal -I
GTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAATTG
catctaggatctgatctcgggaccttcgtaggtccttcagtcggattttgacgaacatggttaac
CTATTGTAAAAAGTGTTCCTTTTCATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCT
gataacatttttcacaacgaaagtaacggttcaaacaagattgttttcggaatccgtagagga
                                E  C
|-->REV      5986
|  \sa
ATGGCAGGAAGAAGCGGA-3'
taccgtccttcttcgcct-5'
o - N I

```

Below is the sense version of the RNA sequence, with all GTX underlined.

CAGAAUUGGGUGUGCGACAUAGCAGAAUAGCGGUACUCGACAGAGGAGAGCAAGAAAUGGAGCCA  
 GUAGAUCUAGACUAGAGCCCUAGCAAGCAUCCAGGAAGUCAGCCUAAAAUCGCUUGUACCAAUUG  
 CUAUUGUAAAAAGUGUUGCUUUCADUUGCCAAGUUUGUUUCAUAACAAAAGCCUUAGGCAUCUCCU  
 AUGGCAGGAAGAAGCGGA-3'

Below is the antisense version of the DNA sequence in antisense proviral clone pXE-a:

5774 HXB2VPR<--|  
 | /sa |  
 CAGAATTGGGTGTCGACATAGagatgcctaaggcttttgttatgaaacaaacttggcaatgaaag  
 gtcttaaccacagctgtatcTCTACGGATTCCGAAAACAATACTTTGTGTGAACCGTTACTTTC  
 Sal -I  
 caacactttttacaatagcaattggtacaagcagtttttaggctgacttcctggatgcttcaggg  
 GTTGTGAAAAATGTTATCGTTAACCATGTTCTCAAAATCCGACTGAAGGACCTACGAAGGTCCC  
  
 ctctagtctaggatctactggctccatttcttgcctcctctgtcgcgagtaacgcctattctgCCT  
 GAGATCAGATCCTAGATGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTGCCGATAAGACgga  
 E c  
 |-->REV 5986  
 | /sa |  
 ATGGCAGGAAGAAGCGGA-3'  
 taccgtccttcttcgcct-5'  
 o - N I

and below is the antisense version of the RNA sequence:

CAGAAUUGGGUGUGCGACAUAGAGAUGCCUAAGGCUUUUGUUAUGAAACAAACUUGGCAAUGAAAG  
 CAACACUUUUUACAAUAGCAAUUGGUACAAGCAGUUUUAGGCUGACUCCUUGGAUGCUUCCAGGG  
 CUCUAGUCUAGGAUCUACUGGCUCCAUUUCUUGCUCUCCUCUGUCGAGUAACGCCUAUUCUGCCU  
 AUGGCAGGAAGAAGCGGA-3'

When the antisense RNA encounters the natural (sense) tat mRNA, it will bind the natural (sense) tat mRNA and block the translation of tat mRNA into TAT protein.

\* \*  
 CAGAAUUGGGUGUGCGACAUAGAGAUGCCUAAGGCUUUUGUUAUGAAACAAACUUGGCAAUGAAAG  
 |||||  
 AGGCGAAGAAGGACGGUAUCCUCUACGGAUUCGAAAACAAUACUUUGUUUGAACCGUUACUUUC  
  
 \* \* \* \*  
 CAACACUUUUUACAAUAGCAAUUGGUACAAGCAGUUUUAGGCUGACUCCUUGGAUGCUUCCAGGG  
 |||||  
 GUUGUGAAAAAUGUUAUCGUUAACCAUGUUCGUCAAAAUCCGACUGAAGGACCUACGAAGGUCCC



Upper Line: Antisense RNA sequence, written 5'-->3';  
Lower line: Natural mRNA sequence, written 3'-->5', with  
all potential ribozyme cleavage sites  
underlined.

U G A U  
A GGCC G  
G CCGG A  
U G U  
C A

See Example 3 for a detailed description of construction of ribozyme proviral clones.

### Construction of Antisense-Ribozyme HIV-2 Pr viral Clones

A ribozyme catalytic sequence can also be incorporated into the HIV-2 antisense clone to cleave (GUU) the tat mRNA at any one or more positions of 5883-5885 (GUC), 6011-6013 (GUA), 6032-6034 (GUC), and 6041-6043 (GUU). These are the four GUX positions in the area to be turned antisense (nt 5793-6062).

### Construction of Antisense-Ribozyme SIV Proviral Clones

A similar ribozyme sequence can also be implanted to the antisense SIV proviral clone(s) to target mRNA at positions 5767-5769 (GUA) or/and positions 6063-6065 (GUU). The 5767-5769 GUA triplet is 18 bases before the tat initiation codon. The cleavage, however, deprives the tat mRNA of leading sequence necessary for its translation into protein. The 6063-6065 GUU sequence is at SIV tat amino acids 59-60.

### Construction of Antisense-Ribozyme Viral Clones of Other Viruses

The same or similar ribozyme sequences can also be fixed into other antisense viral clones wherever a "GUX" triplet is present in the sense mRNA sequences.

## COMPARISONS OF NATURAL, ANTISENSE AND ANTISENSE-RIBOZYME HIV-1 MOLECULAR CLONES

### A. Natural (Wild Type) HIV-1 Clones (pXE or pX or pNL4-3)

1. Contain intact LTRs, gag, pol, env, vif, vpr, tat, rev, vpu, nef genes.
2. Replication competent: produce normal virions.

3. Infectious: virions carry on their envelope membranes normal gp120 and gp41. Gp120 is capable of attaching to CD4 molecules (act as receptors for the viruses) and introducing the virion contents into the cells.

4. Pathogenic: viral components are synthesized, virions assembled and exported, resulting in the death of host cells.

5. Cause Illness: mainly because of CD4(+) lymphocyte depletion and subsequent opportunistic infections and tumors.

#### B. Antisense HIV-1 Molecular Clones (pXE-a & pXE-b)

1. Contain intact LTRs, gag, pol, env, vif, vpr, vpu genes. A portion of tat-1 gene is inverted. Rev is either intact (pXE-a) or abraded (pXE-b).

2. Replication impaired, but can be complemented by transactivating factor tat (and rev for pXE-b). In the existence of tat (and rev) protein to provide necessary regulation, replication capability is restored, though may not necessarily be complete. Virus particles can be formed which are otherwise normal except carrying inverted tat-1 sequence (and the mutated rev initiation codon).

3. The assembled virions are infectious in that they can bind to CD4 molecules, can be taken up by CD4(+) cells, be reverse-transcribed into double-stranded DNA, be transported to the cell nucleus, and be integrated into the cellular genome. In the event that the cells are activated and dividing, the integrated proviral sequences will also be copied into each daughter cell along with the cellular DNA. In the absence of the essential tat (and rev) protein(s), however, the proviral sequences cannot produce virus particles.

4. These replication-impaired HIV-1 derivatives are non-pathogenic.

5. They cannot make people ill.

6. In the presence of tat (and rev) protein(s), provided either by expression vectors or by naturally infecting HIV-1 viruses, the inert provirus can be re-activated; the provirus can be transcribed into mRNA and translated into proteins with the exception of tat and, in some cases, vpr and rev.

7. The expressed antisense tat RNA can bind and inactivate the natural sense tat mRNA, consequently inactivating the natural viruses.

#### C. Antisense-Ribozyme HIV-1 Molecular Clones (pXE-ar, pXE-br)

1. Contain intact LTRs, gag, pol, env, vif, vpr, vpu genes. A portion containing tat-1 is inverted and one or more ribozyme catalytic domains have been inserted in such portion. The rev gene is either intact (pXE-ar) or inactivated (pXE-br).

2. Replication impaired, but can be complemented by transactivation factor, tat (and rev for pXE-br). In the existence of tat (and rev) protein to provide necessary regulation, replication capability are restored, though may not necessarily be complete. Virus particles can be formed which are otherwise normal except carrying inverted tat-1 sequence and one or more ribozyme catalytic domains (with mutated rev initiation codon in pXE-br).

3. The assembled virions are infectious in that they can bind to CD4 molecules, can be taken up by CD4(+) cells, be reverse-transcribed into double-stranded DNA, be transported to the cell nucleus, and be integrated into the cellular genomes. In the event that the cells are activated and dividing, the integrated proviral sequences will also be copied into each daughter cell. In the absence of the essential tat (and rev) protein(s), however, the proviral sequences cannot produce the virus particles.

4. Non-pathogenic.
5. They cannot make people ill.
6. In the presence of tat (and rev) protein(s), provided either by expression vectors or by naturally infecting HIV-1 viruses, the inert provirus can be re-activated; the provirus can be transcribed into mRNA and translated into proteins with the exception of tat and, in some cases, vpr and rev.
7. The expressed antisense tat RNA can bind and inactivate the natural sense tat mRNA. Moreover, the tat mRNA is cut into pieces by the incorporated ribozymes. Consequently the natural viruses is eliminated.

#### Antisense/Ribozyme Clone Functionality Tests

1. The natural HIV-1 clone, pX or pXE, when transfected alone, produces viruses which replicate rapidly as indicated by RT (reverse transcriptase) activity, viral protein detection, syncytium formation, and cell killing - positive control.
2. The antisense/ribozyme recombinant clone(s), when transfected alone, do not produce virus, as indicated by background RT activity, no syncytium formation, normal cell growth.
3. An antisense/ribozyme clone produces viruses if co-transfected with a positive TAT-expression clone, or if transfected into cells constitutively expressing TAT protein, as indicated by raised RT activity, viral protein detection, possible syncytium formation, possible cell killing.
4. Supernatant from cultures co-transfected with an antisense/ribozyme clone and a TAT-expressing clone contains virus particles (EM visible, RT activity, p24 ELISA, etc.).

5. Virus particles contained in the co-transfected supernatant can be taken up by CD4(+) cells.

If the cells contain TAT, new viruses are produced as indicated by RT, p24, and cytopathogenesis.

If the cells do not contain TAT, they will grow normally, even though the antisense/ribozyme proviral sequences might have integrated into the cellular DNA.

6. An antisense/ribozyme recombinant clone co-transfected with a natural clone results in a period of time during which both clones are replicating as indicated by a considerable rise of RT activity, viral protein detection, syncytium formation, even cell killing. After that period of time, however, RT drops gradually, syncytia disappear, and cells grow normally.

7. If both supernatants from natural clone-transfected culture and antisense/ribozyme recombinant clone-transfected culture is used to infect normal CD4+ cells, infection occurs and production of virus occurs briefly, then the cells gradually return to normal with the viruses eliminated.

8. Virus particles can be purified from cell cultures co-transfected with a antisense/ribozyme proviral clone and a TAT-expression clone.

9. Introduction of purified antisense/ribozyme viruses into cell cultures producing natural viruses results in gradual decrease and eventual cessation of natural virus as well as antisense/ribozyme virus production.

10. When purified antisense/ribozyme virus particles are administered to patients infected with HIV-1, virus production decreases

gradually and eventually ceases.

#### Individualization of Antisense/Ribozyme Viruses

Individualization of an antisense/ribozyme virus is achieved with an individualized antisense/ribozyme proviral clone. An individualized antisense/ribozyme proviral clone is constructed by replacing a selected section of a gene of an existing functional proviral clone with an individualized antisense/ribozyme fragment. This individualized antisense/ribozyme fragment is synthesized in a single PCR reaction, using as the template the nucleic acid specimen from a particular patient which contains integrated or unintegrated viral sequences. The antisense/ribozyme primers are the same as detailed above. The PCR products are used to replace the corresponding section of a gene in the existing proviral molecular clone. The resultant recombinant clone has an individualized antisense/ribozyme fragment which, when expressed into RNA forms a perfect duplex with (and in the case of an antisense ribozyme virus - cleaves the mRNA of) the particular virus strain infecting the particular patient. With individualization of antisense/ribozyme virus, it is only necessary to individualize the antisense/ribozyme fragment. The other components of the viral genome are those of any existing functional virus clone available.

Individualization for treatment is a distinct advantage of the subject invention. Mutation permits the AIDS virus to escape and finally destroy the human immune system. Individualization of antisense/ribozyme viruses is an effective way to neutralize the mutating AIDS viruses.

The individualization method discussed are applicable to HIV-1, HIV-2 and SIV viruses as well as other viruses (as discussed above).

### Complemental Gene Expression Vectors

The antisense/ribozyme molecular clones, as mentioned above, cannot replicate on their own. In the case of HIV, when the antisense/ribozyme clones are transfected into cells, the cells do not make viruses because the clones are missing the tat (and rev) gene function(s). For the cells to be able to make viruses, the cells must provide tat (and rev) gene protein(s) which are necessary for, but are not produced by, the antisense/ribozyme clones. Gene-expression molecular clones have therefore been designed to provide tat, optionally rev and vpr, functions which are missing from the antisense/ribozyme clones because of sequence inversion. pX and pNL are used for the construction of gene-expression clones.

One of three following methods is employed.

The first method is to truncate major genes of HIV-1 except tat, rev and vpr (which overlap with each other). In practice the coding region for env is also kept intact along with the long terminal repeats (LTRs). The truncated clone, when introduced into cells, expresses tat and rev which trans-activate the antisense/ribozyme clones. Env and vpr proteins also are expressed which can help the antisense/ribozyme virus assembly.

The second method is to insert the tat (and rev as well) coding sequences into gene expression vectors driven by promoters from sources other than HIV-1.

The third option is to insert chemically synthesized tat-coding DNA sequence into one of the many gene expression vectors commercially available. Many gene-expression vectors are commercially available for expressing a cloned gene in mammalian cells. Such gene-expression vectors are described in detail in at least two laboratory manuals (Sambrook J, Fritsch EF & Maniatis T. Molecular Cloning, a laboratory manual, second edition, Cold Spring Harbor Laboratory Press, 1989, chapter 16; Kriegler M. Gene transfer and expression, a laboratory



manual, Stockton press, 1990, chapter 2). The choice of a vector is based on the gene to be expressed and the host cells in which the gene will be expressed. For expressing HIV-1 TAT (and REV) proteins in CD4+ cell lines of human origin, for example, a retrovirus long terminal repeat (LTR)-driven gene-expression vector can be used (Rosen CA et al. 1986. J Virol 57:379-384; Vickers T et al. 1991. Nucleic Acids Res 19:3359-68; Rhodes A & James W. 1991. AIDS 5:145-51). An advantage of using HIV-1 LTR-driven gene-expression vectors to express HIV-1 TAT protein (Guyader M et al. 1987. Nature 326:662-9) is the reciprocal augmentation of the transcriptional activation and the gene-expression product. Other promoters which have been used to express HIV genes are SV40 regulatory sequences (Arya SK et al. 1985. Science 229:69-73; Dillon PJ et al. 1991. J Virol 65:4490-3), Drosophila hsp70 promoter (Schweinfest CW et al. 1988. Gene 71:207-10), SR-a (Mallon R et al. 1990. J Virol 64:6282-5).

For selecting only the expression-vector-containing cells, neomycin resistance gene expression cassettes are inserted into the expression vectors. With the inclusion of antibiotic G418 in the culture medium, only those cells transfected with Neo(r) gene (together with HIV-1 tat and other genes) survive, assuring that every cell in the culture has the capability to support the making of antisense/ribozyme viruses.

All principles and methodologies presented for constructing the gene expression vector clones apply to HIV-2, SIV and other viruses as well as to HIV-1. Examples of construction of these vectors are shown in the Examples 5-7 below.

#### Antisense/Ribozyme Virus Producer Cell Lines

Transfection of either an antisense/ribozyme proviral clone or a tat-expression vector alone into cells does not result in the production of antisense/ribozyme virus. It is necessary to introduce both the antisense/ribozyme proviral clone and the tat-expression vector into the same cell in order for the antisense/ribozyme virus particles to be

made. Practically, a tat-expression vector can be transfected into a cell line (Jurkat for example), selected by including G418 in the culture medium, tested for the production of tat and other proteins, then kept in cell culture or frozen for later transfection of the antisense/ribozyme proviral clones. It has been shown that the Jurkat cell line can be stably transfected with a plasmid that constitutively expresses antisense tat RNA even after eight months in cell cultures (KostR et al, Clin Res; 38(2):278A, 1990). It can be expected that the same cell line will also be able to be stably transfected with a plasmid that constitutively expresses sense tat RNA (mRNA) and protein.

Advantageously, the antisense/ribozyme virus producer cell lines for HIVs are CD4+ and of human origin. CD4 positivity ensures that, once the cell line has been engineered to constitutively express TAT (and/or other) protein, the antisense/ribozyme virions released from one cell will be capable of infecting other cells in the culture, enabling quick production of large quantities of antisense/ribozyme virus stocks. Human origin of the producer cell lines minimizes the possibility of provoking adverse immunoreactions by the antisense/ribozyme inocula. Advantageously, the above mentioned Jurkat, a CD4+ lymphoid cell line frequently utilized to express HIV-1 genes (Venkatesh LK et al. PNAS 87:8746-50, 1990; Maitra RK et al. Virology 182:522-33, 1991), will be a good choice as an antisense/ribozyme virus producer cell line. Other CD4+ lymphoid cell lines such as H9, HUT78, MT4, CEM, MOLT4, and monocyte/macrophage cell lines such as U937, THP-1, AND GCT, frequently used in HIV-1 transfection experiments (Aldovini A & Feinberg MB. 1990. Transfection of molecularly cloned HIV genomes. in Techniques in HIV Research, A. Aldovini & BC Walker, eds, Stockton Press, ppl47-175), are useful for HIV-1 antisense/ribozyme virus producer cell lines. Some adherent cell lines, that are normally not susceptible to infection yet capable of expressing HIV genes and producing virus upon transfection, are regularly employed in studies of HIV gene regulation (ibid). The HeLa cell lines, for example, either CD4-negative (Mallon R et al. J Virol. 64:6282-5, 1990) or better CD4-positive, HeLaCD4 and HeLaT4+ (Schroder HC et al. FASEB J 4:3124-30, 1990) can be used for HIV-1

antisense/ribozyme virus producer cell lines. The 293 human embryonic kidney cell line, which supports high levels of expression of HIV trans-activation (Jakobovits A et al. EMBO J 9:1165-70, 1990), is another good host cell line.

For producer antisense/ribozyme virions for other viruses, other cell lines are chosen according to considerations known to those skilled in the art.

Cell line transfected with one of the HIV-1 tat-expression vectors are cultured in medium supplemented with antibiotic G418, and the surviving cells are tested for the production of HIV-1 proteins.

pX-CSneo transfected cells express vpr, tat, rev, and env proteins; while pX-neo transfected cells express no viral proteins.

SFneo-t/r(+) transfected cells express tat protein, and possibly rev protein; while SFneo-t/r(-) or SFneo transfected cells produce no HIV-1 protein.

SFneo-tat(+) transfected cells express tat protein only; while SFneo-tat(-) or SFneo transfected cells produce no HIV-1 protein at all.

If TAT activity is detected (by CAT assay), the transfected cells are propagated. Part of the cells are frozen. Another part are passed through long-term culture to test the stability of TAT gene expression. Cells stably expressing TAT and other proteins are used as antisense/ribozyme virus producer cells and are transfected with HIV-1 antisense/ribozyme clones. The doubly transfected cells are assayed for the production of HIV-1 viruses (antisense/ribozyme viruses). P24 ELISA, RT activity and electronic microscopy are employed to detect the presence of the viruses.

If the cells are producing the viruses, the conditioned medium (containing virus particles), optionally concentrated, is used to infect

CD4(+) cells (H9, Molt-3, CEM, U937, etc.) and the production of progeny viruses is assayed.

When a cell line is transfected with an HIV-2 or SIV TAT-expression vector, it becomes an antisense/ribozyme virus producer cell line for HIV-2 or SIV.

#### Compositions of the Invention

Also comprehended by the invention are pharmaceutical compositions comprising therapeutically effective amounts of products of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in antiviral therapy. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Where a product of the subject invention is used as a prophylactic medicine, a therapeutically effective amount is that amount which prevents infection.

The compositions of the invention are liquids, gels, ointments, or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent adsorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc. or into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, spheroplasts, skin patches, or other known methods of releasing or packaging pharmaceuticals. Such compositions will influence

the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the antisense and/or antisense-ribozyme viruses. The choice of composition will depend on the physical and chemical properties of the antisense and/or antisense-ribozyme viruses. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitory factors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, topical (skin or mucosal) and oral.

The invention also comprises compositions including one or more additional antiviral factors such as 3'-azidodeoxythymidine (AZT) or deoxycytidine (ddC). The administration of antisense and/or antisense-ribozyme viruses with other antiviral agents, is temporally spaced or given together. The route of administration may be intravenous, intraperitoneal sub-cutaneous, intramuscular, topical, oral or nasal.

Antisense and/or antisense-ribozyme viruses of the invention may be "labelled" by association with a detectable marker substance (e.g., radiolabeled, enzyme labelled, or biotinylated).

The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.

#### THE EXAMPLES

##### Example 1: PCR STRATEGY FOR ANTISENSE CONSTRUCTION

A PCR strategy was developed to accomplish the sequence inversion (flip-over). For ease in understanding, the amino acid sequences encoded

by the DNA is not shown and the complementary DNA strand (negative strand, antisense strand, written in small characters) is shown for the DNA sequence of the tat gene to be inverted:

CAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCA  
gtcttaacccacagctgtatcgtcttatccgcaatgagctgtctcctctcgttctttacctcggg  
Sal -I

GTAATCCTAGACTAGAGCCCTCGAAGCATCCAGGAAGTCAGCCTAAACTGCTTGATACCAATTG  
catctaggatctgatctcgggaccttcgttaggtccttcagtcggattttgacgaacatgggtaac

CTATTGTAAGAAAGTGTTCCTTTCAATGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCT  
gataacatttttcacaacgaaagtaacggttcaaacaaagtattgttttcggaatccgtagagga

ATGGCAGGAAGAAGCGGA-3'  
taccgtccttcttcgcct-5'  
Eco-NI

A special design for the primers (antisense primers) is essential for the recombinant PCR strategy to be successful and convenient. Basically, each antisense primer comprises two parts which are separated in the natural DNA sequence: an annealing sequence corresponding to one end of the 171-bp fragment to be turned over and a 15-base tail from the other side immediately beyond the area to be inverted. The 5' antisense primer is to anneal to the negative strand at the beginning of the sequence to be inverted, but it has a 15-base tail whose sequence corresponds to the 15 bases right after the sequence to be inverted where the unique EcoNI site is located. On the other hand, the 3' antisense primer is to anneal to the positive strand at the end of the sequence to be inverted, but it has a 15-base tail whose sequence corresponds to the 15 bases right before the sequence to be inverted where the unique SalI site is located. In the primers shown below, capital letters represent sequence from positive (sense) strand and small letters are used for the negative (antisense) strand.

E c o - N I  
tcttcctgccatagg

CAGAATAGGCGTTACTCGACAGAG  
CAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCA  
gtcttaacccacagctgtatcgtcttatccgcaatgagctgtctcctctcgttctttacctcggg  
Sal -I

GTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAATTG  
catctaggatctgatctcgggaccttcgtaggtccttcagtcggattttgacgaacatggttaac

CTATTGTAAAAAGTGTTCCTTTTCATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCT  
gataacatttttcacaacgaaagtaacggttcaaacaaagtattgttttcgggaatccgtagagga  
gtattgttttcgggaatccgtaga  
GAT

o - N I  
ATGCCAGGAAGAAGCCGA-3'  
taccgtccttcttcgcct-5'

ACAGCTGTGGGT  
Sal -I

Primers for flip-over PCR are as follows. The numbering is of the natural proviral sequences.

Trev 5795, 5' antisense primer:

REV<---|  
EcoNI |  
TCT TCC TGC CAT AGG CAG AAT AGG CGT TAC TCG ACA GAG  
-----|----->  
TAILrev(5980-5966) Annealing sequence(5795-5818)

SEQ ID NO:1

TCTTCCTGCC ATAGGCAGAA TAGGCGTTAC TCGACAGAC

39

Tvpr 5965, 3' antisense primer:

5960 5952  
VPR<---| |  
Sal-I | S a u - I  
TGG GTG TCG ACA TAG AGA TGC CTA AGG CTT TTG TTA TG  
-----|----->  
TAILvpr(5780-5794) Annealing sequence(5965-5943)

TGGGTGTCGA CATAGAGATG CCTAAGGCTT TTGTTATG

The PCR procedure can be illustrated as follows.

+++++SSS+++++EEE+++++

-----sss-----eee-----

```

--eee+++++++>

```


**<-----SSS+++**

---eee+++++++>

++++++SSS+++++EEE+++++  
 -----sss-----eee-----  
 <-----SSS+++

-50-





```

+++++++SSS+++++++EEE+++++++
-----sss-----<-----SSS+++

    ---eee+++++++>+++++++sss---
    -----sss-----<-----SSS+++

    ---eee+++++++>+++++++sss---
    +++EEE-----<-----SSS+++

    ---eee+++++++>+++++++sss---
    -----SSS-----<-----SSS+++

    ---eee+++++++>+++++++EEE+++++++
    +++EEE-----<-----SSS+++

    ---eee+++++++>+++++++sss---
    +++EEE-----<-----SSS+++

    ---eee+++++++>+++++++EEE+++++++
    +++EEE-----<-----SSS+++

    ---eee+++++++>+++++++EEE+++++++
    -----SSS-----eee-----

```

```

| PCR
| 35 cycles
| The majority of the fragments
| will be
v

```

```

---eee+++++++>+++++++sss---
+++EEE-----<-----SSS+++

```

To align this fragment with the original strands in term of the restriction sites SalI and EcoNI, it will be necessary to turn the PCR fragment around.

Original strands:

```

+++++++SSS+++++++EEE+++++++
-----sss-----eee-----

```

PCR inverted fragment:

```

+++SSS----->-----EEE+++
---sss+++++++<+++++++eee---

```

The actual sequence of the PCR inverted fragment (antisense fragment):

5'-TGGGTGTCGACATAGagatgcctaaggcttttgttatgaaacaaacttggcaatgaaag  
 3'-acccacagctgtatcTCTACGGATTCCGAAACAATACTTTGTTTGAACCGTTACTTTC  
 Sal -I  
 caacactttttacaatagcaattggtacaagcagtttttaggctgacttcctggatgcttccaggg  
 GTTGTGAAAAATGTTATCGTTAACCATGTTTCGTCAAAATCCGACTGAAGGACCTACGAAGGTCCC  
 E c  
 ctctagtctaggatctactggctccatttcttgcctcctctgtcgcagtaacgcctattctgCCT  
 GAGATCAGATCCTAGATGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTCCGGATAAGACgga  
 o - N I  
 ATGGCAGGAAGA-3'  
 taccgtccttct-5'

## SEQ ID NO:3 (ANTISENSE FRAGMENT)

TGGGTGTCGA CATAGAGATG CCTAAGGCTT TTGTTATGAA ACAAACTTGG	50
CAATGAAAGC AACACTTTTT ACAATAGCAA TTGGTACAAG CAGTTTTAGG	100
CTGACTTCCT GGATGCTTCC AGGGCTCTAG TCTAGGATCT ACTGGCTCCA	150
TTTCTTGCTC TCCTCTGTG AGTAACGCCT ATTCTGCCTA TGCCAGGAAG A	201

Antisense molecular clones are made by "swapping" the original SalI-EcoNI fragment on pXE with the PCR-made SalI-EcoNI fragment.

## Original strands:

```

+++++++SSS+++++++EEEE+++++++
-----sss-----eee-----

```

## PCR inverted fragment:

```

+++SSS----->-----EEE+++
---SSS+++++++<+++++++eee---

```

| Restriction digestion  
 | with SalI & EcoNI  
 | simultaneously  
 v

```

+++++++S SS+++++++E EE+++++++
-----ss s-----ee e-----

```

```

+++S SS----->-----E EE+++
---ss g+++++<+++++ee e---
          |
          | Ligation with
          | T4 DNA ligase
          | (Note the bold-type fragments
          | will be ligated together.)
          |
          v
+++++++SSS----->-----EEE+++++
-----sss+++++<+++++eee-----

```

In the antisense proviral clone, the sequence between nt 5774 and 5986 will become as follows. Note in the flipped-over bold-type area the negative (antisense) strand has been linked to the original positive (sense) strand.

```

5774   HXB2VPR<--|
      |  \sa      |
CAGAAATGGGTGTCGACATAGagatgcctaaggcttttgttatgaacaaacttggcaatgaang
gtcttaaccacagctgtatcTCTACGGATTCCGAAAACAATACTTTGTTTGAACCGTTACTTTC
          Sal -I
caacactttttacaatagcaattggtacaagcagtttttaggctgacttcctggatgcttcagg
GTTCGAAAAATGTTATCGTTAACCATGTCGTCAAAATCCGACTGAAGGACCTACGAAGGTCCC

ctctagctctaggatctactggctccatttcttgcctctctctgtcgagtmacgcctattctgCCT
GAGATCAGATCCTAGATGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTGCGGATAAGACgga
                                     E c

|-->REV      5986
      |  \sa      |
ATGGCAGGAAGAAGCGGA-3'
taccgtccttcttcgcct-5'
o - N I

```

During transcription where the positive strand of the double-stranded DNA is transcribed into RNA, the above shown sequence will be transcribed into antisense RNA against natural tat mRNA.

```

CAGAAUUGGGUGUCGACAUAGAGAUGCCUAAGGCUUUUGUUAUGAAACAAACUUGCCAAUGAAAG
CAACACUUUUUACAAUAGCAAUUGGUACAAGCAGUUUUAGGCUGACUUCCUGGAUGCUUCCAGGG
CUCUAGUCUAGGAUCUACUGGCUCCAUUUCUUGCUCUCCUCUGUCGAGUAACGCCUAUUCUGCCU
AUGGCAGGAAGAAGCGGA-3'

```

The antisense RNA will bind complementarily to the natural (sense) tat mRNA and block the translation of tat mRNA into TAT protein.

```

CAGAAUUGGGUGUCGACAUAGAGAUGCCUAAGGCUUUUGUUAUGAAACAAACUUGGCAUUGAAAG
|||||
AGGCGAAGAAGGACGGUAUCCUCUACGGAUCCGAAACAAUACUUUGUUUGAACCGUACUUUC
CAACACUUUUUACAAUAGCAAUUGGUACAAGCAGUUUUAGGCUGACUUCUGGAUGCUUCCAGGG
|||||
GUUGUGAAAAAUGUUAUCGUUAACCAUGUUCGUCAAAAUCCGACUGAAGGACCUACGAAGGUCCC
CUCUAGUCUAGGAUCUACUGGCUCCAUUUUCUUGCUCUCCUCUGUGCGAGUAAAGCCUATUUCGCCU
|||||
GAGAUCAUAUCCUAGAUACCGAGGUAAAGAACGAGAGGAGACAGCUCAUUGCGGAUAAGACGAU
AUGGCAGGAAGAAGCCGA-3'
ACAGCUGUGGGUUAAGAC-5'

```

Upper Line: Antisense RNA sequence, written 5'-->3';  
 Lower line: Natural mRNA sequence, written 3'-->5'.

By binding together, the natural mRNA and the antisense RNA block each other from being translated into proteins, resulting in the depletion of tat protein, and subsequently all viral proteins, for the natural as well as the antisense HIV-1 viruses.

=====

For eliminating the rev gene at the same time, the rev initiation codon was changed into a non-initiation one:

	5962	5980
Original sequence	ATCTCCTATGGCAGGAAGA-3'	
EcoNI recognition	CCTNNNNNAGG	
Rev initiation codon	ATG	
Changed to	AGG	
Rev(-) sequence	ATCTCCTAGGGCAGGAAGA-3'	
New AvrII site	CCTAGG	

Primers for flip-over PCR are as follows. The numbering is of the natural sequences.

Trev(-) 5795 (name), 5' antisense primer

```

      REV<---|
      EcoNI  |
TCT TCC TGC CCT AGG CAG AAT AGG CGT TAC TCG ACA GAG
-----|----->
TAILrev-(5980-5966) Annealing sequence(5795-5818)

```

SEQ ID NO:4

TCTTCCTGCC CTAGGCAGAA TAGGCGTTAC TCGACAGAG

39

Tvpr 5965, 3'antisense primer, SEQ ID NO:2 as aforementioned.

```

                        5960 5952
                        |   |
      VPR<---|         S a u - I
      Sal-I  |         |
TGG GTG TCG ACA TAG AGA TGC CTA AGG CTT TTG TTA TG
-----|----->
TAILvpr(5780-5794) Annealing sequence(5965-5943)

```

The PCR procedure used was exactly the same as aforementioned. The actual sequence of the PCR inverted fragment (antisense fragment) using primers Trev(-) 5795 and Tvpr 5965 is as follows.

```

5'-TGGGTGTCGACATAGagatgcctaaggcttttgttatgaaacaaacttggcaatgaaag
3'-acccacagctgtatcTCTACGGATTCCGAAAACAATACTTGTGTTGAACCGTTACTTTC
      Sal -I
caacactttttacaatagcaattggtacaagcagtttttaggctgacttcctggatgcttccaggg
GTTGTGAAAAATGTTATCGTTAACCATGTTTCGTCAAAATCCGACTGAAGGACCTACGAAGGTCCC
                        E c
ctctagtctaggatctactggctccatttcttgcctctcctctgtcgagtaacgcctattctgCCT
GAGATCAGATCCTAGATGACCGAGGTAAAGAACGAGAGGACAGCTCATTGCCGATAAGACgga
o - N I
AGGGCAGGAAGA-3'
tcccgtccttct-5'

```

SEQ ID NO:5 [REV(-) ANTISENSE FRAGMENT]

TGGGTGTCGA CATAGAGATG CCTAAGCCTT TTGTTATGAA ACAAACCTTGG	50
CAATGAAAGC AACACTTTTT ACAATAGCAA TTGGTACAAG CAGTTTTAGG	100
CTGACTTCCT GGATGCTTCC AGGGCTCTAG TCTAGGATCT ACTGGCTCCA	150
TTTCTTGCTC TCCTCTGTCTG ACTAACGCCT ATTCTGCCTA GGGCAGGAAG A	201

Note that SEQ ID NO:5 is only a single base pair different from SEQ ID NO:3, i.e., the base at position 191 is a "T" in SEQ ID NO:3 but a "G"

in SEQ ID NO:5.

Rev(-) antisense molecular clones can be made by replacing the original Sall-EcoNI fragment on pXE with the Sall-EcoNI fragment on SEQ ID NO:5.

---

The flip-over PCR system consisted of:

pX, 1 µg/ml		2 µl
Reaction buffer, 10x		5 µl
Tris-HCl, pH8.3	500 mM	
KCl	500 mM	
MgCl <sub>2</sub>	20 mM	
Gelatine	0.05 %	
dNTP, 2.5 mM each		3 µl
Primer Tvpr 5965, 60 µg/ml		2 µl
Primer Trev 5795, 60 µg/ml		2 µl
(or Trev[-]5795)		
AmpliTag DNA polymerase, 5 u/µl		0.2 µl
(from Perkin Elmer Cetus)		
Double distilled water		35.8 µl
		-----
		50.0 µl

The samples, with proper controls, were run on a DNA Thermal Cycler (Perkin Elmer Cetus) for 35 cycles each consisting of 94°C for 20 seconds, 60°C for 20 seconds and 74°C for 30 seconds.

10 µl of each PCR product was run on agarose gel (NuSieve 3:1, FMC). The correct size of the PCR product is 201 base pairs, which was confirmed by agarose gel electrophoresis.

Each inverted PCR product (antisense fragment) was extracted with phenol-chloroform-isoamyl alcohol (25:24:1), precipitated with alcohol and resuspended in 20 µl of TE solution (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA). The purified PCR product was then mixed with plasmid DNA of pXE and digested with both restriction enzymes Sall and EcoNI:

Inverted PCR product, extracted	5 $\mu$ l
pXE, 500 $\mu$ g/ml	2 $\mu$ l
Reaction buffer, 10x	5 $\mu$ l
Tris-acetate, pH 7.9	20 mM
Magnesium acetate	10 mM
Potassium acetate	50 mM
DTT	1 mM
EcoNI, 15 u/ $\mu$ l, NEB	1 $\mu$ l
Sal I, 10 u/ $\mu$ l, NEB	1 $\mu$ l
Double distilled water	37 $\mu$ l
	-----
	50 $\mu$ l

Incubation was at 37°C for at least 3 hours.

Ten microliter of the digest was run on agarose gel to make sure that the digestion had been satisfactory. The digest was heat-inactivated at 65°C for 10 minutes and used directly for ligation:

Above digest, undiluted	4 $\mu$ l
Ligase reaction buffer, 5x	4 $\mu$ l
T4 DNA ligase, 1 u/ $\mu$ l, BRL	1 $\mu$ l
Double distilled water	11 $\mu$ l
	-----
	20 $\mu$ l

Incubation was at 15°C for at least 3 hours.

The PCR-derived SalI - EcoNI fragment, containing the inverted sequence and outnumbering the plasmid-derived SalI -EcoNI fragment, competitively inserted itself into the SalI and EcoNI sites of the plasmid molecule.

One microliter of the 10-fold dilution of the ligation was used to transform 20  $\mu$ l of competent HB101 E. Coli cells according to the instruction of the manufacturer (BRL). Briefly, 1  $\mu$ l of the diluted ligation was gently mixed with the cells in a 1.5 ml microcentrifuge tube. After placing in ice for 30 minutes, the cells were heat shocked at 42°C for 45 seconds then quickly returned to ice for two more minutes. 180  $\mu$ l of S.O.C. Solution (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 10 mM MgSO<sub>4</sub>, 20 mM glucose) was added and mixed, then the tube was incubated at 37°C with constant agitation for 1 hour. The cells were spread on LB agar plate supplemented with



ampicillin to the final concentration of 50 µg/ml. The plate was incubated at 37°C overnight. Colonies were picked into 2 ml LB medium supplemented with ampicillin (LBamp) in the final concentration of 50 µg/ml. The bacterial cultures were placed at 37°C shaker-incubator overnight.

The bacteria were harvested and miniplasmid DNA extracted according to Sambrook, Fritsch and Maniatis (Molecular Cloning, a laboratory manual, second edition, Cold Spring Harbor Laboratory Press, 1989) with minor modifications as necessary. Briefly, 1.5 ml of each overnight culture was pipetted into a microcentrifuge tube and spun in tabletop microcentrifuge for 1 minute. The pellet was completely dispersed in 100 µl of Solution I (50 mM glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0). After adding 200 µl of freshly prepared Solution II (0.2 N NaOH, 1% SDS), the tube was inverted several times to mix. 150 µl of cold Solution III (5 M potassium acetate 60 ml, glacial acetic acid 11.5 ml, H<sub>2</sub>O 28.5 ml) was added and the tube vortexed briefly. The tube was then microcentrifuged for 2 minutes, the supernatant transferred to a new tube and extracted once with phenol:chloroform:isoamylalcohol (25:24:1). Plasmid DNA was precipitated with 1 ml of 100% ethanol, washed once with 75% ethanol, air-dried and resuspended in 30 µl of TE solution (10 mM Tris-HCl pH 7.5, 1 mM EDTA).


#### Example 2: SCREENING FOR ANTISENSE MOLECULAR CLONES

Miniplasmids were screened for the antisense molecular clones primarily by restriction endonuclease digestion followed by agarose gel electrophoreses. The clone constructed with Trev(+) primer was named pXE-a, and the clone constructed with Trev(-) primer was named pXE-b.

Comparing the original with the antisense proviral molecular clones, the Sau-I (Bsu36I) restriction enzyme site at the original position 5954 has been moved to position 5800 in the antisense clone. The different positions of this Sau-I site in the natural versus antisense clone is employed for easy screening for the antisense clones.

AS= Antisense    B = BamHI    C = ClaI    E = EcoNI  
 N = NdeI        R = EcoRI    S = SalI    X = XhoI

Original proviral clone, pXE:




Fragment sizes:	/ (3702) \	1360 \	1695 \
SauI positions:	(2252)	5954	7314    9009

Fragment sizes:	/ 3420 \	230 \	2339 \
AvrII positions:	2010	5430	5660    7999


Antisense proviral clone, pXE-a:



Fragment sizes: / (3548) \ 1514 \ 1695 \  
 SauI positions: (2252) 5800 7314 9009

Fragment sizes: / 3420 \ 230 \ 2339 \  
 AvrII positions: 2010 5430 5660 7999

Antisense proviral clone, pXE-b:



Fragment sizes:           /(3548) \ 1514 \ 1695 \  
 SauI positions:       (2252)   5800   7314   9009

Fragment sizes:           / 3420 \ 230 \ 306 \ 2033 \  
 AvrII positions:       2010   5430   5660   5966   7999

**Restriction Digestion Patterns of Molecular HIV-1  
 (HXB2) Full-Length Clones and Major Subclones.**

If the exact size of a particular fragment (band) is known, it is indicated by the exact number in bp (base pairs); If the exact size is not known, the estimated size is indicated by kb (kilobase). Bold-type are major clones or bands of interest for the particular restriction enzyme digestion.

X = pX                   E = pXE                   Ea = pXE-a           Eb = pXE-b  
 Ear = pXE-ar       Ebr = pXE-br       N = pX-N       NE = pX-N-E  
 E2 = pX-E2       E = pXE       XCS = pX-CS

**Bsu36I (SauI)**

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
13.0kb	-	-	-	-	-	-	-	-	-	-	-
8.5kb	-	-	-	-	-	-	-	-	-	-	-
1695bp	-	-	-	-	-	-	-	-	-	-	-
1514bp	-	-	-	-	-*	-*	-	-	-	-	-
1360bp	-	-	-	-	-	-	-	-	-	-	-
0.7kb	-	-	-	-	-	-	-	-	-	-	-

\* This band is 21 base pairs larger than 1514 in pXE-ar and pXE-br because of the inclusion of the ribozyme catalytic sequence.

Bsu36I (SauI) is an excellent choice for distinguishing antisense/ribozyme proviral clones from the wild type clones (either pX or pXE). The 1360-base-pair wild type band changes to 1514 base pairs in antisense clones and to 1535 in antisense-monori-bozyme clones. For the antisense-bi- and tri-ribozyme clones (not listed in the chart), this band will become 1556 (1514 + 21x2) and 1577 base pairs (1514 + 21 x 3). When samples are run side by side, the distinction between wild type clones and antisense/ribozyme clones is unmistakably obvious.

Note: The restriction sites are cited from GeneBank. The *SauI* site at nt 2252 is missing in pX as is in pXE. Missing with the site is the 3702-bp band.

Restriction digestion patterns of molecular HIV-1 (HXB2) full-length clones and major subclones.

#### AvrII

	X	E	Ea	Eb	Ea	Ebr	N	NE	E2	E	XCS
3420bp	-	-	-	-	-	-	?	?	-	-	?
2339bp	-	-	-		-		?	?	-	-	?
2033bp				-		-					
306bp				-		-					
230bp	-	-	-	-	-	-	?	?	-	-	-

These restriction site reorganizations were confirmed by individual or combined enzyme digestion followed by agarose gel electrophoreses.

Armed with 171-base antisense RNA targeted to the essential *tat* gene of HIV-1 while still carrying all information of HIV-1, the antisense proviral clones pXE-a and pXE-b will make artificial antisense viruses which will neutralize the natural HIV-1 viruses.

#### Open Reading Frames in the Inverted Sequence

Analyzing the inverted 171 base pairs, two open reading frames (ORFs) were found with methionine initiation codon of 12 and 25 amino acids in length respectively. Global screening of PC/gene data bases has found no match, even allowing up to eight mismatches. The binding by natural mRNA blocks the formation of these putative proteins, just as it blocks the natural mRNA.

Open reading frames with methionine initiation codons:

5'-AGATGCCTAAGGCTTTTGTATGAAACAAACTTGGCAATGAAAG  
M K  
M P K A F V M K E T W Q \*  
CAACACTTTTACAATAGCAATTGGTACAAGCAGTTTATAGGCTGACTTCCTGGATGCTTCCAGG  
A T L F T I A I G T S S F R L T S W M L P G  
CTCTAGTCTAGGATCTACTGGCTCCATTTCCTGCTCTCCTCTGTCGAGTAACGCCTATTCTG-3'  
L \*

The tat coding region in relation to the antisense area is shown in the sequence below. Bold-type represents inverted sequence. Nucleotide sequence in small characters is extension sequence beyond the PCR product.

5'-TGGGTGTCGACATAG=AGATGCCTAAGGCTTTTGTATGAAACAAACTTGGCAATGAAAG  
TAT aa sequence: <--I--G--L--A--K--T--I--F--C--V--Q--C--H--F--  
M K  
"New protein" M P K A F V M K E T W Q \*  
"New protein" CAACACTTTTACAATAGCAATTGGTACAAGCAGTTTATAGGCTGACTTCCTGGATGCTTCCAGG  
C--C--K--K--C--Y--C--N--T--C--A--T--K--P--Q--S--G--P--H--K--W--P--  
A T L F T I A I G T S S F R L T S W M L P G  
CTCTAGTCTAGGATCTACTGGCTCCATTTCCTGCTCTCCTCTGTCGAGTAACGCCTATTCTG=CC  
-E--L--R--P--D--V--P--E--H  
L \*


TATGCCAGGAAGAagcggagacagcgacgaagagctcatcagaacagtcagactcatcaagcttc  
M A G R S G D S D E E L I R T V R L I K L  
|--->rev protein (unchanged)

∇sd  
tctatcaaagcagtaagtagtacatgt-3'  
L Y Q S S K \*

### Example 3: ANTISENSE-(MONO)RIBOZYME PROVIRAL CLONES

The 22-nucleotide-long catalytic domain was fixed into the antisense sequences to replace a "G", and thus was directed to cut the sense RNA at GUC which occurs once on tat mRNA:

CAGAAUUGGGUGUGGACAUAGAGAUGCCUAAGGCUUUUGUUAUGAAACAAACUUGCCAAUGAAAG  
|||||  
AGGCGAAGAAGGACCGUAUCCUCUACGGAUCCGAAACAAUACUUUGUUUGAACCGUUACUUUC



CAACACUUUUUACAADUAGCAAUUGGUACAAGCAGUUUUAGGCU ACUCCUGGAUGCUUCCAGGG  
 |||||  
 GUUGUGAAAAAUGUUAUCGUUAACCAUGUUCGUCAAAAUCCGACUGAAGGACCUACGAAGGUCCC  
 |||||  
 CUCUAGUCUAGGAUCUACUGGCUCCAUUCUUGCUCUCCUCUGUCCGAGUAAAGCCCUAUUCUGCCU  
 |||||  
 GAGAUCAUAUCCUAGAUGACCGAGGUAAAGAACGAGAGGAGACAGCUCAUUGCGGAUAAGACGAU  
 |||||  
 AUGGCAGGAAGAAGCGGA-3'  
 ACAGCUGUGGGUUAAGAC-5'

Upper Line: Antisense RNA sequence, written 5'-->3', with  
 one ribozyme catalytic domain incorporated.  
 Lower line: Natural mRNA sequence, written 3'-->5', with  
 all potential ribozyme cleavage sites  
 underlined.

The antisense RNA sequences with the incorporated ribozyme domain are written into DNA with complementary sequences added.

(5774)

CAGAATTGGGTGTCGACATAGAGATGCCCTAAGGCTTTTGTATGAACAAACTTGGCAATGAAAG  
 |||||  
 GTCTTAACCCACAGCTGTATCTCTACCGATTCCGAAAACAATACTTTGTTTGAACCGTTACTTTC  
 |||||  
 CAACACTTTTTTACAATAGCAATTGGTACAAGCAGTTTTAGGCTCTGATGAGGCCTGATGGCCGAA  
 |||||  
 GTTGTGAAAAATGTTATCGTTAACCATGTTTCGTCAAAATCCGAGACTACTCCGGACTACCGGCTT  
 |||||  
 ACTTCTGGATGCTTCCAGGGCTCTAGTCTAGGATCTACTGGCTCCATTTCTTGCTCTCTCTGT  
 |||||  
 TGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGATGACCGAGGTAAAGAACCAGACGAGACA  
 |||||

(5986)

CGAGTAACGCCCTATTCTGCCTATGGCAGGAAGAAGCGGA-3'  
 |||||  
 GCTCATTCGGGATAAGACGGATACCGTCCTTCTTCGCCT-5'

PCR technology was utilized to incorporate the ribozyme catalytic

domain. To accomplish this, three primers were designed which correspond to the positions shown below.

```

5774 |----- Tvpr 5965 ----->|
      | TGGGTGTCGACATAGAGATGCCTAAGGCTTTTGTATG
CAGAATTGGGTGTCGACATAGAGATGCCTAAGGCTTTTGTATGAAACAAACTTGGCAATGAAAG
|||||
GTCTTAACCCACAGCTGTATCTCTACGGATTCCGAAACAATACTTTGTTTGAACCGTTACTTTC

                                     |<---- Ribozyme ---->|
CAACACTTTTTTACAATAGCAATTTCGTACAAGCAGTTTTAGGCTCTGATGAGGCCTGATGGCCGAA
|||||
GTTGTGAAAAATGTTATCGTTAACCATGTTTCGTCAAAATCCGAGACTACTCCGGACTACCGGCTT
CATGTTTCGTCAAAATCCGAGACTACTCCGGACTACCGGCTT
|<----- Pribo 5859-RB-5897 ----

ACTTCCTGGATGCTTCCAGGGCTCTAGTCTAGGATCTACTGGCTCCATTTCCTTCTCTCTGT
|||||
TGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGATGACCGAGGTAAAGAACGAGAGGAGACA
TGAAGGACCTACGAAGGTC                                     GAGACA
-----|<-----

                                     (5986)
CGAGTAACGCCTATTCTGCCTATGGCAGGAAGAAGCGGA-3'
|||||
GCTCATTGCGGATAAGACGGATACCGTCCTTCTTCGCCT-5'
GCTCATTGCGGATAAGACGGATACCGTCCTTCT
-----Trev 5795 -----|

```

Primers "Tvpr 5695" and "Trev 5795" are actually SEQ ID NO:2 and SEQ ID NO:1 as aforementioned for antisense PCR. Therefore, only one more primer (Pribo) was needed to make the antisense-ribozyme proviral clone.

Pribo 5859-RB-5897, numbering is of the wild type sequences:

```

CTGGAAGCATCCAGGAAGTTTCGGCCATCAGGCCTCATCAGAGCCTAAACTGCTTGTAC
|          ||<---- Ribozyme ---->||
5859          5877          5879          5897

```

SEQ ID NO:6

```

CTGGAAGCAT CCAGGAAGTT TCGCCCATCA GGCCTCATCA GAGCCTAAAA      50
CTGCTTGTAC                                     60


```


The following graphs illustrate how the Pribo primer inserts the ribozyme sequence into the PCR products. All three primers were put into the PCR system, with Pribo at a concentration about one tenth the



concentration of either of the two end primers. pX was chosen as template. All full length clones, i.e., pXE, pXE2, pXE-a, pXE-b and pNL are all eligible for being templates and will result in the same PCR product, with the Pribo primer inserted its sequence into some of the amplified DNA fragments.

Original template sequence and primers:





PCR product without ribozyme sequence is 201 bps, while that containing ribozyme sequence would be 222 bps as follows.

Sal -I

5'-TCGGTGTTCGACATAGAGATGCCTAAGGCTTTTGTATGAAACAACTTGGCAATGAAAG  
3'-ACCCACAGCTGTATCTCTACGGATTCCGAAACAATACTTTGTTTGAACCGTTACTTTC

Stu -I

CAACACTTTTTACAATAGCAATTGGTACAAGCAGTTTTAGGCTCTGATGAGGCCTGATGGCCGAA  
GTTGTGAAAAATGTTATCGTTAACCATGTTTCGTCAAAATCCGAGACTACTCCGGACTACCGGCTT  
|<---- Ribozyme ---->|

ACTTCCTGGATGCTTCCAGGGCTCTAGTCTAGGATCTACTGGCTCCATTTCTTGCTCTCCTCTGT  
TGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGATGACCGAGGTAAAGAACCAGAGGAGACA

Eco - N I

CGAGTAACGCCCTATTCTGCCTATGGCAGGAAGA-3'  
GCTCATTGCGGATAAGACGGATACCGTCCTTCT-5'


SEQ ID NO:7  
 TGGGTGTCGA CATAGAGATG CCTAAGGCTT TTGTTATGAA ACAAACTTGG 50  
 CAATGAAAGC AACACTTTTT ACAATAGCAA TTGGTACAAG CAGTTTTAGG 100  
 CTCTGATGAG GCCTGATGGC CGAAACTTCC TGGATGCTTC CAGGGCTCTA 150  
 GTCTAGGATC TACTGGCTCC ATTCTTGCT CTCCTCTGTC GAGTAACGCC 200  
 TATTCTGCCT ATGGCAGGAA GA 222

Where primer Trev(-), SEQ ID NO:4, is used instead of primer Trev(+), SEQ ID NO:1, the fragment will be 1 bp different, i.e., nt 212 "T" will be a "G":


SEQ ID NO:8  
 TGGGTGTCGA CATAGAGATG CCTAAGGCTT TTGTTATGAA ACAAACTTGG 50  
 CAATGAAAGC AACACTTTTT ACAATAGCAA TTGGTACAAG CAGTTTTAGG 100  
 CTCTGATGAG GCCTGATGGC CGAAACTTCC TGGATGCTTC CAGGGCTCTA 150  
 GTCTAGGATC TACTGGCTCC ATTCTTGCT CTCCTCTGTC GAGTAACGCC 200  
 TATTCTGCCT AGGGCAGGAA GA 222

pXE together with "antisense-ribozyme PCR" product were digested with Sall and EcoNI simultaneously then self-ligated. The ligation was used to transform competent HB101 cells as detailed in the Examples. Miniplasmids were screened by digesting with StuI restriction enzyme (see below).

The genomic organization of the rev(+) antisense-(mono)ribozyme clone, pXE-ar(2):



And the genomic organization of the rev(-) antisense-(mono)ribozym clone, pKE-br(2):



#### ANTISENSE-(MONO-, BI- or TRI-)RIBOZYME HIV-1 PROVIRAL CLONES

To guarantee at least one cleavage would occur to the sense tat mRNA even when there are mutations, multiple ribozymes targeted to different areas were arranged into the antisense sequences. Besides the "GUC" chosen, as mentioned above, two "GUA" triplets also were chosen as ribozyme targets. Potentially, four "GUU" and another "GUA" can also be chosen as targets if desired. The three sites chosen with their incorporated 22-base ribozyme catalytic domains are as follows. At the site of incorporation, the ribozyme sequence replaces a "G", or "U" of the antisense RNA.

```

CAGAAUUGGGUGUCGACAUAGAGAUGCCUAAGCCUUUUGUUAUGAAACAAACUUGGCAAUGAAAG
|||||
AGGCGAAGAAGGACGGUAUCCUCUACGGAUUCCGAAAACAAUACUUGUUGAACCUGUACUUUC

```

```

      G A      U
      U      GGCC G
A (1) CCGG A
      G      G      U
      U      A
      C A

```

```

      G A      U
      U      GGCC G
A (2) CCGG A
      G      G      U
      U      A
      C A

```

```

CAACACUUUU ACAAUAGCAAUUGGUACAAGCAGUUUUAGGCU ACUCCUGGAUGCUUCCAGGG
|||||
GUUGUGAAAAAUGUUAUCGUUAACCAUGUUCUGUAAAAUCCGACUGAAGGACCUACGAAGGUCCC

```

```

      G A      U
    U   GCCC   G
  A (3) CCGG   A
    G       U
      U   A
        C A
CUCUAGUCUAGGAUC ACUGCCUCCAUUUCUUGCUCUCCUCUGUCGAGUAACGCCUAUUUCGCCU
|||||
GAGAUCAAGAUCCUAGAUGACCGAGGUAAGAAGACGAGAGACAGCUCAUUGCCGAUAAGACGAU
AUGGCAGGAAGAAGCGGA-3'
ACAGCUGUGGGUUAAGAC-5'

```

Upper Line: Antisense RNA sequence, written 5'-->3', with 3 ribozyme catalytic domains incorporated.  
 Lower line: Natural mRNA sequence, written 3'-->5', with all potential ribozyme cleavage sites underlined.

Below, the antisense strand is written into DNA with complementary sequences. Note the ribozyme sequences. The first base pair corresponds to the wild type nt 5774 and the last 5986.

5774  
 | Sal -I  
 CAGAATTGGGTGTCCACATAGAGATGCCCTAAGGCTTTTGTATGAAACAACTTGGCAATGAAAG  
 GICTTAACCCACAGCTGTATCTCTACGGATTCCGAAAACAATACTTTGTTTGAACCGTTACTTTC

Stu -I  
 CAACACTTTTCTGATGAGGCCTGATGGCCGAAACAATAGCAATTGGTACAAGCAGTTTATGGCTC  
 GTTGTGAAAAGACTACTCCGGACTACCGGCTTTGTATCGTTAACCATGTTTCGTCAAAATCCGAG  
 |<--- Ribozyme 1 --->|

Stu -I BamH-I St  
 TGATGAGGCCTGATGGCCGAAACTTCCTGGATGCTTCCAGGGCTCTAGTCTAGGATCCTGATGAG  
 ACTACTCCGGACTACCGGCTTTGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGGACTACTC  
 <--- Ribozyme 2 --->| <--- Ri-

u -I E c o  
 GCCTGATGGCCGAAACTGGCTCCATTTCTTGCTCTCCTCTGTCTGAGTAACGCCTATTCTGCCTAT  
 CGGACTACCGGCTTTGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTCGGGATAAGACCGGATA  
 bozyme 3 --->|

(5986)  
 - N I  
 |  
 GCCAGGAAGAAGCGGA-3'  
 CCGTCCTTCTTCGCCT-5'

Primers needed to synthesize the DNA sequences are shown at the corresponding regions on the fragment to be made.

5774 0--->  
 | TGGGTGTCGACATAGAGATGCCTAAGGCTTTTGTATG CAATGAAAG  
 CAGAATTGGGTGTCGACATAGAGATGCCTAAGGCTTTTGTATGAAACAACTTGGCAATGAAAG  
 GTCTTAACCCACAGCTGTATCTCTACGGATTCCGAAACAATACTTTGTTTGAACCGTTACTTTC

1--->  
 CAACACTTTTCTGATGAGGCCTGATGGCCGAAACAATAGCAATTGGTACAA  
 CAACACTTTTCTGATGAGGCCTGATGGCCGAAACAATAGCAATTGGTACAAAGCAGTTTTAGCCTC  
 GTTGTGAAAAGACTACTCCGGACTACCGGCTTTGTTATCGTTAACCATGTTTCGTCAAAATCCGAG  
 CATGTTTCGTCAAAATCCGAG  
 <---2

AGGGCTCTAGTCTAGGATCCTGATGAG  
 TGATGAGGCCTGATGGCCGAAACTTCTCGGATGCTTCCAGGGCTCTAGTCTAGGATCCTGATGAG  
 ACTACTCCGGACTACCGGCTTTGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGGACTACTC  
 ACTACTCCGGACTACCGGCTTTGAAGGACCTACGAAGGTC

3--->  
 CCCTGATGGCCGAAACTGGCTCCATTTCTTGCT  
 GCCTGATGGCCGAAACTGGCTCCATTTCTTGCTCTCCTCTGTGCGAGTAACGCCTATTCTGCCTAT  
 CCGACTACCGGCTTTGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTGCGGATAAGACGGATA  
 GAGACAGCTCATTGCGGATAAGACGGATA  
 <---4

(5986)  
 |  
 GGCAGGAAGAAGCGGA-3'  
 CCGTCCTTCTTCGCCT-5'  
 CCGTCCTTCT

Primers needed to construct the above fragment are as follow (all written from 5' to 3', nucleotide position numbering is of wild type HXB2 sequences):

(0) Tvpr 5965

TGGGTGTCGACATAGAGATGCCTAAGGCTTTTGTATG  
 | ^ |  
 5780 5794 5965 5943

SEQ ID NO:2 as depicted previously.

## (1) Pribo 5930-RB-5892

```

CAATGAAAGCAACACTTTTCTGATGAGGCCTGATGGCCTAAACAATAGCAATTGGTACAA
|          ||<---- Ribozyme ---->||
5930          5912          5910          5892

```

SEQ ID NO:9

```

CAATGAAAGC AACACTTTTC TGATGAGGCC TGATGGCCTA AACAATAGCA      50
ATTGGTACAA                                           60

```

## (2) Pribo 5859-RB-5897

```

CTGGAAGCATCCAGGAAGTTTCGCCCATCAGGCCTCATCAGAGCCTAAACTGCTTGTA
|          ||<---- Ribozyme ---->||
5859          5877          5879          5897

```

SEQ ID NO:6 as depicted previously for antisense-(mono)ribozyme fragment pXE-ar(2) & pXE-br(2).

## (3) Pribo 5860-RB-5822

```

AGGGCTCTAGTCTAGGATCCTGATGAGGCCTGATGGCCGAAACTGGCTCCATTCTTGCT
|          ||<---- Ribozyme ---->||
5860          5842          5840          5822

```

SEQ ID NO:10

```

AGGGCTCTAG TCTAGGATCC TGATGAGGCC TGATGGCCGA AACTGGCTC      50
CATTCTTGCT                                           60

```

## (4) Trev 5795

```

TCTTCCTGCCATAGGCAGAAATAGGCGTTACTCGACAGAG
|          ^          |
5980          5966  5795          5818

```

SEQ ID NO:1 as depicted previously.

Ribozymes 1, 2 & 3, occurring alone[(1), (2), (3)] or in combinations [(1,2), (1,3), (2,3) (1,2,3)], were incorporated into the antisense sequence by a single PCR reaction.

PCR system for REV(+) antisense-mono-, bi- or tri-ribozyme fragments:

pX, 1 ug/ml									2 µl
Reaction buffer, 10x									5 µl
Tris-HCl, pH8.3	500 mM								
KCl	500 mM								
MgCl <sub>2</sub>	20 mM								
Gelatine	0.05 %								
dNTP, 2.5 mM each									3 µl
(0)Tvpr 5965, 60ug/ml									2 µl
(1)Pribo 5930-RB-5891, 6ug/ml									2 µl
(2)Pribo 5859-RB-5897, 6ug/ml									2 µl
(3)Pribo 5860-RB-5822, 6ug/ml									2 µl
(4)Trev(+) 5795, 60ug/ml									2 µl
Taq DNA polymerase, 5u/µl (from Perkin Elmer Cetus)									0.2 µl
Double distilled water to									29.8 µl
<hr/>									
Members of ribozymes incorporated	/	1	2	3	1,2	1,3	2,3	1,2,3	
Total ribozyme copy incorporated	0	1	1	1	2	2	2	3	
Size of PCR fragments (bp)	201	222	222	222	243	243	243	264	
<hr/>									

Thermal cycling was for 50 cycles, each consisting of 94 degree C for 20 seconds, 60 degree C for 30 seconds and 74 degree C for 30 seconds.

All three Pribo primers were present in the PCR system. Each Pribo primer, by chance, inserted its sequence (carrying one member of the ribozymes) into the PCR amplification product, which was a mixture of antisense-ribozyme fragments with 0, 1, 2 or 3 ribozyme domains incorporated in a random fashion.

The synthesized fragment, using primer Trev(+) 5795, SEQ ID NO:1, with all three members of ribozyme incorporated is 264-bp:



TCGGTGTCTGACATAGAGATGCCTAAGGCTTTTGTATGAAACAACTTGGCAATGAAAG  
 ACCCACAGCTGTATCTCTACGGATTCCGAAACAATACTTTGTTTGAACCGTTACTTTC

Stu -I

CAACACTTTTCTGATGAGGCTTGATGGCCGAAACAATAGCAATTGGTACAAGCAGTTTATAGGCTC  
 GTTGTGAAAAGACTACTCCGGACTACCGGCTTTGTTATCGTTAACCATGTTTCGTCAAAATCCGAG  
 |<--- Ribozyme 1 --->|

Stu -I

BamH-I St

TGATGAGGCTTGATGGCCGAAACTTCCTGGATGCTTCCAGGGCTCTAGTCTAGGATCCTGATGAG  
 ACTACTCCCGACTACCGGCTTTGAAGGACCTACGAAGGTCCCGAGATCAGATCCTAGGACTACTC  
 <--- Ribozyme 2 --->| |<--- Ri-

u -I E c o  
 GCCTGATGGCCGAAACTGGCTCCATTTCTTGCTCTCCTCTGTCTGAGTAACGCCTATTCTGCCTAT  
 CGGACTACCGGCTTTGACCGAGGTAAAGAACGAGAGGAGACAGCTCATTGCGGATAAGACGGATA  
 bozyme 3 --->|

N - I

GGCAGGAAGA  
 CCGTCCTTCT

SEQ ID NO:11

TCGGTGTCTGA CATAGAGATG CCTAAGGCTT TTGTTATGAA ACAAACCTTGG	50
CAATGAAAGC AACACTTTTC TGATGAGGCC TGATGGCCGA AACAATAGCA	100
ATTGGTACAA GCAGTTTTAG GCTCTGATGA GGCCTGATGG CCGAAACTTC	150
CTGGATGCTT CCAGGGCTCT AGTCTAGGAT CCTGATGAGG CCTGATGGCC	200
GAAACTGGCT CCATTTCTTG CTCTCCTCTG TCGAGTAACG CCTATTCTGC	250
CTATGGCAGG AAGA	264

Where primer Trev(-) 5795, SEQ ID NO:4, is used to replace primer Trev 5795, SEQ ID NO:1, in the above PCR system with everything else remaining the same, the fragment will be one base pair different, i.e., nt 254 "T" will be a "G".

## SEQ ID NO:12

TGGGTGTCGA CATAGAGATG CCTAAGCCTT TTGTTATGAA ACAAACCTGG	50
CAATGAAAGC AACACTTTTC TGATGAGGCC TGATGGCCGA AACAAATAGCA	100
ATTGGTACAA GCAGTTTTAG GCTCTGATGA GGCCTGATGG CCGAAACTTC	150
CTGGATGCTT CCAGGGCTCT AGTCTAGGAT CCTGATGAGG CCTGATGGCC	200
GAAACTGGCT CCATTTCTTG CTCTCCTCTG TCGAGTAACG CCTATTCTGC	250
CTAGGGCAGG AAGA	264


PCR fragments with any two ribozymes incorporated would be 243-bp long. Those with any one ribozyme would be 222-bp, and those without ribozyme would be 201-bp.

PCR products, together with plasmid pXE, were digested with SalI plus EcoNI then self-ligated. The ligations were used to transform competent HB101 cells as detailed earlier.

Alternatively, ribozyme domains are implanted one by one. Another alternative is to isolate the right DNA fragment after each PCR reaction, then use it as template for next round of PCR implantation/amplification.

Miniplasmids were screened by StuI digestion for various antisense-ribozyme clones. There are two StuI sites (nt 5404 and 6831) in the provirus sequences of the 3XB2, producing a fragment of 1427 bps with the area to be turned antisense lying in between. This StuI fragment remains the same in antisense clones pXE-a and pXE-b. Since every ribozyme catalytic domain contains one StuI site, the implantation of one, two or three ribozymes will, respectively, interrupt the StuI fragment into two, three or four bands whose exact sizes can be calculated as indicated in the following graphics, where

S = StuI site,  
R1 = Ribozyme 1,  
R2 = Ribozyme 2,  
R3 = Ribozyme 3.



Clones of pKE-br series are exactly the same as those of pKE-ar f r StuI digestion.

pK as well as pKE has two other StuI sites in the plasmid vector sequence. The internal proviral band (1427 bps) is the smallest. Moreover, the addition of the StuI sites in the ribozyme sequences results in even smaller bands. So the screening of the miniplasmids using StuI digestion proved to be handy and precise. Note the incorporation of one ribozyme has effectively inserted 21 bps into the sequence (plus 22-bp ribozyme, minus 1 bp the ribozyme replaced), causing the sum of base pairs with antisense-ribozyme clones to be larger than 1427.

**Restriction Digestion Patterns of Molecular HIV-1 (HXB2)  
Full-Length Clones and Major Subclones.**

If the exact size of a particular fragment (band) is known, it is indicated by exact number in bp (base pairs); If the exact size is not known, the estimated size will be indicated by kb (kilobase). Bold-type indicates major clones or bands of interest for the particular restriction enzyme digestion.

X = pX                      E = pXE                      Ea = pXE-a                      Eb = pXE-b  
 Ear = pXE-ar              Ebr = pXE-br              N = pX-N                      NE = pX-N-E  
 E2 = pX-E2                E = pXE                      XCS = pX-CS

**StuI**

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
7.8kb	-	-	-	-	-	-	?	?	-	-	?
4.3kb	-	-	-	-	-	-	?	?	-	-	?
3.5kb	-	-	-	-	-	-	?	?	-	-	?
1427bp	-	-	-	-					-	-	-
964bp						-	-				
484bp						-	-				

Note: The only antisense-ribozyme clones listed in all restriction digestion charts are pXE-ar(2) and pXE-br(2), shown as Ear and Ebr.

The "antisense-ribozyme HIV-1 proviral clones" pXE-ar series [constructed with Trev(+) primer] and pXE-br series [constructed with Trev(-) primer] are transfected into antisense/ribozyme virus producer cell line (see below). The virus particles produced (antisense-ribozyme viruses, ARV) are very powerful in inhibiting the replication of the natural HIV-1 viruses. In addition to the blockage activity as that of antisense viruses (ASV), the ARV also possess the ability to cleave the bound tat mRNA at 1 to 3 loci, rendering tat mRNA impossible to be translated into TAT protein.

**Example 4: PREPARATION OF HIV-1 PLASMID CLONE FOR ANTISENSE/  
RIBOZYME PROVIRUS CONSTRUCTIONS**

The construction of antisense/ribozyme HIV-1 proviral clones began with pX. pNL was employed for some special purposes.

Restriction site rearrangements became necessary after the area to be turned antisense was chosen and the restriction sites to be used were selected. Before the HIV-1 antisense/ribozyme proviral clones could be constructed with precision and convenience, it was necessary to obtain pXE. As discussed above, pXE contains a unique Sall site and a unique EcoNI site. The DNA sequence between these two unique sites can be replaced conveniently and precisely by antisense/ribozyme fragments, with the replacement products becoming antisense/ribozyme proviral clones.

Restriction mapping shows that there are three EcoNI sites in pX, yielding three bands of about 11.5, 3.8 and 1.7 kb respectively (see Figure 2). Since it was necessary that the EcoNI site at nt 5966 be unique for convenient and precise antisense/ribozyme clone construction, the other two EcoNI sites were removed from the plasmid. The product of having the other two EcoNI sites removed is pXE.

pX contains another EcoNI site at nt 7631 in the proviral sequence (the corresponding site is also present in pNL). The third EcoNI site in pX is about 1.8 kb beyond the 3'-LTR of the proviral sequences, most likely located in the cellular sequence flanking the provirus. The EcoNI site outside the proviral sequence can be deleted by any means without having to worry about any adverse effect. The nt7631 EcoNI site, however, must be removed in a way that preserves the gene in which it resides.

The plasmid preparation strategy, in order to obtain pXE, was to protect the nt 5966 EcoNI site by removing the NdeI fragment (nt 5121-6402 containing the 5966 EcoNI site) from pX. The resultant clone (pX-N) was then subjected to point-mutation of nt 7631 EcoNI by recombinant PCR, followed by DNA polymerase filling-in to erase the EcoNI site outside the HIV-1 sequence. The resultant EcoNI-free subclone, pX-N-E, was reinstalled with the 5121-6402 NdeI fragment. The reestablished full-length proviral clone with the unique EcoNI site at nt 5966, pXE, was used as wild type HIV-1 plasmid and as parental plasmid for constructing all antisense/ribozyme HIV-1 proviral clones.

Similar rearrangements for restriction endonuclease sites are also made to pSE (HIV-2), pK102 (SIV) and p239F (SIV) for the precision and convenience in constructing antisense/ribozyme proviral clones.

This Example explains in detail the steps taken in preparing pXE, the restriction-site-rearranged HIV-1 wild type plasmid clone which has been used directly for the construction of HIV-1 antisense/ribozyme proviral clones.

#### REMOVAL OF ECONI SITE AT NT 5966 FROM PX

(1) pX was digested with NdeI (CA|TATG) which occurs in HIV-1 sequence only at position 5121 and 6402, between which lies the HIV-1 EcoNI site at position 5966. Also in between is the unique Sall site at nt 5785.

pX, 500 ug/ml		5 µl
Reaction buffer, 10x		5 µl -
Tris-acetate, pH 7.9	20 mM	
Magnesium acetate	10 mM	
Potassium acetate	50 mM	
DTT	1 mM	
Nde I, 20 u/µl, NEB		1 µl
Double distilled water		39 µl
		-----
		50 µl

Incubation was in 37°C for 1 hours.

(2) Ten microliter of the digest was run on agarose gel to ensure that the digestion was satisfactory. NdeI cuts pX twice, yielding two bands of 1281 bp and 16 kb respectively. The digest was heat-inactivated at 65°C for 10 minutes and used directly for ligation:

Above digest, undiluted	4 µl
Ligase reaction buffer, 5x	4 µl
T4 DNA ligase, 1 u/µl, BRL	1 µl
Double distilled water	1 µl
	-----
	20 µl



(3) 20 µl of competent E. coli cell strain HB101 was transfected with 1 µl of 10-fold dilution of the ligation according to the instruction of the manufacturer (BRL) of the competent cells with minor modifications as necessary. After incubating the LBamp agar plate in 37°C overnight, single colonies were picked into 2 ml LB medium supplemented with ampicillin in the final concentration of 50 ug/ml (LBamp). The bacterial cultures were placed in 37°C shaker-incubator overnight.

(4) The bacteria were harvested and miniplasmid DNA extracted according to Sambrook, Fritsch and Maniatis (Molecular Cloning, a laboratory manual, second edition, Cold Spring Harbor Laboratory Press, 1989) with minor modifications as necessary.


(5) Miniplasmids were digested with BglII. pX was also digested and used as control.

Miniplasmid DNA,		3 µl
Reaction buffer, 10x		3 µl
Tris-HCl, pH 7.9	50 mM	
MgCl <sub>2</sub>	10 mM	
NaCl	100 mM	
Dithiothreitol	1 mM	
BglII, 8u/µl		0.2 µl
Double distilled water		23.8 µl
		-----
		30.0 µl

Incubation was at 37°C for at least 3 hours.

For a cleaner agarose gel picture, ribonuclease A (RNase A, Sigma Chemicals) is regularly included at a final concentration of 50 ug/ml in the restriction enzyme digestion system for miniplasmids to destroy the contaminating RNAs. The resultant pictures were much better than restriction digestion without the RNase addition.

Compared to pX parental clone, the subclone with NdeI fragment deleted, pX-N, has one of the Bgl-II fragment (between positions 2095 and 7040) reduced from 4945 bp to a smaller fragment of 3663 bp.



Restriction digestion patterns of molecular HIV-1 (HXB2) full-length clones and major subclones.

If the exact size of a particular fragment (band) is known, the exact number in bp (base pairs) is indicated; if the exact size is not known, the estimated size is indicated by kb (kilobase). Bold-type is used for major clones or bands of interest for the particular restriction enzyme digestion.

X = pX                    E = pXE                    Ea = pXE-a                    Eb = pXE-b  
 Ear = pXE-ar            Ebr = pXE-br            N = pX-N                    NE = pX-N-E  
 E2 = pX-E2              E = pXE                    XCS = pX-CS

#### BglIII

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
<b>4.9kb</b>	=	=	=	=	=	=	-	-	=	=	-
<b>3663bp</b>							-	-			
<b>3.0kb</b>	-	-	-	-	-	-	-	-	-	-	-
<b>1622bp</b>	-	-	-	-	-	-	-	-	-	-	<b>1430bp</b>
<b>580bp</b>	-	-	-	-	-	-	-	-	-	-	<b>-507bp</b>

Restriction enzyme HindIII is also used to screen HIV-1 plasmids.

**HindIII**

	<b>X</b>	<b>E</b>	<b>Ea</b>	<b>Eb</b>	<b>Ear</b>	<b>Ebr</b>	<b>N</b>	<b>NE</b>	<b>E2</b>	<b>E</b>	<b>XCS</b>
<b>5.1 kb</b>							-	-			
<b>4.3kb</b>	=	=	=	=	=	=	-	-	=	=	-
<b>3.0kb</b>	-	-	-	-	-	-	-	-	-	-	-
<b>2114bp</b>	-	-	-	-	-	-			-	-	-
<b>1475bp</b>	-	-	-	-	-	-	-	-	-	-	-
<b>1011bp</b>											-
<b>627bp</b>	-	-	-	-	-	-	-	-	-	-	<b>553bp</b>
-	-	-	-	-	-	-	-	-			

Note: BglII and HindIII are routinely used in the construction procedures for HIV-1 plasmid clones. The enzymes are used either to do the first screening of miniplasmids or to further check the correctness of general structure of all HIV-1 plasmid clones. These digestion patterns should be referred to where a BglII or HindIII digestion is discussed.

(6) The deletion subclone pX-N had only two EcoNI sites both of which were to be removed. One was at nt 7631 while the other was about 1.8 kb beyond 3'-LTR of the HIV-1 sequence, most likely within the flanking cellular sequence. Digestion of pX-N with EcoNI yielded only two bands, about 12.0 and 3.8 kb respectively.

Restriction digestion patterns of molecular HIV-1 (HXB2) full-length clones and major subclones.

If the exact size of a particular fragment (band) is known, the exact number in bp (base pairs) is indicated; if the exact size is not known, the estimated size is indicated by kb (kilobase). Bold-type is used for major clones or bands of interest for the particular restriction enzyme

digestion.

X = pX	E = pXE	Ea = pXE-a	Eb = pXE-b
Ear = pXE-ar	Ebr = pXE-br	N = pX-N	NE = pX-N-E
E2 = pX-E2	E = pXE	XCS = pX-CS	

#### EcoNI

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
17.0kb		-	-	-	-	-		*		-	
15.7kb											
15.3kb											
12.0kb							-				
11.5kb	-										
7.0kb											-
3.8kb	-						-				-
1665bp	-										-

Note: This digestion pattern should be referred to while reading the text, especially in this Example at an EcoNI digestion. This Example fully details manipulations taken to achieve a wild type HIV-1 plasmid clone with unique EcoNI site at proviral position nt 5966 (pXE). The purpose of constructing pXE is to facilitate the subsequent construction steps for antisense/ribozyme proviral clones. \* not cut by EcoNI

#### POINT-MUTATION OF ECONI SITE AT NT 7631 BY PCR

(7) To erase the EcoNI site at nt 7631, a point mutation was made to change the nt 7633 "T" to a "G", without altering the encoded envelope protein sequence, since the original codon CCT and the changed codon CCG both encode for the same amino acid proline. (orig nt = original nucleotides; orig pt = original protein; chge to = change to; same pt = same protein; B primer = Bridging primer)

Orig nt: GAG TCC GAG ATC TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC  
 Orig pt: E S E I F R P G C G D M R D

EcoNI: CCT NNN NNA GG

Chge to: GAG TCC GAG ATC TTC AGA CCG GGA GGA GGA GAT ATG AGG GAC  
 Same pt: E S E I F R P G G G D M R D

B primer: CC GAG ATC TTC AGA CCG GGA GGA GGA GAT ATG AGG G

EcoNI removed: CCG NNN NNA GG

The point-mutation and the EcoNI recognition site elimination were accomplished by a special PCR protocol of the subject invention, bridging PCR. Bridging PCR usually involves three (or more) primers instead of two in the traditional PCR system. For the elimination of the nt 7631 EcoNI site, the three primers used were as follows:

5'primer: EcoRI-down 4623

GGGCGGGAATCAAGCAGG  
 |-- 4623-4640 -->|

SEQ ID NO:13

GGGCGGGAAT CAAGCAGG

18

3'primer: HTX 8670

TTGAGAATTCTAACAGCACTATTCTTTAG  
 |----- 8670-8642 ----->|

SEQ ID NO:14

TTGAGAATTC TAACAGCACT ATTCTTTAG

29

Bridging primer: B 7633


CCGAGATCTTCAGACCGGGAGGAGGAGATATGAGGG  
 |----- 7617-7652 ----->|


SEQ ID NO:15


CCGAGATCTT CAGACCGGGA GGAGGAGATA TGAGGG

36

The sequential events of this Bridging PCR employed to introduce the point mutation into the sequence is illustrated as follows:









The bridging PCR reaction system consisted of:

pX-N, EcoNI digest, about 50 ng/ $\mu$ l	2 $\mu$ l
Reaction buffer, 10x	5 $\mu$ l
Tris-HCl, pH8.3	500 mM
KCl	500 mM
MgCl <sub>2</sub>	20 mM
Gelatine	0.05 %
dNTP, 2.5 mM each	3 $\mu$ l
5'primer, 4623-4640 60 ug/ml	2 $\mu$ l
3'primer, 8670-8642 60 ug/ml	2 $\mu$ l
"B"primer, 7617-7652 6 ug/ml	2 $\mu$ l
AmpliTag DNA polymerase, 5 u/ $\mu$ l (from Perkin Elmer Cetus)	0.2 $\mu$ l
Double distilled water	33.8 $\mu$ l
	-----
	50.0 $\mu$ l

The sample with proper controls was run on a DNA Thermal Cycler (Perkin Elmer Cetus) for 50 cycles each consisting of 94°C for 20 seconds, 50°C for 20 seconds and 74°C for 120 seconds. 10  $\mu$ l of the PCR product was run on agarose gel (NuSieve 3:1, FMC). The correct size of the PCR product should be 2766 base pairs, which was confirmed.

To establish whether the point mutation had been made, PCR products were digested with EcoNI. PCR product from reaction using undigested pX-N template, 5' and 3' (without bridging) primers, was cut into two bands of 1731 and 1035 bps. The bridging PCR product amplified with the system described above was not cut, indicating that the EcoNI site had been eliminated.

(8) The bridging PCR product was digested with EcoRI and BamHI simultaneously and the EcoRI-BamHI fragment of 2546 bp was used to replace the corresponding fragment of pX-N.

The bridging PCR product was extracted once with phenol-chloroform-isoamyl alcohol (25:24:1), mixed with plasmid DNA of pX-N and digested with both restriction enzymes EcoRI and BamHI:

"Bridging" PCR product, extracted	5 µl
pX-N, about 500 ug/ml	2 µl
Reaction buffer, 10x	5 µl
Tris-HCl, pH 8.0	20 mM
MgCl <sub>2</sub>	10 mM
NaCl	100 mM
EcoRI, 10 u/µl, BRL	1 µl
BamHI, 10 u/µl, BRL	1 µl
Double distilled water	36 µl
	-----
	50 µl

Incubation was at 37°C for at least 3 hours.

Ten µl of the digest was run on agarose gel to make sure that the digestion had been satisfactory. The digest was heat-inactivated at 65°C for 10 minutes and used directly for ligation:

Above digest, undiluted	4 µl
Ligase reaction buffer, 5x	4 µl
T4 DNA ligase, 1 u/µl, BRL	1 µl
Double distilled water	11 µl
	-----
	20 µl


Incubation was at 15°C for at least 3 hours.


One microliter of the 10-fold dilution of the ligation was used to transform 20 µl of competent HB101 cells. Colonies were picked and miniplasmids were extracted and digested by BglII as well as EcoNI. Successful recombinant clones (pX-N-E1) were cut only once by EcoNI instead of twice for pX-N; while the BglII digestion pattern of pX-N-E1 was the same as that for pX-N. In fact, pX-N-E1 had the same structure as pX-N except the nt 7633 "T" is changed to a "G". (see the restriction digestion patterns).

#### ELIMINATION OF OUTSIDE ECONI SITE BY POLYMERASE "FILL-IN"

(9) To abolish the remaining EcoNI site outside of the proviral sequence, pX-N-E1 (5 µg) was cut with EcoNI. The digest was purified by

PCI extraction, ethanol precipitation and was resuspended in 50  $\mu$ l of 1x TaqI DNA polymerase reaction buffer (diluted from 10x buffer of Perkin Elmer Cetus) with 50  $\mu$ M of each dNTP and 1.0 unit of TaqI DNA polymerase. The mixture was placed in 70°C for 1 minute ("fill-in" took place here) then subjected to PCI extraction (phenol-chloroform-isoamyl alcohol (25:24:1)). 4  $\mu$ l of the mixture was used for ligation in a 20  $\mu$ l system as in paragraph (8) above. One microliter of the 10-fold dilution of the ligation was used to transform 20  $\mu$ l of competent DM1 cells which are dam methylase negative (GIBCO BRL). Colonies were picked and miniplasmids were extracted and digested by HindIII as well as EcoNI. Successful recombinant clones (pX-N-E) were not cut by EcoNI, but showed the same HindIII digestion pattern as pX-N and pX-N-E1 (see the restriction digestion patterns). In fact, pX-N-E has the same structure as pX-N except the nt 7633 "T" is changed to "G" and the outside EcoNI is eliminated.





EcoNI cuts the sequence CCT(N)5AGG. When there are six (6) bases in between CTT and AGG, i.e., CCT(N)6AGG, EcoNI will not cut any more.

#### REINSTALLATION OF THE NDEI FRAGMENT


Because of the limited availability of convenient restriction sites, the re-installation of the NdeI fragment took two-steps: first to reconstruct full-length plasmid (pX-E2), then to mutate the EcoNI site at nt 7631 again.

(10) pX-N-E and parental pX (both prepared from transformed DM1 cells) were digested simultaneously with ClaI (nt 829) and BamHI (nt 8474). The digest mixture was self-ligated and used to transform competent HB101 E. Coli cells.

(11) Miniplasmids were screened by BglIII and HindIII digestion. Those with the same digestion patterns as pX would be the full-length clones.

(12) The full-length clones were further checked by digesting with

EcoNI, and the clone cut twice and yielding a band of 1665 bps was chosen and named as pXE-2. pXE-2 is the same wild type clone as pX but with the outside EcoNI site removed.



(13) Another bridging PCR, in order to mutate the EcoNI site at nt 7631 which had been reinstated into pXE-2.

pX, 1 ug/ml		1 µl
Reaction buffer, 10x		5 µl
Tris-HCl, pH8.3	500 mM	
KCl	500 mM	
MgCl <sub>2</sub>	20 mM	
Gelatine	0.05 %	
dNTP, 2.5 mM each		3 µl
5'primer, 5738-5761 60 ug/ml		2 µl
3'primer, 8670-8642 60 ug/ml		2 µl
"B"primer, 7617-7652 6 ug/ml		2 µl
AmpliTag DNA polymerase, 5 u/µl		0.2 µl
(from Perkin Elmer Cetus)		
Double distilled water		34.8 µl
		-----
		50.0 µl

Here only the 5'primer is new, the other two are SEQ ID NO:14 & 15.

5' primer: HTX 5738


ATAAGAATTCTGCAACAACTGCTG  
|----- 5738-5761 ----->|

SEQ ID NO:16


ATAAGAATTC TGCAACAACT GCTG

24


The samples were run on a DNA Thermal Cycler (Perkin Elmer Cetus) for 50 cycles each consisting of 94°C for 20 seconds, 60°C for 20 seconds and 74°C for three minutes. 10 µl of the PCR product was run on agarose gel (NuSieve 3:1, FMC). The correct size of the PCR product should be 2932 base pairs, which was confirmed.









It becomes clear that, even with an intact template, the bridging primer would be able to insert its sequence into some of the amplified fragments. To confirm the successful implantation of the "T --> G" (i.e., CCTNNNNNAGG --> CCGNNNNNAGG) point mutation at nt 7633, the PCR products were digested with EcoNI. Control with only 5' and 3' primers the whole fragment was 2932 bps. The product was cut into three bands of 232, 1665 and 1035 bps respectively.



For the PCR with three primers, the undigested product was a mixture containing two bands of 2932 and 1053 respectively. When cut with EcoNI, four bands appeared. Besides the 1665, 1053+1035, and 232 bp bands, another band appeared at 2.7 kb, due to considerable amount of the product carrying the point mutation at nt 7633 resulting in the elimination of EcoNI site at nt 7631.



The PCR product with 2.7 kb band was digested along with pXE-2 plasmid by restriction enzymes SalI and BamHI. The digest was self-ligated. The ligation was used to transform competent HB101 cells. Miniplasmids were screened with HindIII then with EcoNI. The clone with nt 7631 EcoNI site mutated, pXE, showed the same HindIII digestion pattern as that of pX or pXE-2, but was cut only once by EcoNI compared to twice for pXE-2 and three times for pX.



pXE was used later for constructing antisense molecular clones. pXE can also be used as wild type control just as pX.

(\*\*) The abolishment of the two extra EcoNI restriction sites can be done in an alternative way. The starting pX plasmid prepared from DM1 competent cells can be digested simultaneously or consecutively with both BclI (nt 2428) and BamHI (nt 8474) then self-ligated.

(Note: BclI and BamHI produce compatible cohesive ends that can be ligated to each other. But the ligation product cannot be recut by either enzyme. Compatible cohesive ends unable to be recut after ligation also occur between SalI and XhoI, see gene-expression vector construction below. BclI recognizes TGATCA and cuts between "T" and "G", but this sequence will not be cut by BclI when the middle "A" is methylated by Dam methylase. DM-1 E. coli cells are Dam methylase negative. DNA prepared from DM-1 cells are not methylated and therefore can be cut by BclI.)

The plasmid clone with BclI - BamHI fragment deleted ("pX-BB") has both proviral EcoNI sites removed. pX-BB can be cut with EcoNI, treated

with TaqI polymerase, self-ligated and used to transform DM1 competent cells. This results in the abolishment of the outside EcoNI site. This clone ("pX-BB-Eo") together with pX can be cleaved simultaneously with ClaI (nt 829, ClaI is also Dam methylation sensitive and demands DM-1 cell prepared DNA for effective cleavage) and XhoI (nt 8896), self-ligated, and used to transform competent cells. The full-length clone with only two proviral EcoNI sites (pX-E2) can be used for sequence swapping with "bridging PCR" product between SalI and BamHI as described in Step (13). The final clone with only one EcoNI site at nt 5966 is pXE.

#### CONSTRUCTION OF FULL-LENGTH ANTISENSE/RIBOZYME MOLECULAR CLONES

(14) PCR reactions were performed using pX or other appropriate plasmids as templates and Tvpr/Trev or/and other primers as depicted previously. The PCR product was checked by running 10 µl on agarose gel. The fragments were shown to be of expected sizes and/or of expected restriction digestion patterns.

(15) Each of the PCR products together with plasmid pXE were digested with SalI and EcoNI, simultaneously.

#### Restriction Digestion Patterns of Molecular HIV-1 (HXB2) Full-Length Clones and Major Subclones.

If the exact size of a particular fragment (band) is known, it is indicated by exact number in bp (base pairs); if the exact size is not known, the estimated size is indicated by kb (kilobase). Bold-type indicates major clones or bands of interest for the particular restriction enzyme digestion.

X = pX	E = pXE	Ea = pXE-a	Eb = pXE-b
E <sub>ar</sub> = pXE-ar	E <sub>br</sub> = pXE-br	N = pX-N	NE = pX-N-E
E <sub>2</sub> = pX-E <sub>2</sub>	E = pXE	XCS = pX-CS	

Sall + EcoNI

	X	E	Ea	Eb	E <sub>ar</sub>	E <sub>br</sub>	N	NE	E <sub>2</sub>	E	XCS
17.0kb		-	-	-	-	-				-	
15.7kb								-			
15.3kb									-		
12.0kb							-				
11.5kb	-										
7.0kb											-
3.8kb	-						-				-
1665bp	-								-		-
206bp					-	-					
185bp	-	-	-	-					-	-	-

Note: Though done in one tube, the construction of antisense/ribozyme proviral clones is actually done stepwise involving the simultaneous digestion of pXE with Sall and EcoNI, and the replacement of the Sall-EcoNI fragment (185 bps) by PCR-inverted antisense/ribozyme fragments (185 bps for pXE-a and pXE-b; 206 bps with one ribozyme incorporated, 227 with two, and 248 with three).

(16) The digestion mixture was self-ligated and used to transform competent HB101 E. Coli cells. Colonies were picked.

(17) Miniplasmids were screened for antisense/ribozyme clones by cutting with Bsu36I, choosing clones whose original 1360 bp band had been changed to 1514 bp or bigger. Digestions with other restriction enzymes have also been used to confirm the correctness of constructions. See previous digestion patterns.

**Restriction Digestion Patterns of Molecular HIV-1 (HXB2)  
Full-Length Clones and Major Subclones.**

If the exact size of a particular fragment (band) is known, it is indicated by the exact number in bp (base pairs); If the exact size is not known, the estimated size is indicated by kb (kilobase). Bold-type indicates major clones or bands of interest for the particular restriction enzyme digestion.

X = pX                      E = pXE                      Ea = pXE-a                      Eb = pXE-b  
Ear = pXE-ar              Ebr = pXE-br              N = pX-N                      NE = pX-N-E  
E2 = pX-E2                E = pXE                      XCS = pX-CS

**Bsu36I (SauI)**

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
13.0kb	-	-	-	-	-	-	-	-	-	-	-
8.5kb											
1695bp	-	-	-	-	-	-	-	-	-	-	-
1514bp	-	-	-	-	-*	-*					
1360bp	-	-									
0.7kb	-	-	-	-	-	-	-	-	-	-	-

\* This band is 1535 bps with one ribozyme incorporated.  
It will be 1556 with two, and 1577 with three.

(18) The antisense/ribozyme molecular constructions are confirmed by dideoxy sequencing of the inverted areas using primer HIV-1 5738-5761, i.e., SEQ ID NO:16.

5'-ATAAGAATTCTGCAACAACTGCTG-3'  
Eco-RI



(3) Primer HTX 835-5320 was used to couple with another primer, Rvpr 5794-5767, in the PCR reaction with pNL as the template.

Rvpr 5794-5767 CTATGTCGACACCCAATTCTGAAATGG

SEQ ID NO:18

CTATGTCGAC ACCCAATTCT GAAATGG

27

This is a negative-strand primer specially designed to restore the "perfect" vpr reading frame by deleting a "T" at 5770 of HXB2. Compare this primer with the original sequences in HXB2 and NL4-3:

HXB2 SEQ	5767	CCATTTTCAGAATTGGGTGTCGACATAG	5794	(positive)
		GGTAAAAGTCTTAACCCACAGCTGTATC		(negative)
Rvpr SEQ	5767	GGT-AAAGTCTTAACCCACAGCTGTATC	5794	(negative)
NL43 SEQ	5768	CCATTTTCAGAATTGGGTGTCGACATAG	5794	(positive)
		GGTAAAGTCTTAACCCACAGCTGTATC		(negative)

It becomes clear that primer Rvpr is actually made of sequences of pNL which preserve intact and functional vpr gene. As discussed previously, the vpr gene has been truncated and is functionless with HXB2, the plasmid clone of which, pX, has been used as parental structure for all the antisense/ribozyme proviral clones. Restoration of vpr function in the gene expression vector benefits the antisense/ribozyme viruses' ability to replicate by providing the antisense/ribozyme virus producer cell lines with the "weak transcriptional activator" (see Fig. 2). That is, the use of pNL sequence is to restore vpr function with the gene-expression vector. The inclusion of the ClaI restriction site is to facilitate the subsequent cloning of the gene-expression vector.



pNL, 1 ug/ml		1 $\mu$ l
Reaction buffer, 10x		5 $\mu$ l
Tris-HCl, pH 8.3	500 mM	
KCl	500 mM	
MgCl <sub>2</sub>	20 mM	
Gelatine	0.05 %	
dNTPs, 2.5 mM each		3 $\mu$ l
HTX 835-5320, 60 ug/ml		2 $\mu$ l
Rvpr 5794-5767, 60 ug/ml		2 $\mu$ l
AmpliTaq DNA polymerase, 5 u/ $\mu$ l		0.2 $\mu$ l
Double distilled water		36.8 $\mu$ l
		-----
		50.0 $\mu$ l

Fifty cycles of thermal cycling were done, each consisting of 94°C for 20 seconds, 50°C for 20 seconds and 74°C for 2 minutes.

The PCR product was 485 bps total. The main part of it was a 474-bp fragment from nt 5320 (pNL nt 5321) to nt 5794 (same for both clones). This 474-bp fragment is of NL4-3 origin, which is 1 bp shorter than and 26 bps different from the corresponding fragment of HXB2. The PCR product further included at its 5' end 11 bps of HXB2 origin (nt 825-835) where the unique Cla-I site is located. The following shows the actual sequences of the PCR product.

## SEQ ID NO:19


TTA GAT CGA TGATAGCACA CAAGTAGACC CTGACCTAGC AGACCAACTA	49
Leu Asp Arg	
ATTCATCTGC ACTATTTTGA TTGTTTTTCA GAATCTGCTA TAAGAAATAC	99
CATATTAGGA CGTATAGTTA GTCCTAGGTG TGAATATCAA GCAGGACATA	149
ACAAGGTAGG ATCTCTACAG TACTTGCCAC TAGCAGCATT AATAAAACCA	199
AAACAGATAA AGCCACCTTT GCCTAGTGTT AGGAAACTGA CAGAGGACAG	249
ATG GAA CAA GCC CCA GAA GAC CAA GGG CCA CAG AGG GAG CCA TAC	294
Met Glu Gln Ala Pro Glu Asp Gln Gly Pro Gln Arg Glu Pro Tyr	
5 10 15	
AAT GAA TGG ACA CTA GAG CTT TTA GAG GAA CTT AAG AGT GAA GCT	339
Asn Glu Trp Thr Leu Glu Leu Leu Glu Glu Leu Lys Ser Glu Ala	
20 25 30	
GTT AGA CAT TTT CCT AGG ATA TGG CTC CAT AAC TTA GGA CAA CAT	384
Val Arg His Phe Pro Arg Ile Trp Leu His Asn Leu Gly Gln His	
35 40 45	
ATC TAT GAA ACT TAC GGG GAT ACT TGG GCA GGA GTG GAA GCC ATA	429
Ile Tyr Glu Thr Tyr Gly Asp Thr Trp Ala Gly Val Glu Ala Ile	
50 55 60	
ATA AGA ATT CTG CAA CAA CTG CTG TTT ATC CAT TTC AGA ATT GGG	474
Ile Arg Ile Leu Gln Gln Leu Leu Phe Ile His Phe Arg Ile Gly	
65 70 75	
TGT CGA CAT AG	485
Cys Arg His Ser	
79	

The first coding region at the beginning of the fragment where only 3 amino acid residues are shown is the carboxyl terminus of the truncated GAG protein. The second coding region starting at nt 250 is VPR which continues beyond this fragment as shown in SEQ ID NO:20.


(4) The PCR product together with full-length pX (prepared from dam methylase negative DM-1 competent cells from GIBCO BRL) were cleaved with Cla-I and Sal-I simultaneously. The digest was religated with T4 DNA ligase and the ligation was used to transform HB101 as well as DM-1 cells. Miniplasmids were screened with restriction enzyme digestion,

looking for the clone where the natural *Cla*I - *Sal*I fragment (4955 bps) had been replaced by the PCR *Cla*I - *Sal*I fragment (470 bps). 4484 bps had been deleted. The miniplasmids were cut with *Bgl*II. The right deletion clone yielded a 2083 bp fragment while the two wild type fragments of 1622 bp (nt 473-2095) and 4945 bp (nt 2095-7040) disappeared. Mathematically, 6567 bp (nt 473-7040) minus 4484 bp (nt 836-5319) equals 2083 bp.


PCR made fragment (SEQ ID NO:19, with the portion truncated)



was used to replace the *Cla*I-*Sal*I fragment of the wild type pX,



and yielded the recombinant truncation clone pX-CS.



#### Restriction Digestion Patterns of Molecular HIV-1 (HXB2) Full-Length Clones and Major Subclones.

If the exact size of a particular fragment (band) is known, it will be indicated by exact number in bp (base pairs); If the exact size is not known, the estimated size will be indicated by kb (kilobase). Bold-type indicates major clones or bands of interest for the particular restriction enzyme digestion.

X = pX	E = pXE	Ea = pXE-a	Eb = pXE-b
Ear = pXE-ar	Ebr = pXE-br	N = pX-N	NE = pX-N-E
E2 = pX-E2	E = pXE	XCS = pX-CS	

**ClaI + SalI**

	X	E	Ea	Eb	Ear	Ebr	N	NE	E2	E	XCS
15.7kb	-	-	-	-	-	-	-	-	-	-	-
12.0kb	-	-	-	-	-	-	-	-	-	-	-
4955	-	-	-	-	-	-	-	-	-	-	-
470	-	-	-	-	-	-	-	-	-	-	-

Note: This enzyme combination was used to construct pX-CS (from which pX-CSneo and pXneo were constructed). Compare "X" and "XCS" where 4955 base pair band in "X" is reduced to 470 base pair band in "XCS".

The recombinant sequences from the beginning of gag to the end of vpr are as follows.

## SEQ ID NO:20

```

ATG GGT GCG AGA GCG TCA GTA TTA TGC GCG GGA GAA TTA GAT CGA      45
Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg
      5                      10                      15

TGATAGCACA CAAGTAGACC CTGACCTAGC AGACCAACTA ATTCATCTGC      95

ACTATTTTCA TTGTTTTTCA GAATCTGCTA TAAGAAATAC CATATTAGGA      145

CGTATAGTTA GTCCTAGGTG TGAATATCAA GCAGGACATA ACAAGGTAGG      195

ATCTCTACAG TACTTGGCAC TAGCAGCATT AATAAAACCA AAACAGATAA      245

AGCCACCTTT GCCTAGTGTT AGGAAACTGA CAGAGGACAG ATG GAA CAA GCC      297
Met Glu Gln Ala

CCA GAA GAC CAA GGG CCA CAG AGG GAG CCA TAC AAT GAA TGG ACA      342
Pro Glu Asp Gln Gly Pro Gln Arg Glu Pro Tyr Asn Glu Trp Thr
      5                      10                      15

CTA GAG CTT TTA GAG GAA CTT AAG AGT GAA GCT GTT AGA CAT TTT      387
Leu Glu Leu Leu Glu Glu Leu Lys Ser Glu Ala Val Arg His Phe
      20                      25                      30

CCT AGG ATA TGC CTC CAT AAC TTA GGA CAA CAT ATC TAT GAA ACT      432
Pro Arg Ile Trp Leu His Asn Leu Gly Gln His Ile Tyr Glu Thr
      35                      40                      45

TAC GGG GAT ACT TGG GCA GGA GTG GAA GCC ATA ATA AGA ATT CTG      477
Tyr Gly Asp Thr Trp Ala Gly Val Glu Ala Ile Ile Arg Ile Leu
      50                      55                      60

CAA CAA CTG CTG TTT ATC CAT TTC AGA ATT CGG TGT CGA CAT AGC      522
Gln Gln Leu Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser
      65                      70                      75

AGA ATA GGC GTT ACT CGA CAG AGG AGA GCA AGA AAT GGA GCC AGT      567
Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn Gly Ala Ser
      80                      85                      90

AGA TCC TAG      576
Arg Ser
      95

```

In this recombinant truncation clone, "pX-CS", the gag gene is truncated to 15 amino acids only; a "perfect" vpr gene has been reinstated (by replacing HXB2 vpr gene with NL4-3 vpr gene); while most of the gag gene, all of pol gene, and the 5' portion of the vif gene have

been deleted. Preserved are the major 5' splice donor site 742/743, splice junction sites 5388/5389, 5462/5463, 5776/5777, 5975/5976, 6044/6045, and 8377/8378. Tat, rev, vpr and env genes are intact. The nef open reading frame (orf) is also intact, but it is interrupted by the insertion of a neo(r) cassette into the unique XhoI site at nt 8896.

(5) The neomycin resistance cartridge from pMCIneoPolyA (Stratagene) is inserted into the XhoI site (8896) of pX-CS. The cartridge is 1146 bp long between XhoI (nt 451 of pMCIneoPolyA) and SalI (nt 1597 of pMCIneoPolyA), containing the neo(r) gene from Tn5, the Herpes Simplex thymidine kinase promoter and the enhancer sequence from polyoma virus Py F441. pX-CS was digested with XhoI, and pMCIneoPolyA was digested with XhoI and SalI. After killing the restriction enzymes' activities by heating the digests at 65°C for 15 minutes, the two digests were mixed together for ligation. SalI and XhoI produce compatible restriction ends capable of ligating to each other, the ligation product of which, however, cannot be cut by either enzyme.

(6) The ligation is then used to transform competent E. Coli HB101 cells. Single colonies were picked into LBamp medium.

(7) Recombinant miniplasmids are digested with BglII and XhoI simultaneously.

Clones without insertion have, among others, two bands of 1276 bp (BglII 7620 - XhoI 8896) and 154 bp (XhoI 8896 - BglII 9050). Note the GenBank BglII site 8085 is missing from pX.

Clones with insertions have either a 1276 bp band and a 1300 bp band ( $154 + 1146 = 1300$ , right orientation), or, a 2422 bp band ( $1276 + 1146 = 2422$ , wrong orientation) and a 154 bp band.

NO INSERTION.

1276 154

...|-----|-----|-----|-----|

BglII XhoI/XhoI BglII


<----- 1276 -----> <154>|

Insertion in right orientation. 1276 1146(insert) 154  
 ...|-----|=====|-----|...  
 BglII XhoI/XhoI SalI/XhoI BglII  
 <----- 1276-----> <----- 1300----->|

Insertion in wrong orientation:  
 1276 1146(insert) 154  
 ...- - - - -| <=====| - - - - -|  
 BglII XhoI/Sall XhoI/XhoI BglII  
 <----- 2422 ----->| <154>|

SallI/XhoI = SallI end ligated to XhoI end. The ligation product  
not be cut by either SallI or XhoI.


**The TAT-expression clone pX-CSneo**



The binding together of the neomycin resistance gene and the tat gene assures the entry of both genes into the cells at the same time, transforming the cells into neomycin resistance and tat expression simultaneously. By including antibiotic G418 in the cell culture medium, every surviving cell produces TAT protein, capable of supporting the production of the antisense/ribozyme viruses.

(9) As control, a tat(-) but neomycin(r)(+) clone is constructed from pX-CSneo. pX-CSneo is simultaneously digested with Sall (cut HIV1 nt 5785 only) and XhoI (cuts the ligation junction HIV1 nt 8896-Xho I and pMCneoPolyA nt 452-XhoI, but does not cut the ligation junction between pMCneoPolyA nt 1597-Sall and HIV1 nt 8897-XhoI, the latter junction is not be cut by Sall either). Religation of the fragments is used to transform competent E. Coli HB101. Miniplasmids are screened for the clone with Sall (5785) to XhoI (8896) fragment (3111 bp) deleted. This clone basically carries two HIV-1 LTRs with the neo(r) gene in between. It is named pX-neo.

The TAT-expression control clone pX-neo



**Example 6: CONSTRUCTION OF TAT-EXPRESSION CLONE USING NON-HIV1 VECTOR**

The aforementioned truncation tat-expression vectors employ identical promoter/enhancer systems with HIV-1 antisense/ribozyme



**The first exon:**

6044

The second exon:

```

      √sa
      ACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAG 8427
(TAT) P T S Q P R G D P T G P K E
(REV) N P P P N P E G T R Q A R R N R R
      Bam-HI
AGAAGGTGGAGAGAGACAGACAGATCCATTGATTAGTGAACCGATCCTGGCACT 8487
      R R W R E R Q R Q I H S I S E R I L G T
TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACT 8547
      Y L G R S A E P V P L Q L P P L E R L T
CTTGATTGTAAACGAGGATTGTGGAACCTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATA 8607
      L D C N E D C G T S G T Q G V G S P Q I
TTGGTGGAATCTCCTACAGTATTGGAGTCAGGAATAAAGAATACTGCTGTTAGCTTGCT 8667
      L V E S P T V L E S G T K E
CAATGCCACAGCC 8680

```

Note: The numbers given on right side of the sequences are the original position for the last base of that line. TAT and REV proteins are lined up with their coding nucleotide sequences. Also given are splice donor (sd) and splice acceptor (sa) sites, as well as some important restriction sites.

For easy demonstration of the procedures by which the two parts of the genes are linked together, the protein sequences are removed and the complementary DNA sequences are added.

Eco -I . . . . . Vsa . . . . . Sal -I . . . . .

ATAATAAGAAATTCGCAACAACCTGCTGTTTATCCATTTTCAGAATTGGGTGTCGACATAG 5794

TATTATTCTTAAAGACGTTGTTGACGTCAAATAGGTAAAAGTCTTAACCCACAGCTGTATC

CAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAG 5854

GTCTTATCCGCAATGAGCTGTCTCCTCTCGTTCCTTTACCTCGGTCATCTAGGATCTGATC

AGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACCTGCTTGTACCAATTGCTATTGTAAAA 5914

TCGGGACCTTCGTAGGTCCTTCAGTCGGATTTTGACGAACATGGTTAACGATAACATTTT

AGTGTGTCTTTCAATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCTATGGCA 5974

TCACAACGAAAGTAACGGTTCAAACAAAGTATTGTTTTCGGAATCCGTAGAGGATACCGT

Vsa . . . . . Sac -I . . . . . HindIII . . . . .

GGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTC 6034

CCTTCTTCGCTCTGTGCGCTGCTTCTCGAGTAGTCTTGTGTCAGTCTGAGTAGTTTCAAGAG

Vsd

TATCAAAGCA

ATAGTTTCGT

6044

Vsa  
 ACCCACCTCCCAACCCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGA 8427  
 TGGGTGGAGGGTTGGGGCTCCCTGGGCTGTCCGGGCTTCCTTATCTTCT  
 Bam-HI  
 AGAAGGTGGAGAGAGAGACAGAGACAGATCCATTTCGATTAGTGAACGGATCCTTGGCACT 8487  
 TCTTCCACCTCTCTCTGTGCGCTGTCTAGGTAAGCTAATCACITGCGCTAGGAACCGTGA  
 TATCTGGGACGATCTGCGGAGCCTGTGCCCTCTTCAGCTACCACCGCTTGAGAGACTTACT 8547  
 ATAGACCCTGCTAGACGCCTCGGACACGGAGAAGTCGATGGTGGCGAACTCTCTGAATGA  
 CTTGATTGTAACGAGGATTGTGGAACCTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATA 8607  
 GAACTAACATTGCTCCTAACACCTTGAAGACCTGCGTCCCCACCCCTTCGGGAGTTTAT  
 TTGGTGAATCTCCTACAGTATTGGAGTCAGGACTAAAGAATAGTGCTGTTAGCTTGCT 8667  
 AACCACCTTAGAGGATGTCATAACCTCAGTCCTTGATTTCTTATCACGACAATCGAACGA  
 CAATGCCACAGCC  
 GTTACGGTGTCCG 8680

-117-

of linking. A "bridging primer" can be either orientation, but amplification may be more efficient if it points to the shorter half of the linked fragment.

For linking together the two exons of tat and rev genes, the three primers are designed as follows.

5'-end primer: HTX 5738, i.e., SEQ ID NO:16

Eco RI  
ATAAGAATTCTGCAACAACCTGCTG  
|-----5738-5761----->|

"Bridging primer": HTX 6044-8378

Hind-III  
CAAGCTTCTCTATCAAAGCAACCCACCTCCCAACCCCGAG  
|----6025-6044----->----8378-8397----->|

SEQ ID NO:21

CAAGCTTCTC TATCAAAGCA ACCCACCTCC CAACCCCGAG

40

3'-end primer: HTX 8670, i.e., SEQ ID NO:14. The 3 bases underlined has been changed to accommodate an EcoRI site.

Eco-RI  
TTGAGAAATTCTAACAGCACTATTCTTTAG  
|-----8670-8642----->|

The primers, in bold-type letters, anneal to the sequences at positions:

Eco RI HTX 5738  
 ATAAGAATTCTGCAACA**ACTGCTG** . . . **∇sa** .Sal -I  
 ATAATAAGAATTCTGCAACA**ACTGCTG**TTTATCCATTTTCAGAATTGGGTGTCGACATAG 5794  
 TATTATTCTTAAGACGTTGTTGACGTCAAATAGGTAAAAGTCTTAACCCACAGCTGTATC

CAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAG 5854  
 GTCTTATCCGCAATGAGCTGTCTCCTCTCGTTCTTTACCTCGGTCATCTAGGATCTGATC

AGCCCTGGAAGCATCCAGGAAGTCAGCCTAA**AACTGCTTGTACCAATTGCTATTGTAAAA** 5914  
 TCGGGACCTTCGTAGGTCCTTCAGTCGGATTTTGACGAACATCGTTAACGATAACATTTT

AGTGTTCCTTTCATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCA 5974  
 TCACAACGAAAGTAACGGTTCAAACAAAGTATTGTTTTCGGAATCCGTAGAGGATACCGT

**∇sa** . . . Sac -I . . . HindIII  
 GGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTC 6034  
 CCTTCTTCGCCTCTGTGCTGCTTCTCGAGTAGTCTTGTCAGTCTGAGTAGTTCGAAGAG

TATCAAAGCA----- 6044  
 TATCAAAGCA  
 ATAGTTTCGT

HTX 6044-8378  
 -----ACCCACCTCCCAACCCCGAG  
 ACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGA 8427  
 TGGGTGGAGGGTTGGGGCTCCCTGGGCTGTCCGGGCTTCCTTATCTTCT

Bam-HI  
 AGAAGGTGGAGAGAGAGACAGAGACAGATCCATTGATTAGTGAACGGATCCTTGCCACT 8487  
 TCTTCCACCTCTCTCTCTGTGCTGTCTAGGTAAGCTAATCACTTGCCCTAGGAACCGTGA

TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCAACCGCTTGAGAGACTTACT 8547  
 ATAGACCTGCTAGACGCCTCGGACACGGAGAAGTCGATGGTGGCGAACTCTCTGAATGA

CTTGATTGTAACGAGGATTGTGGAACCTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATA 8607  
 GAACATAACATTGCTCCTAACACCTTGAAGACCCTGCGTCCCCACCCCTTCGGGAGTTTAT

TTGGTGGAAATCTCCTACAGTATTGGAGTCAGGAATAAAGAATAGTGCTGTTAGCTTGCT 8667  
 AACCACCTTAGAGGATGTCATAACCTCAGTCCTTGATTTCCTTATCAGGACAATCGAACGA  
 GATTTCCTTATCAGGACAATCTTAAGA


HTX 8670


CAATGCCACAGCC  
 GTTACGGTGTCCG  
 GTT

8680

The "bridging primer" (HTX 6044-8378, 40 mer) was composed of the sequence 6025-6044 (20 mer) and the sequence 8378-8397 (also 20mer), pointing down towards the 3'-end of HIV genome. Although the "bridging primer" also anneals to the negative strand at the positions of 6025-6044, only when it bound to the position 8378-8397 can the polymerization (elongation) be initiated. Therefore the "bridging primer" pairs with the 3'-end primer (8670-8642) to amplify the fragment from 8378 to 8670 plus 20 base pairs corresponding to the positions 6025-6044, totaling 312 base pairs in length. When there are more 3'-end primer than the "bridging primer", more negative strands (initiated by 3'-end primer) than positive ones (initiated by "bridging primer") are amplified. The negative strands would carry at their 3'-ends the complementary sequence to the "bridging primer." The very 3'-end of these single-stranded DNA would anneal to the positive strands at position 6025-6044 of the original templates or to the single-stranded DNA initiated by the 5'-end primer (5738-5761). As soon as the "bridging primer complementary sequence"-initiated DNA elongation reached the positions 5738-5761, the two fragments are physically linked together. From then on the amplification depends only on two primers annealing to either end of the linked fragment. The events are illustrated as follows:

"B" = "Bridging primer", HTX 6044-8378  
5' = 5'-end primer, HTX 5738  
3' = 3'-end primer, HTX 8670





"Bridging PCR" reaction system:

pX, 1 ug/ml		1 $\mu$ l
Reaction buffer, 10x		5 $\mu$ l
Tris-HCl, pH 8.3	500 mM	
KCl	500 mM	
MgCl <sub>2</sub>	20 mM	
Gelatine	0.05 %	
dNTP's, 2.5 mM each		3 $\mu$ l
5'-primer, HTX 5738-5761, 60 ug/ml		2 $\mu$ l
3'-primer, HTX 8670-8642, 60 ug/ml		2 $\mu$ l
"B"primer, HTX 6044-8378, 6 ug/ml		2 $\mu$ l
AmpliTag DNA polymerase, 5 u/ $\mu$ l		0.2 $\mu$ l
(from Perkin Elmer Cetus)		
Double distilled water		34.8 $\mu$ l
		-----
		50.0 $\mu$ l



The thermal cycling setting was 50 cycles, each consisting of 94°C for 20 seconds, 54°C for 20 seconds and 74°C for 60 seconds.

The amplified fragments would have the sequences 5738-6044 (307 bp) and 8378-8670 (293 bp) linked into one piece (600 bp) containing full-length tat and rev sequences in continuation.

```

      Eco -I                      . V/sa . Sal -I .
ATAAGAATTCTGCAACAACCTGCTGTTTATCCATTTTCAGAATTGGGTGTCGACATAG 5794
TATTCCTTAAGACGTTGTTGACGTCAAATAGGTAAAAGTCTTAACCCACAGCTGTATC

CAGAATAGCCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAG 5854
GTCTTATCCGCAATGAGCTGTCTCCTCTCGTTCCTTACCTCGGTCATCTAGGATCTGATC

AGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACCTGCTTGTACCAATTGCTATTGTAAAA 5914
TCGGGACCTTCGTAGGTCCCTTCAGTCGGATTTTGACGAACATGGTTAACGATAACATTTT

AGTGTGTGCTTTTCAATTGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCA 5974
TCACAACGAAAGTAACGGTTCAAACAAAGTATTGTTTTCGGAATCCGTAGAGGATACCGT

V/sa                      Sac -I                      . HindIII .
GGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTC 6034
CCTTCTTCGCCTCTGTGCTGCTTCTCGAGTAGTCTTGTGAGTCTGAGTAGTTCGAAGAG

6044 8378
sdV/sa
TATCAAAGCAACCCACCTCCCAACCCCGAGGGGACCCGACAGCCCCGAAGGAATAGAAGA 8427
ATAGTTTTCGTTGGGTGAGGGTTGGGGCTCCCTGGGCTGTCCGGGCTTCCTTATCTTCT

AGAAGGTGGAGAGAGAGACAGAGACAGATCCATTGATTAGTCAACGGATCCTTGGCACT 8487
TCTTCCACCTCTCTCTGTGCTGCTAGGTAAGCTAATCACTTGCCTAGGAACCGTGA

TATCTGGGACGATCTGCGGAGCCTGTGCTCTTTCAGCTACCACCGCTTGAGAGACTTACT 8547
ATAGACCCCTGCTAGACGCCTCGGACACGGAGAAGTCGATGGTGGCGAACTCTCTGAATGA

CTTGATTGTAACGAGGATTGTGGAACCTTCTGGGACGCACGGGGTGGGAAGCCCTCAAATA 8607
GAACTAACATTGCTCCTAACACCTTGAAGACCCTGCGTCCCCCACCCTTCGGGAGTTTAT

```

Eco-RI.

TTGGTGGAAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATACTGCTGTTAGAAATTCT 8667  
 AACCACCTTAGAGGATGTCATAACCTCAGTCCTTGATTTCCTTATCACGACAATCTTAAGA

CAA  
 GTT

8670

SEQ ID NO:22 (without coding information)

ATAAGAATTC TGCAACAACT GCTGTTTATC CATTTTCAGA ATTGGGTGTC	50
GACATAGCAG AATAGGCGTT ACTCGACAGA GGAGAGCAAG AAATGGAGCC	100
ACTAGATCCT AGACTAGAGC CCTGGAAGCA TCCAGGAAGT CAGCCTAAAA	150
CTGCTTGAC CAATTGCTAT TGTAAAAAGT GTTGCTTTCA TTGCCAAGTT	200
TGTTTCATAA CAAAAGCCTT AGGCATCTCC TATGGCAGGA AGAAGCGGAG	250
ACAGCGACGA AGAGCTCATC AGAACAGTCA GACTCATCAA GCTTCTCTAT	300
CAAAGCAACC CACCTCCCAA CCCCAGGGG ACCCGACAGG CCCGAAGGAA	350
TAGAAGAAGA AGGTGGAGAG AGAGACAGAG ACAGATCCAT TCGATTAGTG	400
AACGGATCCT TGGCACTTAT CTGGGACGAT CTGCGGAGCC TGTGCCTCTT	450
CAGCTACCAC CGCTTGAGAG ACTTACTCTT GATTGTAACG AGGATTGTGG	500
AACTTCTGGG ACGCAGGGGG TGGGAAGCCC TCAAATATTG GTGGAATCTC	550
CTACAGTATT GGAGTCAGGA ACTAAAGAAT AGTGCTGTTA GAATTCTCAA	600

SEQ ID NO:22 (with TAT protein sequence)

ATAAGAATTC TGCAACAAC TCTGTTTATC CATTTTCAGA ATTGGGTGTC	50
GACATAGCAG AATAGGCGTT ACTCGACAGA CGAGAGCAAG AA ATG GAG CCA	101
Met Glu Pro	
GTA GAT CCT AGA CTA GAG CCC TGG AAG CAT CCA GGA AGT CAG CCT	146
Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro	
5 10 15	
AAA ACT GCT TGT ACC AAT TGC TAT TGT AAA AAG TGT TGC TTT CAT	191
Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His	
20 25 30	
TGC CAA GTT TGT TTC ATA ACA AAA GCC TTA GGC ATC TCC TAT GGC	236
Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly	
35 40 45	
AGG AAG AAG CGG AGA CAG CGA CGA AGA GCT CAT CAG AAC AGT CAG	281
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln	
50 55 60	
ACT CAT CAA GCT TCT CTA TCA AAG CAA CCC ACC TCC CAA CCC CGA	326
Thr His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg	
65 70 75	
GGG GAC CCG ACA GGC CCG AAG GAA TAGAAGAAGA AGGTGGAGAG	370
Gly Asp Pro Thr Gly Pro Lys Glu	
80 85	
AGAGAGGAG ACAGATCCAT TCGATTAGTG AACGGATCCT TGGCACTTAT	420
CTGGGACGAT CTGCGGAGCC TGTGCCTCTT CAGCTACCAC CGCTTGAGAG	470
ACTTACTCTT GATTGTAACG AGGATTGTGG AACTTCTGGG ACGCAGGGGG	520
TGGGAAGCCC TCAAATATTG GTGGAATCTC CTACAGTATT GGAGTCAGGA	570
ACTAAGAAT AGTCCTGTTA GAATTCTCAA	600

SEQ ID NO:22 (with REV protein sequence)


ATAAGAATTC TGCAACAACCT GCTGTTTATC CATTTCAGCA ATTGGGTGTC	50
GACATAGCAG AATAGGCGTT ACTCGACAGA GGAGAGCAAG AAATGGAGCC	100
AGTAGATCCT AGACTAGAGC CCTGGAAGCA TCCAGGAACT CAGCCTAAAA	150
CTGCTTGAC CAATTGCTAT TGTAAGAACT GTTGCTTTCA TTGCCAAGTT	200
TGTTTCATAA CAAAAGCCTT AGGCATCTCC T ATG GCA GGA AGA AGC GGA	249
Met Ala Gly Arg Ser Gly	5
GAC AGC GAC GAA GAG CTC ATC AGA ACA GTC AGA CTC ATC AAG CTT	294
Asp Ser Asp Glu Glu Leu Ile Arg Thr Val Arg Leu Ile Lys Leu	10 15 20
CTC TAT CAA AGC AAC CCA CCT CCC AAC CCC GAG GGG ACC CGA CAG	339
Leu Tyr Gln Ser Asn Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln	25 30 35
GCC CGA AGG AAT AGA AGA AGA AGG TGG AGA GAG AGA CAG AGA CAG	384
Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln	40 45 50
ATC CAT TCG ATT AGT GAA CGG ATC CTT GGC ACT TAT CTG GGA CGA	429
Ile His Ser Ile Ser Glu Arg Ile Leu Gly Thr Tyr Leu Gly Arg	55 60 65
TCT GCG GAG CCT GTG CCT CTT CAG CTA CCA CCG CTT GAG AGA CTT	474
Ser Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Gln Arg Leu	70 75 80
ACT CTT GAT TGT AAC GAG GAT TGT GGA ACT TCT GGG ACG CAG GCG	519
Thr Leu Asp Cys Asn Glu Asp Cys Gly Thr Ser Gly Thr Gln Gly	85 90 95
GTG GGA AGC CCT CAA ATA TTG GTG GAA TCT CCT ACA GTA TTG GAG	564
Val Gly Ser Pro Gln Ile Leu Val Glu Ser Pro Thr Val Leu Glu	100 105 110
TCA GGA ACT AAA GAA TAGTGCTGTT AGAATTCTCA A	600
Ser Gly Thr Lys Glu	115

The EcoRI fragment (586 bp) of the PCR product is inserted into EcoRI site of SFneo (see Figure 5). The recombinant plasmid are screened with Sal-I enzyme digestion. The plasmid without the insert yield a single band of 7227 bps (SFneo only). Plasmid with inserts show two


bands, the smaller of which is either 743 bps (insertion in right orientation) or 1247 bps (insertion in wrong orientation). The recombinant plasmid in right orientation, SFneo-t/r(+), (stands for tat/rev positive or sense) is advantageously chosen as the complementary gene expression vector for antisense/ribozyme proviral clones. The one in wrong orientation, "SFneo-t/r(-)" (stands for tat/rev negative or antisense), is used in the experiments of vector-expressed antisense tat-rev RNA inhibition of wild type HIV-1 viruses.

E = EcoRI  
S = Sali

Insertion in right orientation [SFneo-t/r(+)]:



Insertion in wrong orientation [SFneo-t/r(-)]:



**Example 7: CONSTRUCTION OF TAT-EXPRESSION VECTORS CONTAINING CHEMICALLY SYNTHESIZED TAT ENCODING SEQUENCE**

With gene-expression vectors constructed by the above-mentioned protocols, either driven by HIV-1 or another promoter, there exists the

possibility that the antisense RNA transcribed from the antisense/ribozyme clones will bind and inactivate the sense tat mRNA from the gene-expression vectors. This potential problem rests on the one-hundred-percent sequence complementation between the tat's in antisense/ribozyme molecular clones and that in the gene expression vectors. If this occurs, there may not be enough TAT protein available for efficient replication of antisense/ribozyme viruses.

Proteins are composed of amino acids which in turn are encoded by nucleotide triplets. The fact that most amino acids (except methionine and tryptophan) are encoded by more than one nucleotide triplet creates the possibility of diversifying nucleotide sequence while keeping the amino acid sequence unchanged for a particular protein.

The following shows one of the diversifications for tat-protein-coding nucleotide sequences. The first line shows the original tat nucleotide sequence (HXB2); the second the amino acid sequence; and the third the diversification of tat nucleotide sequence. Of the 87 codons, all except two (the initiator methionine and the eleventh residue tryptophan) can be altered at at least one base. 8 arginines and 3 leucines can be changed at two bases. The 7 serines can be changed at all three bases. The stop codon too can be changed at two bases. In total, 111 out of 261 (42.5%) nucleotides can be changed, enough to nullify complementation.

```

ATG GAG CCA GTA GAT CCT AGA CTA GAG CCC TGG AAG CAT CCA GGA AGT
M  E  P  V  D  F  R  L  E  P  W  K  H  P  G  S
ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA
      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *
CAG CCT AAA ACT GCT TGT ACC AAT TGC TAT TGT AAA AAG TGT TGC TTT
Q  P  K  T  A  C  T  N  C  Y  C  K  K  C  C  F
CAA CCA AAG ACA GCA TGC ACC AAC TGT TAC TGC AAG AAA TGC TGT TTC
      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *
CAT TGC CAA GTT TGT TTC ATA ACA AAA GCC TTA GGC ATC TCC TAT GGC
H  C  Q  V  C  F  I  T  K  A  L  G  I  S  Y  G
CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA
      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *
AGG AAG AAG CGG AGA CAG CGA CGA AGA GCT CAT CAG AAC ACT CAG ACT
R  K  K  R  R  Q  R  R  A  H  Q  N  S  Q  T
CGT AAA AAA AGA CGT CAA AGG AGG CGT GCA CAC CAA AAT TCA CAA ACA
      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *
CAT CAA GCT TCT CTA TCA AAG CAA CCC ACC TCC CAA TCC CGA GGG GAC
H  Q  A  S  L  S  K  Q  P  T  S  Q  S  R  G  D
CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT
      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *
CCG ACA GGC CCG AAG GAA TAG
P  T  G  P  K  E  *
CCT ACT GGG CCC AAA CAG TGA
      *  *  *  *  *  *  *

```

Since the expression vectors will also be utilized for the production of antisense-ribozyme viruses (ARV), care has been taken to nullify the potential ribozyme target sites, in order to avoid the binding of diversified tat mRNA by ribozymes expressed by the ARVs.

Removing the original nucleotide sequence:

```

M   E   P   V   D   P   R   L   E   P   W   K   H   P   G   S
ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA

Q   P   K   T   A   C   T   N   C   Y   C   K   K   C   C   F
CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC TGC AAG AAA TGC TGT TTC

H   C   Q   V   C   F   I   T   K   A   L   G   I   S   Y   G
CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA

R   K   K   R   R   Q   R   R   R   A   H   Q   N   S   Q   T
CGT AAA AAA AGA CGT CAA AGG AGG CGT GCA CAC CAA AAT TCA CAA ACA

H   Q   A   S   L   S   K   Q   P   T   S   Q   S   R   G   D
CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT

P   T   G   P   K   E   *
CCT ACT GGG CCC AAA GAG TGA

```

Removing the amino acid sequence as well. This is the diversified HIV-1 tat gene to be synthesized chemically.

```

ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA
CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC TGC AAG AAA TGC TGT TTC
CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA
CGT AAA AAA AGA CGT CAA AGG AGG CGT GCA CAC CAA AAT TCA CAA ACA
CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT
CCT ACT GGG CCC AAA GAG TGA

```

To facilitate the post-synthesis gene construction, to each end was added a 12-base tail which contains an EcoRI restriction enzyme site:



GTC GGA ATT CAC

ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA  
 CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC TGC AAG AAA TGC TGT TTC  
 CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA  
 CGT AAA AAA AGA CGT CAA AGG AGG CGT GCA CAC CAA AAT TCA CAA ACA  
 CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT  
 CCT ACT GGG CCC AAA GAG TGA CAG AAT TCC GAG

This is the whole artificial gene of diversification to be  
 synthesized chemically.

SEQ ID NO:23

GTCGGAATTC AC ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG	45
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp	
5 10	
AAA CAC CCT GGT TCA CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC	90
Lys His Pro Gly Ser Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr	
15 20 25	
TGC AAG AAA TGC TGT TTC CAC TGT CAG GTA TGC TTT ATT ACT AAG	135
Cys Lys Lys Cys Cys Phe His Cys Gln Val Cys Phe Ile Thr Lys	
30 35 40	
GCA CTT GGG ATT AGT TAC GGA CGT AAA AAA AGA CGT CAA AGG AGG	180
Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg	
45 50 55	
CGT GCA CAC CAA AAT TCA CAA ACA CAC CAG GCA AGC TTG AGT AAA	225
Arg Ala His Gln Asn Ser Gln Thr His Gln Ala Ser Leu Ser Lys	
60 65 70	
CAG CCG ACG AGT CAG AGT AGG GGC GAT CCT ACT GGG CCC AAA GAG	270
Gln Pro Thr Ser Gln Ser Arg Gly Asp Pro Thr Gly Pro Lys Glu	
75 80 85	
TGACAGAATT CCGAG	285

A PCR strategy was developed for the synthesis of the artificial  
 gene. To demonstrate, complementary sequence is added to the diversified  
 gene below:

Eco-RI  
GTC GGA ATT CAC  
CAG CCT TAA GTG

Nco-I  
ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA  
TAC CTT GGA CAC CTG GGT CCA AAC CTT GGT ACC TTT GTG GGA CCA AGT

Sph-I  
CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC TGC AAG AAA TGC TGT TTC  
GTT GGT TTC TGT CGT ACG TGC TTG ACA ATG ACG TTC TTT ACG ACA AAG  
CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA  
GTG ACA GTC CAT ACG AAA TAA TGA TTC CGT GAA CCC TAA TCA ATG CCT

Apa-LI  
CGT AAA AAA AGA CGT CAA AGG AGG CGT GCA CAC CAA AAT TCA CAA ACA  
GCA TTT TTT TCT GCA GTT TCC TCC GCA CGT GTG GTT TTA AGT GTT TGT  
CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT  
GTG GTC CGT TCG AAC TCA TTT GTC GGC TGC TCA GTC TCA TCC CCG CTA

Apa-I  
CCT ACT GGG CCC AAA GAG TGA CAG AAT TCC GAG  
GGA TGA CCC GGG TTT CTC ACT GTC TTA AGG CTC

For the effectiveness of the synthesis, the whole fragment totaling 285 base pairs is broken down and synthesized as six oligonucleotides, each has a 15-base overlap with the adjacent oligonucleotides, because the middle oligo overlap with two other oligos.

1. GTCGGAATTCACATGGAACCTGTGGACCCACGTTTGGAAACCATGGAAACACCCCTGGTTCA
2. ACAGCATTTCTTGCAGTAACAGTTTCGTGCATGCTGTCTTTGGTTGTGAACCAGGGTGTTC
3. TGCAAGAAATGCTGTTTCCACTGTCAGGTATGCTTTATTACTAAGGCACTTGGGATTAGT
4. ATTTTGGTGTGCACGCCTCCTTTGACGTCCTTTTACGTCCGTAACCTAATCCCAAGTGC
5. CGTGCACACCAAAATTCACAAACACACCAGGCAAGCTTGAGTAAACAGCCGACGATCAG
6. CTCGGAATTCTGTCACTCTTTGGGCCAGTAGCATCGCCCCTACTCTGACTCGTCGGCTG

## SEQ ID NO:24 (#1)

GTCCGAATTC ACATGGAACC TGTGGACCCA CGTTTGGAAC CATGGAAACA 50  
 CCCTCGTTCA 60

## SEQ ID NO:25 (#2)

ACAGCATTTC TTGCAGTAAC AGTTCGTGCA TGCTGTCTTT GGTGTGAAC 50  
 CAGGCTGTTT 60

## SEQ ID NO:26 (#3)

TGCAAGAAAT GCTGTTTCCA CTGTCAGGTA TGCTTTATTA CTAAGGCACT 50  
 TGGGATTAGT 60

## SEQ ID NO:27 (#4)

ATTTTGGTTC GCACGCCTCC TTGACGTCT TTTTACGT CCGTAACTAA 50  
 TCCCAAGTTC 60

## SEQ ID NO:28 (#5)

CGTGCACACC AAAATTCACA AACACACCAG GCAAGCTTGA GTAAACAGCC 50  
 GACGAGTCAG 60

## SEQ ID NO:29 (#6)

CTCCGAATTC TGTCACCTTT TGGGCCCACT AGCATCGCCC CTACTCTGAC 50  
 TCGTCGGCTG 60

The corresponding positions of the oligonucleotides are shown in bold-type or underlined in the sequence below. Also shown are the overlapping areas of the adjacent oligonucleotides.

GTC GGA ATT CAC  
CAG CCT TAA GTG

1-->

ATG GAA CCT GTG GAC CCA CGT TTG GAA CCA TGG AAA CAC CCT GGT TCA  
TAC CTT GGA CAC CTG GGT GCA AAC CTT GGT ACC TTT GTG GGA CCA AGT  
<--2

CAA CCA AAG ACA GCA TGC ACG AAC TGT TAC TGC AAG AAA TGC TGT TTC  
GTT GGT TTC TGT CGT ACG TGC TTG ACA ATG ACG TTC TTT ACG ACA AAG

3-->

CAC TGT CAG GTA TGC TTT ATT ACT AAG GCA CTT GGG ATT AGT TAC GGA  
GTG ACA GTC CAT ACG AAA TAA TGA TTC CGT GAA CCC TAA TCA ATG CCT  
<--4

CGT AAA AAA AGA CGT CAA AGG ACG CGT GCA CAC CAA AAT TCA CAA ACA  
GCA TTT TTT TCT GCA GTT TCC TCC GCA CGT GTG GTT TTA AGT GTT TGT

5-->

CAC CAG GCA AGC TTG AGT AAA CAG CCG ACG AGT CAG AGT AGG GGC GAT  
GTG GTC CGT TCG AAC TCA TTT GTC GGC TGC TCA GTC TCA TCC CCG CTA  
<--6


CCT ACT GGG CCC AAA GAG TGA CAG AAT TCC GAG  
GGA TGA CCC GGG TTT CTC ACT GTC TTA AGG CTC

The oligonucleotides, each with a 15-base overlap with the adjacent oligonucleotide, were linked into the full-length DNA fragment of 285 bps. All the oligonucleotides were mixed together, with the first and the last ones (numbers 1 & 6) added in amounts ten times as much as the others. In the presence of dNTP's and TaqI DNA polymerase, the mixture underwent thermal cycling just as in an ordinary PCR reaction. By priming to each other, the oligonucleotides were linked together and amplified, as shown below:

The full-length fragment to be made:

-----  
-----

Chemically synthesized single stranded oligonucleotides, arrows point from 5' to 3':



The reaction product was cleaved with EcoRI and the 273 bp fragment inserted into SFneo at EcoRI site. The recombinant clones were screened with NcoI restriction enzyme digestion. Clones without insertions (SFneo per se) yield two bands of 6024 and 1023 bps respectively. Clones with insertions have three bands which are either 5114, 1363 and 1023 bps [insertion in right orientation, "SFneo-tat(+)" ] or 5317, 1160 and 1023 bps [insertion in wrong orientation, "SFneo-tat(-)" ]. See Figure 7.

=====

Similarly, the coding sequence for HIV-1 rev can also be diversified:

The original HIV-1 IIIB rev nucleotide and amino acid sequences, is shown below. Note the splice junction site at 26th codon.

ATG	GCA	GGA	AGA	AGC	GGA	GAC	AGC	GAC	GAA	GAG	CTC				
M	A	G	R	S	G	D	S	D	E	E	L				
											sd\sa				
ATC	AGA	ACA	GTC	AGA	CTC	ATC	AAG	CTT	CTC	TAT	CAA	AGC	AAC	CCA	CCT
I	R	T	V	R	L	I	K	L	L	Y	Q	S	N	P	P
CCC	AAC	CCC	GAG	GGG	ACC	CGA	CAG	GCC	CGA	AGG	AAT	AGA	AGA	AGA	AGG
P	N	P	E	G	T	R	Q	A	R	R	N	R	R	R	R
TGG	AGA	GAG	AGA	CAG	AGA	CAG	ATC	CAT	TCG	ATT	AGT	GAA	CGG	ATC	CTT
W	R	E	R	Q	R	Q	I	H	S	I	S	E	R	I	L
GGC	ACT	TAT	CTG	GGA	CGA	TCT	GCG	GAG	CCT	GTG	CCT	CTT	CAG	CTA	CCA
G	T	Y	L	G	R	S	A	E	P	V	P	L	Q	L	P
CCG	CTT	GAG	AGA	CTT	ACT	CTT	GAT	TGT	AAC	GAG	GAT	TGT	GGA	ACT	TCT
P	L	E	R	L	T	L	D	C	N	E	D	C	G	T	S
GGG	ACG	CAG	GGG	GTG	GGA	AGC	CCT	CAA	ATA	TTG	GTG	GAA	TCT	CCT	ACA
G	T	Q	G	V	G	S	P	Q	I	L	V	E	S	P	T
GTA	TTG	GAG	TCA	GGA	ACT	AAA	GAA	TAG							
V	L	E	S	G	T	K	E	*							

Keeping the amino acid sequence unchanged, the nucleotide sequence can be diversified at points marked by stars:

ATG GCA GGA AGA AGC GGA GAC AGC GAC GAA GAG CTC  
 M A G R S G D S D E E L  
 ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

sd\sa

ATC AGA ACA GTC AGA CTC ATC AAG CTT CTC TAT CAA AGC AAC CCA CCT  
 I R T V R L I K L L Y Q S N P P  
 ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

CCC AAC CCC GAG GGG ACC CGA CAG GCC CGA AGG AAT AGA AGA AGA AGG  
 P N P E G T R Q A R R N R R R R  
 CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CCG CCG  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

TGG AGA GAG AGA CAG AGA CAG ATC CAT TCG ATT AGT GAA CGG ATC CTT  
 W R E R Q R Q I H S I S E R I L  
 TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

GGC ACT TAT CTG GGA CGA TCT GCG GAG CCT GTG CCT CTT CAG CTA CCA  
 G T Y L G R S A E P V P L Q L P  
 GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

CCG CTT GAG AGA CTT ACT CTT GAT TGT AAC GAG GAT TGT GGA ACT TCT  
 P L E R L T L D C N E D C G T S  
 CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

GGG ACG CAG GGG GTG GGA AGC CCT CAA ATA TTG GTG GAA TCT CCT ACA  
 G T Q G V G S P Q I L V E S P T  
 GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆

GTA TTG GAG TCA GGA ACT AAA GAA TAG  
 V L E S G T K E ☆  
 GTT CTT GAA AGT GGT ACA AAG GAG TGA  
 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆





Removing the amino acid sequence as well:

```

      ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG
        *   *   *   *   *   *   *   *   *   *   *
ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG
  *   *   *   *   *   *   *   *   *   *   *   *
CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CGG CGC
  *   *   *   *   *   *   *   *   *   *   *   *
TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA
  *   *   *   *   *   *   *   *   *   *   *   *
GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT
  *   *   *   *   *   *   *   *   *   *   *   *
CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC
  *   *   *   *   *   *   *   *   *   *   *   *
GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT
  *   *   *   *   *   *   *   *   *   *   *   *
GTT CTT GAA AGT GGT ACA AAG GAG TGA
  *   *   *   *   *   *   *   *   *   *   *

```

Removing the stars:

```

      ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG
ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG
CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CGG CGC
TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA
GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT
CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC
GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT
GTT CTT GAA AGT GGT ACA AAG GAG TGA

```

Adding to each end a 12 basepair tail carrying an Eco RI site:

GAC TGA ATT CAT ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG  
 ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG  
 CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CGG CGC  
 TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA  
 GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT  
 CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC  
 GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT  
 GTT CTT GAA AGT GGT ACA AAG GAG TGA TCG AAT TCC GTC

Adding the complementary strand:

Eco-RI Nde-I

GAC TGA ATT CAT ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG  
 CTC ACT TAA GTA TAC CGA CCA GCA AGC CCA CTA AGC CTA CTC CTT AAC  
 ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG  
 TAT GCA TGA CAC GCA AAC TAT TTT AAT AAC ATG GTC AGC TTA CGA GGC

S a l -I

CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CGG CGC  
 GGA TTA GGA CTT CCA TGC TCC GTT CGA TCC GCA TTG GCA GCT GCC GCG  
 TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA  
 ACC GCA CTT GCA GTT GCA GTT TAT GTG TCG TAG AGT CTC TCT TAT AAT  
 GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT  
 CCC TGT ATG AAT CCA TCC TCG CGG CTT GGT CAG GGT AAT GTT AAC GGA  
 CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC  
 GGA AAC CTT GCA AAC TGT AAT CTG ACC TTA CTT CTG ACC CCA TGT TCG  
 GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT  
 CCA TGG GTT CCA CAG CCA AGC GGT GTC TAG GAT CAG CTC TCG GGT TGA

Eco-RI

GTT CTT GAA AGT GGT ACA AAG GAG TGA TCG AAT TCC GTC  
 CAA GAA CTT TCA CCA TGT TTC CTC ACG AGC TTA AGG CAG

To synthesize this fragment, eight (8) oligonucleotides are needed. The positions of the oligonucleotide primers are shown in bold-type characters or underlined with numbering and arrows pointing to their 3' ends:

## Eco-RI Nde-I

GAC TGA ATT CAT-ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA TTG  
 CTC ACT TAA GTA-TAC CGA CCA GCA AGC CCA CTA AGC CTA CTC CTT AAC

1--&gt;

ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT CCT CCG  
 TAT GCA TGA CAC GCA AAC TAT TTT AAT AAC ATG GTC AGC TTA GGA GGC

&lt;--2

S a l -I

CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT CGA CGG CGC  
 GGA TTA GGA CTT CCA TGC TCC GTT CGA TCC GCA TTG GCA GCT GCC GCG

3--&gt;

TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA GAG AGA ATA TTA  
 ACC GCA CTT GCA GTT GCA GTT TAT GTG TCG TAG AGT CTC TCT TAT AAT

&lt;--4

GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC CCA TTA CAA TTG CCT  
 CCC TGT ATG AAT CCA TCC TCG CGG CTT GGT CAG GGT AAT GTT AAC GGA

5--&gt;

CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT GAA GAC TGC GGT ACA AGC  
 GGA AAC CTT GCA AAC TGT AAT CTG ACG TTA CTT CTG ACG CCA TGT TCG

&lt;--6

GGT ACC CAA GGT GTC GGT TCG CCA CAG ATC CTA GTC GAG AGC CCA ACT  
 CCA TGG GTT CCA CAG CCA AGC GGT GTC TAG GAT CAG CTC TCG GGT TGA

7--&gt;

Eco-RI

GTT CTT GAA AGT GGT ACA AAG GAG TGA-TCG AAT TCC GTC  
 CAA GAA CTT TCA CCA TGT TTC CTC ACG-AGC TTA AGG CAG

&lt;--8

SEQ ID NO:30 (diversified rev DNA sequence with protein)

GACTGAATTC AT ATG GCT GGT CGT TCG GGT GAT TCG GAT GAG GAA	45
Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu	
5 10	
TTG ATA CGT ACT GTG CGT TTG ATA AAA TTA TTG TAC CAG TCG AAT	90
Leu Ile Arg Thr Val Arg Leu Ile Lys Leu Leu Tyr Glu Ser Asn	
15 20 25	
CCT CCG CCT AAT CCT GAA GGT ACG AGG CAA GCT AGG CGT AAC CGT	135
Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg	
30 35 40	
CGA CGG CGC TGG CGT GAA CGT CAA CGT CAA ATA CAC AGC ATC TCA	180
Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile His Ser Ile Ser	
45 50 55	
GAG AGA ATA TTA GGG ACA TAC TTA GGT AGG AGC GCC GAA CCA GTC	225
Glu Arg Ile Leu Gly Thr Tyr Leu Gly Arg Ser Ala Glu Pro Val	
60 65 70	
CCA TTA CAA TTG CCT CCT TTG GAA CGT TTG ACA TTA GAC TGC AAT	270
Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn	
75 80 85	
GAA GAC TGC GGT ACA AGC GGT ACC CAA GGT GTC GGT TCG CCA CAG	315
Glu Asp Cys Gly Thr Ser Gly Thr Gln Gly Val Gly Ser Pro Gln	
90 95 100	
ATC CTA GTC GAG AGC CCA ACT GTT CTT GAA AGT GGT ACA AAG GAG	360
Ile Leu Val Glu Ser Pro Thr Val Leu Glu Ser Gly Thr Lys Glu	
105 110 115	
TGATCGAATT CCGTC	375
Oligonucleotide primers needed to synthesize SEQ ID NO:30	

SEQ ID NO:31 (#1)

GACTGAATTC ATATGGCTGG TCGTTCGGGT GATTCCGATC AGGAATTGAT 50

ACGTACTGTG CGT 63

SEQ ID NO:32 (#2)

ACCTTCAGGA TTAGCCGGAG GATTCCGACTG GTACAATAAT TTTATCAAAC 50

GCACAGTACG TAT 63

SEQ ID NO:33 (#3)

CCTAATCCTG AAGGTACGAG GCAAGCTAGG CGTAACCGTC GACGGCGCTG 50

GCGTGAACGT CAA 63

SEQ ID NO:34 (#4)

ACCTAAGTAT GTCCCTAATA TTCTCTCTGA GATGCTGTGT AATTGACGTT 50

GACGTTACCG CCA 63

SEQ ID NO:35 (#5)

GGGACATACT TAGGTAGGAG CGCCGAACCA GTCCCATTTAC AATTGCCTCC 50

TTTGGAACGT TTG 63

SEQ ID NO:36 (#6)

GACACCTTGG GTACCGCTTG TACCGCAGTC TTCATTGCAG TCTAATGTCA 50

AACGTTCCAA AGG 63

SEQ ID NO:37 (#7)

GGTACCCAAG GTGTCGGTTC GCCACAGATC CTAGTCGAGA GCCCAACTGT 50

TCTTGAAAGT GGT 63

SEQ ID NO:38 (#8)

GACGGAATTC GAGCACTCCT TTGTACCACT TTCAAGAAC 39

---

#### Example 8: CO-TRANSFECTION EXPERIMENTS

Transfection of pXE (or pX), pXE-a, pXE-b, pXE-ar and pXE-br into a cell line optionally transfected with one of the tat-expression vectors

tat-neo or with neo- nly control, the viral pr ducti n, infectivity and viral replication upon infection with or without further TAT complementation is as follows:

	Transfection		Virion Production	Virion Infectivity	Viral Replication Upon infection of	
	1st	2nd			CD4+ Cells	CD4+/Tat+ Cells
(1)	none	none	No	No	No	No
(2)	none	pXE	Yes	Yes	Yes	Yes
(3)	none	pXE-a	No	No	No	No
(4)	none	pXE-b	No	No	No	No
(5)	none	pXE-ar	No	No	No	No
(6)	none	pXE-br	No	No	No	No
(7)	-neo	none	No	No	No	No
(8)	-neo	pXE	Yes	Yes	Yes	Yes
(9)	-neo	pXE-a	No	No	No	No
(10)	-neo	pXE-b	No	No	No	No
(11)	-neo	pXE-ar	No	No	No	No
(12)	-neo	pXE-br	No	No	No	No
(13)	tat-neo	none	No	No	No	No
(14)	tat-neo	pXE	Yes	Yes	Yes	Yes
(15)	tat-neo	pXE-a	Yes	Yes	No	Yes
(16)	tat-neo	pXE-b	Yes	Yes	No	Yes
(17)	tat-neo	pXE-ar	Yes	Yes	No	Yes
(18)	tat-neo	pXE-br	Yes	Yes	No	Yes

#### Virus Co-Infection Experiments

When supernatant from different transfections (numbered as in the above table) are collected and the combination is used to infect CD4+ cell line, the results are as follows:

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
1	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
3	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
4	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
5	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
6	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
7	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
8	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
9	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
10	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
11	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
12	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
13	-	+	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-
14	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
15	-	±	-	-	-	-	-	±	-	-	-	-	-	±	-	-	-	-
16	-	±	-	-	-	-	-	±	-	-	-	-	-	±	-	-	-	-
17	-	±	-	-	-	-	-	±	-	-	-	-	-	±	-	-	-	-
18	-	±	-	-	-	-	-	±	-	-	-	-	-	±	-	-	-	-

- + Virus particles are produced;  
 - Virus particles are not produced;  
 ± Virus particles are produced transiently.

☆ ☆ ☆

While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

The features disclosed in the foregoing description, in the following claims and/or in the accompanying drawings may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof.

WHAT IS CLAIMED IS:

1. An antisense virus comprising:  
a viral coat sufficiently duplicative of a naturally occurring virus viral coat to allow the infectivity of said naturally occurring virus,  
and  
nucleic acid including an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein.
2. An antisense virus as in Claim 1 wherein said antisense virus is replication defective.
3. An antisense virus as in Claim 1 wherein said nucleic acid includes all of the structural genes of said naturally occurring virus.
4. An antisense virus as in Claim 1 wherein said nucleic acid includes all of the regulatory genes of said naturally occurring virus except said gene encoding a transactivating protein.
5. An antisense virus as in Claim 1 wherein except for said antisense fragment which encodes antisense RNA, said antisense virus is the same as said naturally occurring virus.
6. An antisense virus as in Claim 1 wherein said naturally occurring virus is an animal virus.
7. An antisense virus as in Claim 1 wherein said naturally occurring virus is a DNA virus.
8. An antisense virus as in Claim 1 wherein said naturally occurring virus is an RNA virus.



9. An antisense virus as in Claim 8 wherein said naturally occurring virus is a retrovirus.

10. An antisense virus as in Claim 9 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2 and SIV.

11. The antisense virus as in Claim 10 wherein said antisense fragment which encodes antisense RNA is a section of a gene selected from the group consisting of tat, rev and vpr, which has been turned antisense.

12. An antisense virus as in Claim 10 wherein said mRNA is an mRNA encoded by a gene selected from the group consisting of tat, rev, and vpr.

13. An antisense virus as in Claim 6 wherein said virus is a human T-lymphotropic virus.

14. An antisense virus as in Claim 6 wherein said virus is hepatitis B virus.

15. An antisense proviral molecular clone including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein.

16. A method of synthesizing an antisense proviral molecular clone comprising the steps of:

- a) inserting DNA encoding a naturally occurring virus into a vector; and
- b) creating an antisense fragment in said DNA by turning antisense a section of a gene of said DNA, said gene encoding a transactivating protein required for said naturally occurring

virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein.

17. A method as in Claim 16 wherein said vector is a plasmid.
18. A method as in Claim 16 wherein said vector is a phagemid.
19. A method as in Claim 16 wherein said vector is a cosmid.
20. A method as in Claim 16 wherein said vector is a bacterial phage lambda.
21. A method of synthesizing an antisense proviral molecular clone comprising the steps of:
  - a) inserting DNA encoding a naturally occurring virus into a vector;
  - b) creating an antisense fragment in said DNA by carrying out a polymerase chain reaction using a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate as a template, said section of a gene is bordered by a unique restriction enzyme A at its first end and by a unique restriction enzyme site B at its second end, and using
    - primer 1 comprising DNA complementary to a first end of said section of DNA as its 3' half, and DNA containing said restriction site B as its 5' half, and
    - primer 2 comprising DNA complementary to a second end of said section of DNA as its 3' half, and DNA containing said restriction site A as its 5' half,as primers to produce PCR amplification products;
  - c) digesting said vector with restriction enzyme A and restriction enzyme B to release said section of a gene;
  - d) digesting said PCR amplification products with restriction enzyme A and restriction enzyme B to release said antisense fragment; and

e) ligating said antisense fragment into said vector, wherein said antisense fragment encodes antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein.

22. A procaryotic or eucaryotic host cell stably transfected with:
- a) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein; and
  - b) a second DNA sequence encoding said transactivating protein; in a manner allowing expression of an antisense virus.

23. A host cell as in claim 22 wherein said second DNA sequence encodes mRNA which does not bind to said antisense RNA.

24. A host cell as in claim 22 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2 and SIV.

25. A process for the production of an antisense virus, said process comprising:

- a) growing under suitable nutrient conditions procaryotic or eucaryotic host cells transfected with:
  - i) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein, and

- ii) a second DNA sequence encoding said transactivating protein in a manner allowing expression of said antisense virus, and
- b) isolating said antisense virus.

26. A process as in Claim 25 wherein said host cells are transfected with said second DNA sequence prior to being transfected with said first DNA sequence.

27. A method of treating a viral infection comprising administering to an infected animal a therapeutically effective amount of an antisense virus as in Claim 1.

28. A method as in Claim 27 wherein said infected animal is a human, and said section of a gene is from said human.

29. A method of preventing a viral infection comprising administering to an animal a therapeutically effective amount of an antisense virus as in Claim 1.

30. A method as in Claim 28 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2, and SIV.

31. An antisense-ribozyme virus comprising:  
a viral coat sufficiently duplicative of a naturally occurring virus viral coat to allow the infectivity of said naturally occurring virus, and nucleic acid including an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding and inactivating mRNA encoded by said gene encoding a transactivating protein, said antisense fragment also encoding at least one ribozyme capable of cleaving said mRNA.

32. An antisense-ribozyme virus as in Claim 31 wherein said antisense-ribozyme virus is replication defective.

33. An antisense-ribozyme virus as in Claim 31 wherein said nucleic acid includes all of the structural genes of said naturally occurring virus.

34. An antisense-ribozyme virus as in Claim 31 wherein said nucleic acid includes all of the regulatory genes of said naturally occurring virus except said gene encoding a transactivating protein.

35. An antisense-ribozyme virus as in Claim 31 wherein except for said antisense fragment which encodes antisense RNA, said antisense-ribozyme virus is the same as said naturally occurring virus.

36. An antisense-ribozyme virus as in Claim 31 wherein said ribozyme is a hammerhead ribozyme.

37. An antisense-ribozyme virus as in Claim 31 wherein said naturally occurring virus is an animal virus.

38. An antisense-ribozyme virus as in Claim 31 wherein said naturally occurring virus is a DNA virus.

39. An antisense-ribozyme virus as in Claim 31 wherein said naturally occurring virus is an RNA virus.

40. An antisense-ribozyme virus as in Claim 39 wherein said naturally occurring virus is a retrovirus.

41. An antisense-ribozyme virus as in Claim 40 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2 and SIV.

42. An antisense-ribozyme virus as in Claim 41 wherein said antisense fragment which encodes antisense RNA is a section of a gene selected from the group consisting of tat, rev and vpr which has been turned antisense and which includes at least one ribozyme.

43. An antisense-ribozyme virus as in Claim 41 wherein said mRNA is an mRNA encoded by a gene selected from the group consisting of tat, rev, and vpr.

44. An antisense-ribozyme proviral molecular clone including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding mRNA encoded by said gene encoding a transactivating protein, said antisense fragment also encoding at least one ribozyme capable of cleaving said mRNA.

45. A method of synthesizing an antisense-ribozyme proviral molecular clone comprising the steps of:

- a) inserting DNA encoding a naturally occurring virus into a vector;
- b) creating an antisense fragment in said DNA by turning antisense a section of a gene of said DNA, said gene encoding a transactivating protein required for said naturally occurring virus to replicate, and
- c) inserting DNA encoding at least one ribozyme in said antisense fragment such that the transcription product of said antisense fragment is antisense RNA capable of binding and cleaving mRNA encoded by said gene encoding a transactivating protein.

46. A method of synthesizing an antisense-ribozyme proviral molecular clone comprising the steps of:

- a) inserting DNA encoding a naturally occurring virus into a vector;
- b) creating an antisense fragment in said DNA by carrying out a polymerase chain reaction using a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate as a template, said section of a gene is bordered by a unique restriction enzyme A of its first end and by a unique restriction enzyme site B at its second end, and using

primer 1 comprising DNA complementary to a first end f said section of DNA as its 3' half, and DNA containing said restriction site B as its 5' half,

primer 2 comprising DNA complementary to a second end f said section of DNA as its 3' half, and DNA containing said restriction site A as its 5' half, and

at least one bridging primer comprising DNA complementary to the 3' side of a ribozyme cleavage site as its 5' third, DNA complementary to the 5' side of said ribozyme cleavage site as its 3' third, and DNA encoding a ribozyme as its middle third,

as primers to produce PCR amplification products;

c) digesting said vector with restriction enzyme A and restriction enzyme B to release said section of a gene;

d) digesting said PCR amplification products with restriction enzyme A and restriction enzyme B to release said antisense fragment; and

e) ligating said antisense fragment into said vector,

wherein said ribozyme cleavage site is selected such that the transcription product of said antisense fragment is antisense RNA capable of binding and cleaving mRNA encoded by said gene encoding a transactivating protein.

47. A procaryotic or eucaryotic host cell stably transfected with:

a) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding mRNA encoded by said gene encoding a transactivating protein, said antisense fragment also encoding at least one ribozyme capable of cleaving said mRNA; and

b) a second DNA sequence encoding said transactivating protein; in a manner allowing expression of an antisense-ribozyme virus.

48. A host cell as in claim 47 wherein said second DNA sequence encodes mRNA which does not bind to said antisense RNA and which is not cleaved by said ribozyme.

49. A host cell as in claim 47 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2, and SIV.

50. A process for the production of an antisense ribozyme virus, said process comprising:

- a) growing under suitable nutrient conditions procaryotic or eucaryotic host cells transfected with:
  - i) a first DNA sequence including structural genes of a naturally occurring virus, and an antisense fragment which is antisense to a section of a gene encoding a transactivating protein required for said naturally occurring virus to replicate, said antisense fragment encoding antisense RNA capable of binding mRNA encoded by said gene encoding a transactivating protein, said antisense fragment also encoding at least one ribozyme capable of cleaving said mRNA, and
  - ii) a second DNA sequence encoding said transactivating protein, in a manner allowing expression of said antisense ribozyme virus, and
- b) isolating said antisense ribozyme virus.

51. A process as in Claim 50 wherein said host cells are transfected with said second DNA sequence prior to being transfected with said first DNA sequence.

52. A method of treating a viral infection comprising administering to an infected animal a therapeutically effective amount of an antisense-ribozyme virus as in Claim 31.

53. A method as in Claim 52 wherein said infected animal is a human and said section of a gene is from said human.



54. A method of preventing a viral infection comprising administering to an animal a therapeutically effective amount of an antisense-ribozyme virus as in Claim 31.

55. A method as in Claim 53 wherein said naturally occurring virus is selected from the group consisting of HIV-1, HIV-2, and SIV.

56. A method of connecting a first DNA segment to a second DNA segment, said first DNA segment and said second DNA segment being separated by a length of DNA, or located on different molecules, comprising the steps of:

carrying out polymerase chain reaction using said DNA segments as templates, and using

a primer A complementary to the 5' end of said first DNA segment,

a primer B complementary to the 3' end of said second DNA segment, and

a bridging primer comprising DNA complementary to the 3' end of said first DNA segment as its 5' half, and DNA complementary to the 5' end of said second DNA segment as its 3' half, as primers.

57. A method as in Claim 56, wherein the molar concentration of primers A and B are the same, and the molar concentration of said bridging primer is about 1/10 of the molar concentration of primer A or B.

58. A method of synthesizing a DNA sequence comprising the steps f:

a) synthesizing a series of oligodeoxynucleotides including:

a first oligodeoxynucleotide having a 5' end complementary to the 5' end of said DNA sequence and a 3' end complementary to the 5' end of one other oligodeoxynucleotide,

internal oligodeoxynucleotides wherein the 3' end of each oligodeoxynucleotide is complementary to the 5' end of one other oligodeoxynucleotide, and

a last oligodeoxynucleotide having a 3' end complementary to the 3' end of said DNA sequence and a 5' end complementary to the 3' end of one other oligodeoxynucleotide,

wherein said series extends the full length of said DNA sequence to be synthesized;

- b) carrying out a thermal cycling connection-amplification reaction on a thermal cycler under reaction conditions suitable for thermal stable DNA polymerase in the presence of:
- i) said oligodeoxynucleotides;
  - ii) four 2'-deoxynucleoside 5'-triphosphatase; and
  - iii) thermal stable polymerase.

59. A method as in claim 58 wherein said first and said last oligodeoxynucleotides are added in equal amounts, and each internal oligodeoxynucleotide is added at about 1/10 that of said first or said last oligodeoxynucleotide.

60. A method as in Claim 58 wherein said DNA sequence is a regulatory gene sequence.

61. A method as in Claim 60 wherein said DNA sequence is a protein coding sequence.

62. A method as in Claim 61 wherein said DNA sequence is a protein coding sequence of a viral gene.

63. A method as in Claim 62 wherein said DNA sequence is a protein coding sequence of a viral gene with a diversified nucleotide sequence.

64. A nucleic acid selected from the group consisting of SEQ ID NO:1-38.




Fig. 1






Fig. 2


**Fig. 3**

**Fig. 4a**




WILD-TYPE  
PROVIRAL CLONE

**Fig. 4b**



ANTISENSE  
PROVIRAL CLONE

**Fig. 4c**



ANTISENSE-RIBOZYME  
PROVIRAL CLONE

(Pa-a)





Fig. 5

**Fig. 6**

6/7

**SUBSTITUTE SHEET**






Fig. 7a




Fig. 7b

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/07179**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(S) : Please See Extra Sheet.

US CL : 424/89, 93; 435/320.1, 69.1, 172.1, 91, 235.1, 240.2, 252.3

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/89, 93; 435/320.1, 69.1, 172.1, 91, 235.1, 240.2, 252.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Medline, biosis, biotech

Search Terms: Antisense virus, ribozyme virus, recombinant

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Proceedings of the National Academy of Sciences, Vol. 88, issued May 1991, L. Han et al., "Inhibition of Moloney Murine Leukemia Virus-Induced Leukemia in Transgenic Mice Expressing Antisense RNA Complementary to the Retroviral Packaging Sequences", pages 4313-4317, see page 4314.	1-64
A	Science, Vol. 253, issued 02 August 1991, Szczylik et al., "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides", pages 562-565, see whole document.	1-64



Further documents are listed in the continuation of Box C.



See patent family annex.

°

Special categories of cited documents:

\*A\*

document defining the general state of the art which is not considered to be part of particular relevance

\*E\*

earliest document published on or after the international filing date

\*L\*

document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (to be specified)

\*O\*

document referring to an oral disclosure, use, exhibition or other means

\*P\*

document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\*

document member of the same patent family

Date of the actual completion of the international search

13 SEPTEMBER 1993

Date of mailing of the international search report

15 OCT 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

DAVID GUZO

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/07179

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Proceedings of the National Academy of Sciences, Vol. 88, issued August 1991, A. G. Day et al., "Expression of an Antisense Viral Gene in Transgenic Tobacco Confers Resistance to the DNA Virus Tomato Golden Mosaic Virus", pages 6721-6725, see page 6723.	1-64

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/07179

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C12N 15/00, 1/20, 5/00, 7/00; C12P 19/34, 21/06; A61K 39/12, 37/00; A01N 63/00